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ABSTRACT 
Chemistry of Transition Metal Complexes with O- and/or N- Donor Ligands: 
Synthesis, Characterization and Study of Reactivity 
Satabdi Roy 
Department of Chemistry, National Institute of Technology, Rourkela-769008, Odisha, 
India 
Chapter 1: In this chapter the scope of the present investigation is delineated briefly 
along with the aim of the work. 
Chapter 2: The synthesis of ethoxido bridged divanadium(IV/IV) complexes        
[(VOL
1-3
)2(µ˗OEt)][Et3NH] (1‒3) of three azo dyes, 2˗(2′˗carboxy˗5′˗X-
phenylazo)˗4˗methylphenol (where X = H (H2L
1
); X = NO2 (H2L
2
)) and 
2˗(2′˗carboxy˗5′˗Br˗phenylazo)˗2˗naphthol (H2L
3
), differing in the substituents of the 
phenyl ring, in order to discern their influence, if any, on their redox potentials, biological 
activities and magnetochemistry, has been discussed. All the synthesized ligands and the 
vanadium(IV) complexes were successfully characterized by various physico-chemical 
techniques, viz. elemental analysis, IR, UV˗vis and NMR spectroscopy, ESI-MS and 
cyclic voltammetry. Molecular structures of [(VOL
1,3
)2(µ˗OEt)][Et3NH] (1 and 3) have 
been determined by X‒ray crystallography. Antiferromagnetic coupling interaction was 
observed between the vanadium d
1˗d1 centers of the complexes and this phenomenon was 
also established theoretically. The complexes were further screened for their in vitro 
cytotoxicity against HeLa and HT˗29 cancer cell lines.  
Chapter 3: Three new monooxidovanadium(IV) [V
IV
OL
1–3
2] (1–3) and two alkoxido 
bridged vanadium(IV) trimeric [V
IV
3O3(µ˗OMe)3(µ3˗OMe)L
4,5
2] (4 and 5), complexes 
have been reported, which were obtained upon reaction of 
2˗{(2˗X)˗diazo)}˗4˗methylphenol (where X = benzo[1,3]dioxol˗5˗yl (HL1), phenyl (HL2) 
and 4˗methoxyphenyl (HL3)), 1˗(2˗(thiazol˗2˗yl)diazenyl)naphthalene˗2˗ol (HL4) and 
2˗(2˗(thiazol˗2˗yl)diazenyl)˗4˗methylphenol (HL5)) with VOSO4.5H2O. The synthesized 
complexes were successfully characterized by elemental analysis, IR, UV˗vis 
spectroscopy, ESI˗MS and their redox properties studied by cyclic voltammetry. 
Molecular structure of 4 has been determined by single crystal X-ray diffraction study. 
The complexes were probed for their in vitro insulin˗mimetic activity against insulin 
responsive L6 myoblast cells. The complexes (1−5) have also been screened for their 
cytotoxicity in human breast adenocarcinoma cell line, MCF-7. The insulin˗mimetic 
activity of complexes 1−5 was also probed on rat L6 myoblast cells. To further confirm 
whether these compounds act via insulin signaling pathway, the immunoblot analysis for 
IRS˗1 was also carried out. 
Chapter 4: The reaction of 2˗(arylazo)phenols (HL) with [Ru(PPh3)3Cl2] in an ethanolic 
medium under basic conditions afforded two organometallic Ru(II) complexes, 
[RuL(PPh3)2(CO)] (1) and [RuL(PPh3)2(CH3CN)] (2). A similar reaction of HL with 
[Ir(PPh3)3Cl] resulted in the formation of the organometallic Ir(III) complex, 
[IrL(PPh3)2(H)] (3). The 2˗(arylazo)phenolate ligand is coordinated to the metal center in 
each complex (1‒3) as a tridentate C, N, O-donor via metal assisted C‒H activation of the 
ligand. The plausible solvent assisted mechanistic pathway for the unprecedented CO 
coordination to the Ru(II) center in the case of 1 has been explained. The synthesized 
complexes have been characterized by various spectroscopic techniques (viz., IR, UV˗vis 
and NMR spectroscopy), ESI-MS and their electrochemical behavior studied by cyclic 
voltammetry. Molecular structures of 1‒3 have been determined by X-ray 
crystallography. 
Chapter 5: Seven hexacoordinated cis-dioxidomolybdenum(VI) complexes, [MoO2L
17
] 
(17) derived from various substituted tetradentate diamino bis(phenolato) “salan” 
ligands, N,Nʹ˗dimethyl˗N,Nʹ˗bis˗(2˗hydroxy˗3˗X˗5˗Y˗6˗Z˗benzyl)˗1,2˗diaminoethane 
(H2L
1
, X = Br, Y = Me, Z = H; H2L
2
, X = Me, Y = Cl, Z = H; H2L
3
, X = 
i
Pr, Y = Cl, Z = 
Me) and N,Nʹ˗bis˗(2˗hydroxy˗3˗X˗5˗Y˗6˗Z˗benzyl)˗1,2˗diaminopropane (H2L
4
, X = Y = 
t
Bu, Z = H; H2L
5
, X = Y = Me, Z = H; H2L
6
, X = 
i
Pr, Y = Cl, Z = Me; H2L
7 
, X = Y = Br, 
Z = H) containing ON donor atoms, have been isolated and structurally characterized. 
The formation of cis-dioxidomolybdenum(VI) complexes was confirmed by elemental 
analysis, IR, UV˗vis and NMR spectroscopy, ESI˗MS and cyclic voltammetry 
measurements. X-ray crystallography showed the O2N2 donor set to define an octahedral 
geometry in each case. [MoO2L
17
] (1‒7) showed moderate DNA binding propensity with 
binding constants ranging from 10
4−105 M-1. The experimental results showed that the 
complexes 1‒7 effectively interact with CT-DNA by both minor and major groove 
binding mode, while complex 2 additionally interacts by partial intercalative mode of 
binding. The dioxidomolybdenum(VI) complexes (1‒3) showed moderate photo-induced 
cleavage of pUC19 supercoiled plasmid DNA. All the complexes (1–7) were tested for 
their in vitro antiproliferative activity against HT-29 and HeLa cancer cell lines. Some of 
the complexes proved to be as active as the clinical referred drugs, and the greater potency 
of 6 and 7 may be dependent on the substituents in the salan ligand environment 
coordinated to the metal. 
Chapter 6: The synthesis and characterization (elemental analysis, UV˗vis spectroscopy, 
ESI-MS and cyclic voltammetry) of Cu(II) complexes ([CuL
1,2
] (1 and 2) and [CuL
3′,4′
]2 
(3 and 4)) using salan ligands, N,Nʹ-dimethyl-N,Nʹ-bis-(2-hydroxy-3-X-5-Y-6-Z-
benzyl)˗1,2-diaminoethane (H2L
1
, X = 
i
Pr, Y = Cl, Z = Me; H2L
2
, X = OCH3, Y = allyl, Z 
= H) and N,Nʹ-bis-(2-hydroxy-3-X–5-Y-6-Z-benzyl)-1,2-diaminopropane (H2L
3
, X = 
i
Pr, 
Y= Cl, Z = Me; H2L
4
, X = Y = CH3, Z = H), have been discussed. Molecular structures of 
1 and 3 have been determined by X‒ray crystallography. An unprecedented ligand 
transformation occurs in the case of 3 and 4, leading to the formation of phenolato bridged 
Cu(II) dimeric complexes, [CuL
3′,4′
]2. The organic transformation in the ligand has been 
mechanistically elucidated to be Cu(II) catalysed. This unusual chemistry of 3 and 4 has 
been compared with Ni
II
, Fe
III 
and Mo
VI
 complexes (5‒7) with similar ligand environment. 
The anomaly in ligand structure was however not observed in the case of other transition 
metal complexes (5‒7). The superoxide dismutase (SOD) activity of the Cu(II) complexes 
(1‒3) has also been investigated; the activity follows the order 3 > 1 > 2. Due to the 
deliquescent nature of 4, its SOD activity could not be evaluated.  
Chapter 7: In this chapter a brief resume of the work embodied in the thesis and 
concluding remarks are stated. The scope for future research work has also been 
discussed. 
Keywords: Azo; Salan; Variable valence transition metals (V(IV), Ru(II), Ir(III), 
Mo(VI), Cu(II)); X-ray crystal structure; Biological activity (DNA interaction, 
Cytotoxicity, Insulin-mimetic, Superoxide Dismutase Mimics); Magnetochemistry; 
Theoretical Study  
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Preface 
The present dissertation describes the design, synthesis, characterization and the 
exploration of chemical and electrochemical properties and the study of bio- and 
magnetochemistry of a series of variable valence transition metal (V, Ru and Ir) 
complexes of bi- and tridentate ON, ONN and ONO donating arylazo ligands and Mo(VI) 
and Cu(II) complexes derived from tetradentate ONNO donating salan ligands. Structures 
of some of the important transition metal (V, Ru, Ir, Mo and Cu) complexes are 
determined by single crystal X-ray analysis. Structure-reactivity relations are discussed 
and implications of structure determination on the design of new complexes using the 
structurally characterized compounds as precursors are elaborated. All the complexes 
described in this dissertation are characterized by various physico-chemical techniques 
such as elemental analysis, IR, UV-vis and NMR spectroscopy and ESI-MS. 
Electrochemical characterization of the complexes were studied by cyclic voltammetry. 
Biological activities particularly, DNA interaction, antiproliferative, insulin-mimetic and 
superoxide dismutase activity of the complexes and the magnetic exchange coupling 
interactions between the metal centers in bridged vanadium(IV) complexes were also 
studied. The subject matter of this dissertation is divided into seven chapters containing an 
the chemistry of V(IV), Ru(II) and Ir(III) ligated to azo ligands, and the Mo(VI) and 
Cu(II) salan complexes, followed by the concluding remarks and future scope of research. 
Chapter 1 is a literature survey and general introduction to the entire work described in 
the present dissertation and spells out the objectives of the thesis. The objectives of the 
works are placed at the end of the general introduction. The entire subject matter of this 
dissertation is organized in the consecutive chapters. 
Chapter 2 deals with the synthesis of ethoxido bridged divanadium(IV/IV) complexes 
[(VOL
1-3
)2(µ-OEt)][Et3NH] (1‒3) of three azo dyes, 2-(2′-carboxy-5′-X-phenylazo)-4-
methylphenol (H2L
1
, X = H; H2L
2
, X = NO2) and 2-(2′-carboxy-5′-Br-phenylazo)-2-
naphthol (H2L
3
), differing in the substituents of the phenyl ring, in order to discern their 
influence, if any, on the redox potentials, bio- and magnetochemistry of the complexes 
has been discussed. All the synthesized ligands and the vanadium(IV) complexes are 
successfully characterized by various physicochemical techniques, viz. elemental 
analysis, IR, UV‒vis and NMR spectroscopy, ESI-MS and cyclic voltammetry. Molecular 
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structures of [(VOL
1,3
)2(µ-OEt)][Et3NH] (1 and 3) have been determined by X‒ray 
crystallography. Antiferromagnetic exchange interaction was observed between the 
vanadium d
1‒d1 centers of the complexes and this phenomenon was also established by 
density fuctional theory (DFT) study. The complexes were also screened for their in vitro 
cytotoxicity against HeLa and HT-29 cancer cell lines and the results indicated that the 
synthesized azo functionalized vanadium(IV) complexes were cytotoxic in nature, with 1 
being the most potent against HeLa cancer cell line. 
Chapter 3 describes the synthesis of three new monooxidovanadium(IV), [V
IV
OL
1–3
2] (1–
3), and two new alkoxido bridged trioxidovanadium(IV), [V
IV
3O3(µ-OMe)3(µ3-
OMe)L
4,5
2] (4 and 5), complexes obtained upon reaction of 2–{(2–X)–diazo)}–4–
methylphenol (where X = benzo[1,3]dioxol–5–yl (HL1), phenyl (HL2) and 4-
methoxyphenyl (HL
3
)), 1–(2–(thiazol–2–yl)diazenyl)naphthalene–2–ol (HL4) and 2–(2–
(thiazol–2–yl)diazenyl)–4–methylphenol (HL5) with VOSO4.5H2O. The synthesized 
complexes were successfully characterized by elemental analysis, IR and UV-vis 
spectroscopy, ESI–MS and their redox properties analysed by cyclic voltammetry. 
Molecular structure of complex 4 has also been characterized by X-ray crystallography. 
The complexes (1−5) were screened for their cytotoxicity in MCF-7 cancer cell line. The 
insulin‒mimetic activity of 1−5 was probed on rat L6 myoblast cells. Insulin signaling 
mechanism of the complexes 2 and 4 was studied by immunoblot analysis for IRS˗1.  
Chapter 4 describes the reaction of 2-(arylazo)phenols (HL) with [Ru(PPh3)3Cl2] in 
ethanolic medium under basic conditions to afford two organometallic Ru(II) complexes, 
[Ru(PPh3)2L(CO)] (1) and [Ru(PPh3)2L(CH3CN)] (2). A similar reaction of HL with 
[Ir(PPh3)3Cl] results in formation of the organometallic Ir(III) complex, [IrL(PPh3)2(H)] 
(3). The 2-(arylazo)phenolate ligand is coordinated to the metal center in each complex 
(1‒3) as a tridentate C, N, O-donor via C‒H activation of the ligand. The sixth 
coordination site in the equatorial plane of 1‒3 is occupied by CO, CH3CN and H
‒
, 
respectively. The plausible solvent assisted mechanistic pathway for the unprecedented 
CO coordination to the Ru(II) center in the case of 1 has been explained. The synthesized 
complexes have been characterized by various spectroscopic techniques (viz., IR, UV-vis 
and NMR spectroscopy), ESI-MS and their electrochemical behavior studied by cyclic 
voltammetry. Molecular structures of 1‒3 have been determined by X-ray 
crystallography. 
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In Chapter 5 the synthesis and structural characterization of seven hexacoordinated cis 
dioxidomolybdenum(VI) complexes [MoO2L
17
] (17) derived from various substituted 
tetradentate diamino bis(phenolato) “salan” ligands containing ON donor atoms, have 
been discussed. The formation of cis-dioxidomolybdenum(VI) complexes was confirmed 
by elemental analysis, IR, UV-vis and NMR spectroscopy, ESI-MS and cyclic 
voltammetry measurements. Molecular structures of 16 were solved by X-ray 
crystallography. The complexes (1–7) were tested for their DNA binding and cleavage 
activity. In addition, the in vitro antiproliferative activity of 1–7 was studied against HT-
29 and HeLa cancer cells.  
In Chapter 6 the synthesis and characterization (elemental analysis, UV-vis spectroscopy 
and ESI-MS) of Cu(II) complexes ([CuL
1,2
] (1 and 2) and [CuL
3′,4′
]2 (3 and 4)) using 
tetradentate diamino bis(phenolato) “salan” ligands, have been discussed. The redox 
property of the complexes has been ascertained by cyclic voltammetry. Molecular 
structures of the complexes (1 and 3) have been determined by X–ray crystallography. 
While 1 and 2 have the expected square planar geometry, with the ligand coordinating to 
the metal center in the usual tetradentate fashion, an unprecedented ligand transformation 
occurs in the case of 3 and 4, leading to the formation of phenolato bridged Cu(II) dimeric 
complexes, [CuL
3′,4′
]2,  having an elongated octahedron structure. The organic 
transformation in the ligands (H2L
3 
and H2L
4
) has been mechanistically elucidated to be 
Cu(II) catalysed. In order to fortify the ligand transformation to be Cu(II) assisted, the 
corresponding Ni
II
, Fe
III
 and
 
Mo
VI
 complexes (5‒7) with the same ligand environment, 
were synthesized and characterized. The anomaly in the ligand backbone was however 
not observed in the case of other transition metal complexes (5‒7). In addition, the 
superoxide dismutase (SOD) activity of the Cu(II) complexes (1‒3) has also been 
investigated; the activity follows the order 3 > 1 > 2. Due to the deliquescent nature of 
[CuL
4′
]2
 
(4), its SOD activity could not be evaluated.  
Chapter 7 is a brief resume of the work embodied in this research work, followed by the 
scope for future research work. 
4 
 
 
 
 
 
 
 
Chapter 1 
 
 
 
 
 
Scope of the Present Investigation 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Chapter 1 
Scope of the present investigation 
Abstract: In this chapter the scope of the present investigation is delineated briefly along 
with the aim of the work. The chapter is divided into two sections. Section 1.1 deals with 
the reviews on transition metal complexes of aromatic azo ligands, while a review on 
transition metal complexes of salan ligands is discussed in Section 1.2. 
1.1. REVIEWS ON TRANSITION METAL COMPLEXES OF AZO LIGANDS 
The coordination behavior of transition metals with azo (–N=N–) ligands is of interest for 
their π-acidity, interesting coordination modes and molecular structures, dyes and 
pigmenting behavior, redox, photo-physical, catalytic and biological properties.
1-9
 These 
properties are attributed to the low lying π* orbitals of the azo functionality. Transition 
metal chelates incorporating arylazooximes,
5
 arylazophenols,
6
 arylazoimines,
7
 
alkylthioazobenzenes
8
 and sulfenylazobenzenes,
9
 are some of the notable examples. Azo-
compounds containing an imidazole moiety have been reported to have the potential to 
photoregulate biofunctions, such as gene–expression and enzymatic action.3b 
1.1.1. Vanadium complexes of azo ligands 
The coordination chemistry of vanadium attracts increasing interest due to the use of 
vanadium complexes as models for the biological functions,
10-13
 such as 
haloperoxidation,
14
 phosphorylation,
15
 insulin mimicking,
16-20
 nitrogen fixation,
21
 tumor 
growth inhibition and prophylaxis against carcinogenesis.
22 
A. Chakravorty et al. reported the chemistry of first structurally characterized O and N 
ligated VO
+3
 in variable valence V
IV
O(ONO)(NN) (Figure 1.1a) and V
V
O(ONO)(ON) 
(Figure 1.1b) families of azophenolato ligands and elucidated that such complexes 
incorporating the V
V
O
3+
 moiety are of special interest in the context of bromoperoxidase 
bioinorganic chemistry.
23
 Similar V
V
O
3+
 moiety containing mixed ligand vanadium(V) 
complex with tridentate 2-hydroxy-2'-carboxy-5-methylazobenzene and bidentate 
quinolin-8-ol was synthesized by the same group and the low temperature EPR 
parameters of its electrogenerated anionic complex were found to be close to those of 
reduced bromoperoxidase (low pH).
24 
In addition they also investigated the chemistry of 
mono and binuclear oxido V
V
, V
V
V
V
, and V
V
V
IV
 azophenolates (Scheme 1.1).
25 
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Figure 1.1a     Figure 1.1b 
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Scheme 1.1 
 
The formation of “bare” V(IV) complexes formed by tridentate (ONO) azo ligands was 
unambiguously proved in aqueous solution around the physiological pH and in the solid 
state by E. Garibba et al.
26
 DFT calculations were used to predict the structure (Figure 
1.2a) and 
51
V hyperfine coupling tensor A of the non-oxido species (Figure 1.2b). It was 
observed that the flexibility of the ligands resulted in an unsymmetric facial coordination 
with a geometry intermediate between the octahedron and the trigonal prism.
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Figure 1.2a      Figure 1.2b 
 
T. Ghosh et al.
27
 reported the synthesis of  mixed-ligand vanadyl(IV) and vanadyl(V) 
complexes derived from tridentate ONO donor azophenolalcoholate [viz., 2-hydroxy-2-
hydroxymethyl-5-methylazobenzene] and bidentate NO [viz., 8-hydroxyquinoline (Hhq)] 
or NN [viz., 2,2-bipyridine (bipy) and 1,10-phenanthroline (phen)] and reported their 
spectroscopic (Figure 1.3a and 1.3b) and electrochemical behavior. Further 
characterization revealed that they exist in two isomeric solid forms viz., monomers and 
polymers, whereas vanadyl(V) complexes exist only in the monomeric form. The azo 
complex synthesized was one of the first reported examples of hepta-coordinated 
alkoxido-bonded mixed-ligand oxovanadium(IV) complexes. 
          
 
Figure 1.3a      Figure 1.3b
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A series of V(IV) azosalophen complexes were synthesized by varying the ligand 
backbone and these were examined by S. Chattopadhyay et al.
28 
for their catalytic activity 
towards H2O2 induced oxidation of organic thioethers to sulphoxide and sulphones 
(Scheme 1.2). Further studies on the cytotoxicity of these azosalophen complexes of 
V(IV) on human lung cancer cells (A549) showed apoptotic pattern of cell death due to 
increase in hypoploid DNA increase in the cells (Figure 1.4a and 1.4b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.2 
 
  
   
Figure 1.4a       Figure 1.4b 
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1.1.2. Ruthenium and Iridium complexes of azo ligands 
S. Bhattacharya et al. had observed an unprecedented chemical transformation of               
2-(2,6-dimethylphenylazo)-4-methylphenol upon its reaction with differing Ru metal 
precursors.
29,30
 It was observed that when [Ru(PPh3)3Cl2] was employed as the starting 
material, one of the methyl group from the phenyl ring of the arylazo fragment migrated 
to the metal center via oxidation to CO, whereas upon its reaction with 
[Ru(PPh3)2(CO)2Cl2], the methyl group at the 2 position underwent migratation to the 
4or 6 position (Scheme 1.3). 
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N N
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Ru
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N
N
Ru
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O
N
N
Ru
PPh3
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CO
II
 
Scheme 1.3 
 
Chakravorty et al. isolated and structurally characterized the first azo anion radical 
complexes of ruthenium by the reaction of different substituted 2-arylazopyridine ligands 
with Ru(H)(Cl)(CO)(PPh3)3 (Figure 1.5a). Upon changing the metal precursor to 
RuCl3.3H2O and RuCl2(bpy)2, the resulting products were however observed to be of a 
different nature. The reaction of the corresponding 2-arylazoimidazoles with RuCl3 
yielded two isomers from the same reaction mixture with cis-trans-cis and trans-cis-cis 
configuration. With the change in configuration the redox and spectral properties (Figure 
1.5b) of the isomeric complexes also varied. It was also observed that a shift of 
Ru(III)/Ru(II) couple to more positive potential and blue shift of MLCT bands occurred 
on going from azoimidazole to azopyridine-ruthenium(II) complexes.
31 
 
10 
 
                      
 
Figure 1.5a     Figure 1.5b 
 
Ding et al. synthesized a series of Ru-azo complexes [(ε6-p-cymene)RuCl(L)] (L = 
azonaphthol/azophenyl group) and studied their catalytic activity in olefin isomerization 
(using allylbenzene and 1-octene as model substrates) (Scheme 1.4).
32
 These Ru 
complexes were highly specific for isomerization, without any dimerization or 
oligomerization and revealed that their catalytic activity for 1-octene strongly depends on 
the steric and electronic effects of the Ru environment. A noteworthy advantage of these 
catalysts is their inertness towards air and moisture, thus preventing a meticulous 
pretreatment.  
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Scheme 1.4 
 
Juan Xie et al.
33
 synthesized a series of photoswitchable arene ruthenium complexes 
containing o-sulfonamide azobenzene ligands (Figure 1.6) and found that they exhibit 
uncommon coordination pattern with an exocyclic N=N bond. These complexes undergo 
E→Z photoisomerization upon irradiation, followed by thermal Z→E isomerization (upon 
resting in the dark) (Figure 1.6), the rate being dependent on the solvent, nature of the 
arene group, sulfonamide moiety, and azobenzene substitution, as revealed by 
structure−property studies. 
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Figure 1.6 
 
C. Das et al. achieved regioselective para amination at three coordinated 2-
(phenylazo)pyridine ligands in [Ru(pap)3]
2+
 (Figure 1.7 and Scheme 1.5). They 
established the role of the mediator complex with respect to site selectivity of the 
amination reaction. Thus they established that for a labile complex, an ortho-fusion 
process is favored. This seems reasonable since prior coordination of an amine residue at 
the vacant site of the metal ion would bring it in close proximity to the ortho-CH of the 
pendent phenyl ring. In the absence of any such vacant site at the metal center, as it occurs 
in the case of a substitutionally inert mediator complex, ArNH2 cannot approach the 
ortho-carbon and hence fusion occurs only at the para-carbon. The generality of the 
fusion reaction was established by the use of different ArNH2 species. The aminated 
ligand HL2, thus formed, has both donor and acceptor chromophores and shows 
interesting optical as well as redox properties.
34
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Figure 1.7                                                        Scheme 1.5  
   
An interesting chemistry of Ir-azo complexes was observed by R. Acharyya et al., who 
had isolated and structurally characterized three different Ir(III) complexes in a single 
reaction using 2-arylazophenols, viz., [Ir(PPh3)2(NO-R)(H)Cl] (R = OCH3, CH3, H, Cl 
and NO2) (Figure 1.8a), [Ir(PPh3)2(NO-R)(H)2] and [Ir(PPh3)2(CNO-R)(H)] in ethanol 
medium, but the same ligand and metal precursor in toluene medium gave two C‒H 
activated products, [Ir(PPh3)2(CNO-R)(H)] and [Ir(PPh3)2(CNO-R)Cl] (Figure 1.8b).
35 
 
 
 
Figure 1.8a     Figure 1.8b 
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This work describes the synthesis and structural characterization of iridium(I)–carbonyl 
complexes of coumarinazoimidazoles, [Ir(CZ-X)(CO)(PPh3)2] derived from Vaska‟s 
complex (Figure 1.9a). The structural characterization shows a distorted square pyramidal 
geometry. The complexes exhibit emissions at room temperature and are redox active. 
DFT calculations revealed that the effect of the phenyl group is more prominent than that 
of the methyl group in the imidazole moiety to tune the energy of the HOMO to a 
significant extent and substantially reduce the energy gap between the HOMO and the 
LUMO (Figure 1.9b).
36 
 
 
 
Figure 1.9a     Figure 1.9b 
 
M. Panda et al. studied the isolation and characterization of bis-chelated Ir(III) and mixed 
ligand Ir(V) complexes of 2-arylazopyridines, obtained from the reaction of hydrated 
iridium(III) chloride (Figure 1.10a). Interestingly, the same ligand coordinates both as an 
anionic C, N-donor as well as a neutral N, N donor in the trivalent iridium complex. They 
further investigated the aromatic ring para-amination reaction of the coordinated ligand of 
the iridium complexes, which they proposed to have occurred via chloride substitution 
and reduction of the intermediate complex (Figure 1.10b).
37 
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 Figure 1.10a       Figure 1.10b 
 
1.2 REVIEWS ON TRANSITION METAL COMPLEXES OF SALAN 
(TETRAHYDROGENATED ANALOGUE OF SCHIFF BASE) LIGANDS 
Use of the salen ligand (Schiff bases(SB)) framework in transition-metal chemistry is 
well-documented, especially in the area of asymmetric catalysis,
38
 however, less common 
is the related salan (hydrogenated analogue of SB) complexes, which often display 
different structural conformation, due to greater flexibility as a consequence of C=N bond 
hydrogenation and increased N-basicity, which leads to different reactivity and 
selectivity.
39
 In contrast to the salen complexes, where the imine moiety is prone to 
decomposition in the presence of water, the higher resistance to hydrolytic decomposition 
of reduced SB compounds deserve special mention.
40 
 
1.2.1. Molybdenum complexes of salan ligands 
Dioxidomolybdenum(VI) complexes have a long standing and successful history in 
mimicking active sites of molybdenum containing enzymes, especially of the sulfite 
oxidase family.
41-46
 It has been known that the presence of sulfur atoms coordinated to 
molybdenum is favorable for complexes of molybdenum to have oxotransfer activity, and 
many model compounds that mimic such oxotransferases have been studied.
47–50 
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H. Yang et al reported the synthesis and characterization of a series of chiral salan-
Mo(VI) dioxido complexes (Scheme 1.6),
51
 which were the first optically active Mo(VI) 
dioxido complexes used in asymmetric reactions, particularly as precatalysts for the 
synthesis of chiral diols by enantioselective pinacol coupling of aryl aldehydes (Scheme 
1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.6 
 
C. J. Whiteoak et al. reported a series of molybdenum(VI) cis-dioxido complexes 
containing tetradentate salan ligands with different para-substitutions on the phenoxy 
group (Figure 1.11a) and studied their catalytic role in the oxygen atom transfer reaction 
between dimethylsulfoxide and triphenylphosphine.
52
 It was observed that during oxo 
transfer catalysis, the complexes were resistant to formation of catalytically inactive 
oxido-bridged dimeric Mo(V) complexes. Structure-activity correlations established by 
electrochemical behavior and Hammett correlations of the Mo(VI)-salan complexes 
showed a linear correlation between the E1/2 values and the Hammett σp parameter (Figure 
1.11b). 
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       Figure 1.11a      Figure 1.11b 
 
Lehtonen et al. synthesised monomeric Mo-salan complexes, [MoO2(ONNO
Me
)] and 
[MoO2(ONNO
tBu
)], derived from MoO2(acac)2 and the tetradentate ligands,                     
N,N
ʹ
-bis(2-hydroxy-3,5-dimethylbenzyl)-N,N
ʹ
-dimethylethane-1,2-diamine (H2ONNO
Me
) 
and N,Nʹ-bis(2-hydroxy-3,5-di-tert-butylbenzyl)-N,Nʹ-dimethylethane-1,2-diamine 
(H2ONNO
tBu
)
 
 respectively (Scheme 1.7) and studied their activity towards oxotransfer 
reactions between DMSO and benzoin or triphenylphosphine.
53
 They further studied the 
catalytic activity of the synthesized complexes in ring opening metathesis polymerization 
of norbornene, using a Et2AlCl. 
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Scheme 1.7 
 
N. C. Mösch-Zanetti et al. synthesized dioxidomolybdenum(VI) complexes with a cis-α 
configuration containing ligands with bipyrrolidine backbone, as efficient catalysts for 
olefin epoxidation (Figure 1.12).
54
 These bis-phenolate ligands were considerably more 
18 
 
stable and soluble than analogues compounds with a diazepane backbone with cis-β 
configuration.  
 
 
 
Figure 1.12 
 
1.2.2. Copper complexes of salan ligands: Copper, an essential element for most aerobic 
organisms is employed as a structural and catalytic cofactor, and is thus involved in many 
biological pathways.
55 
Copper forms diverse coordination complexes in oxidation states 
Cu(II) and Cu(I), and rare copper(III) compounds, with ligands of different hapticity, 
from monodentate to hexadentate, and characterized by different donor atoms (O, N, S, P, 
and C) which gave rise to different geometrical arrangements.
56
 
 
Synthesis of Cu-salan 
complexes have started as early as 1993,
57
 and developments in this field are still in 
progress.
58‒63 
 
P. Adão et al.
58
 evaluated the catalytic efficiency of optically active Cu(II)-salan 
compounds (Scheme 1.8) in sulfoxidation, alkene oxidation, and oxidative naphthol 
coupling. Their synthesized Cu(II) complexes undergo degradation by oxidative 
dehydrogenation of the ligand when in the presence of H2O2, as observed during the ESI-
MS experiments and also during EPR, CD and electronic absorption studies. They had 
also isolated and characterized the main oxidative dehydrogenation product the “half-
salen” variant. 
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Scheme 1.8 
 
CuI–[H4]salen-catalyzed asymmetric Henry reaction have been reported to deliver 
excellent enantioselectivities for aromatic, heteroaromatic, enal, and aliphatic aldehydes 
(Scheme 1.9). Predominantly, the Cu catalysts have been successfully applied to the 
synthesis of (S)-norphenylephrine, starting from commercially available m-
hydroxybenzaldehyde. Moreover the catalytic pathway is air tolerant and can be easily 
manipulated with readily available reagents.
59 
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Scheme 1.9 
L. Jia et al.
60
 studied the antitumor activity of three ternary dinuclear copper (II) 
complexes with a reduced Schiff base ligand and diimine coligands (Scheme 1.10), in 
vitro and in vivo. The DNA binding of these complexes occurs primarily through 
intercalative interactions and were found to reduce cell viability and induce apoptosis in 
human tumor cell lines HeLa, PC3, and HepG2 in a dose-dependent manner (Figure 
1.13). In addition, the complexes inhibited human tumor cell growth in vivo using a nude 
mouse xenograft model.   
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Figure 1.13 
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H. Hosseini et al.
61
 synthesized two new dimeric Cu(II) complexes bridged by phenoxide-
O atom using Cu(NO3)2·3H2O and salan ligands, N,Nʹ-bis(o-hydroxybenzyl)-1,2- 
diaminocyclohexane (H2[H4]L
1
); N,Nʹ-bis(o-hydroxybromobenzyl)-1,2-
diaminocyclohexane H2[H4]L
2
, and characterized them by spectroscopic techniques and 
determined their molecular structures by X-ray diffraction analyses (Figure 1.14a). 
Interestingly while H2[H4]L
1
 coordinates to copper centers as a monoanionic ligand in a 
tetradentate mode, [Cu(H[H4]L
1
)]2·2NO3·2H2O; H2[H4]L
2
 behaves as a dianionic ligand 
resulting in the formation of [Cu([H4]L
2
)]2·0.4H2O, via the O,N,Nʹ,Oʹ-donor atoms. The 
complexes also showed high catalytic activities with good-to-excellent selectivity in the 
oxidation of olefins, benzyl alcohol and ethyl benzene with H2O2 in acetonitrile (Figure 
1.14b). 
 
 
 
                            Figure 1.14a                                                     Figure 1.14b 
G. Zhang et al.
62
 structurally characterized square planar Cu(II) complexes from salan 
ligands, R,R-H21 (derived from cyclohexylamine and para-hydroxymethybenzoate). This 
ligand, R,R-H21, was further modified by hydrolysis of the pendant ester to carboxylic 
acid functionality R,R-H22. 2HCl. Resultant Cu(II) complex of the modified ligand was 
however a  distorted octahedron, where apart from the tetradentate ligand, the Cu(II) 
center was axially coordinated to the CO2H carbonyl units. They thus assembled a 
polymeric copper(II) complex of ligand R,R-H42 in a 2D coordination network    
[Cu(R,R-H22)]n, where the stacked sheets involved interdigitation of the cyclohexyl 
domains giving a porous architecture featuring carboxylic acid functionality.  Ball-stick 
22 
 
representation of an extended 2D network, stacked 2D sheets and space filling 
representation of the 3D stacking of sheets in [Cu(R,R-H22)] is given in Figure 1.15. 
  
 
Figure 1.15 
Early investigations in the coordination chemistry of Cu(II) tetrahydrosalen derivatives by 
Valko et al
63
 revealed that the loss of conjugation in coordinated tetrahydrosalens as 
compared to the salen derivatives, generate interesting electronic and magnetic properties. 
They observed that while the corresponding tetrahydrosalen type complexes, Cu[H4]L, 
and N,Nʹ-dimethylated tetrahydrosalen, Cu[H2Me2]L were air-stable at ambient 
temperature, the complex Cu(
t
Bu,Me)[H4]salphen [H2(
t
Bu,Me)[H4], (salphen = N,Nʹ-
bis(2-hydroxy-3-tert-butyl-5-methylbenzyl)-1,2-diaminobenzene) interacts with dioxygen 
and the ligand is thereby oxidatively dehydrogenated (–CH –NH– → –C=N–) to form 
Cu(
t
Bu,Me)[H2]salphen and finally, in the presence of base, is converted to 
Cu(
t
Bu,Me)salphen. It was seen that both factors, planarity and conjugation, are essential 
for the observation of distant hydrogen shf splitting in CuL. Due to the C=N bond 
hydrogenation, the coordination polyhedra of the complexes Cu[H4]L and Cu[H2Me2]L is 
more sensitive and flexible to ligand modification than that of CuL. Schematic 
representation of their work is presented in Scheme 1.11. 
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Scheme 1.11 
 
1.3. AIM OF THE PRESENT WORK 
The aim of the present work has been to study the synthesis and chemistry of variable 
valence V, Ru and Ir arylazo functionalised complexes and Mo and Cu salan complexes. 
All the synthesized ligand systems and their corresponding metal complexes are 
collectively summarized below (Scheme I‒VI): 
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1.4. THE MAIN OBJECTIVES OF THE PRESENT STUDY 
 
1. Molecular design and synthesis of several bi- and tridentate ON, ONO and ONN 
donating arylazo and tetradentate ONNO coordinating salan derivatives, and consequently 
develop mono and dibasic (O-N- donor) ligand systems. 
2. Develop versatile variable valence vanadium, ruthenium and iridium complexes of 
arylazo functionality as well as some Mo and Cu complexes, employing salan ligands, for 
use as reagents in some biological reactions, and analyze the magnetic properties of the 
paramagnetic species. This work uses synthetic and analytical approaches to generate and 
study the metal complexes, relying upon current mechanistic understanding of their mode 
of action. 
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3. Study of spectral and redox behavior of the synthesized metal complexes, solve 
their X–ray structure and develop the structure–reactivity correlation. 
4. Investigate the pharmacological properties (DNA interaction, insulin‒mimetic, 
antiproliferative and superoxide dismutase activity) of the synthesized complexes.  
5. Study of the magnetochemical behavior of paramagnetic metal complexes, 
particularly multinuclear vanadium complexes. 
6. Further evaluation of the magnetic properties by density functional theory (DFT) 
methods. 
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Chapter 2 
 
Magnetic exchange coupling interaction of µ–ethoxido bridged azo functionalized 
oxidovanadium(IV) dimeric anions: Synthesis, X–ray structure, characterization 
and cytotoxicity  
ABSTRACT 
________________________________________________________________________ 
The synthesis of ethoxido bridged dioxidovanadium(IV/IV) [(VOL
1-3
)2(µ-OEt)][Et3NH] 
(1‒3) complexes of three azo dyes, 2-(2′-carboxy-5′-X-phenylazo)-4-methylphenol (H2L
1
, 
X = H; H2L
2
, X = NO2) and 2-(2′-carboxy-5′-Br-phenylazo)-2-naphthol (H2L
3
), differing 
in the substituents of the phenyl ring, in order to discern their influence, if any, on their 
redox potentials, biological activity and magnetochemistry, has been discussed. All the 
synthesized ligands and the vanadium(IV) complexes have been successfully 
characterized by various physico-chemical techniques, viz. elemental analysis, IR and  
UV‒vis spectroscopy, ESI‒MS and cyclic voltammetry. Molecular structures of 
[(VOL
1,3
)2(µ-OEt)][Et3NH] (1 and 3) have been determined by X‒ray crystallography. 
Antiferromagnetic coupling interaction was observed between the vanadium d
1‒d1 centers 
of the complexes and this phenomenon was also established theoretically. The complexes 
were also screened for their in vitro cytotoxicity against HeLa and HT-29 cancer cell lines 
and the results indicated that the synthesized azo functionalized vanadium(IV) complexes 
were cytotoxic in nature, with 1 being the most potent against HeLa cancer cell line. 
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2.1. INTRODUCTION 
Potential biomedical applications of vanadium compounds with polydentate ligands in 
biological systems, especially its insulin enhancing action,
1
 anticancer efficacy,
1h,i,2
 and 
more recently in vitro antiamoebic activity against Entamoeba histolytica
3
 and 
antitrypanosomal activity against Trypanosoma cruzi
4
 have driven a substantial body of 
research. Vanadium as an ion occupies the active site metalloenzyme centers in 
nitrogenases
5
 and haloperoxidases
6
 and controls activation/inhibition of key metabolic 
enzymes in the biological environment.  
After successful accomplishment of phase I clinical trial in humans for the treatment of 
type 1 and type 2 diabetes mellitus,
7
 vanadium complexes are treated as the emerging 
class of agents that can show potent antitumor activity.
7a,8
 Therefore, development of new 
vanadium complexes with improved pharmacological activity is of current interest. 
Oxidovanadium containing compounds have been reported to suppress growth of 
malignant cells and the spread of tumors by limiting tumor cell proliferation and 
triggering apoptosis.
9-11
 There are a number of reports which have demonstrated that 
complexation of a ligand fragment to vanadium(IV) ion remarkably improved their 
antitumor and antioxidant properties,
12
 as in case of flavonoids,
13 
and in some substituted 
isoniazids.
14
 Recently studies are also going on to synthesize new oxidovanadium(IV) 
complexes that can act as an effective probe for photodynamic therapy (PDT).
15
 Despite 
promising results, a deeper understanding on their mode of action, as well as selectivity 
towards their biological target, remains the main focus of current research.  
In addition to their biological activities, there has been an ongoing interest in the magnetic 
exchange interactions of bridged di–, tri– and polynuclear vanadium complexes.16,17 This 
has been driven by the desire to design and produce molecular scale magnetic devices.
18-20
 
The magnetic properties of polynuclear transition–metal systems have also aroused 
substantial interest due to their relevance for the understanding of the function of 
metalloproteins, as well as their potential applications as magnetic materials.
21,22 
While, 
most dimeric oxidovanadium(IV) complexes exhibit an antiferromagnetic coupling,
23,24
 a 
few have also been reported to show strong ferromagnetic interaction.
25,21a,24f 
The 
contribution of Carrano et al is worth mentioning in this respect, since they presented the 
first X-ray crystallographic structural information for ligand derived dialkoxo bridged 
V(IV) dimer, which had then served to clarify the previously disparate 
36 
 
magnetochemistry.
21a
 Further analysis of temperature dependant (2–300 K) magnetic 
susceptibility measurements of solvent derived alkoxo bridging mixed ligand 
oxidovanadium(IV) dimers, was provided by Y. Sun et al.
24
 It is relevant to mention that, 
despite numerous investigations on the study of the magnetic coupling interaction of oxo 
and hydroxo bridged divanadium(IV) complexes,
25
 the magnetochemistry of the 
corresponding solvent derived alkoxo bridged divanadium(IV) complexes remains 
inadequately addressed.
24
 The variation of exchange coupling in hydroxido- and alkoxido- 
bridged dioxidodivanadium(IV) compounds has also been explained theoretically by 
Rodrίguez-Fortea et al.26 In order to explain this variation in a better way and to overcome 
the paucity in literature of solvent derived alkoxido bridged dinuclear vanadium(IV) 
complexes, further probe needs to be done. 
On the other hand, the coordination behavior of transition metals with azo (–N=N–) 
ligands is of interest for their π-acidity, interesting coordination modes and molecular 
structures, dyes and pigmenting behavior, redox, photo-physical, catalytic and biological 
properties.
27-35
 These properties are attributed to the low lying π* orbitals of the azo 
functionality. Transition metal chelates incorporating arylazooximes,
31
 arylazophenols,
32
 
arylazoimines,
33
 alkylthioazobenzenes
34
 and sulfenylazobenzenes,
35
 are some of the 
notable examples. Azo-compounds containing an imidazole moiety have been reported to 
have the potential to photoregulate biofunctions, such as gene–expression and enzymatic 
action.  
Over the past few years, we have been studying the chemistry of oxido–metal complexes 
including those of vanadium, in N,O–donor environments36 along with electro-generation 
of mixed-valence divanadium(IV,V),
36a,b
 and some highly stable nonoxido vanadium(IV) 
complexes.
1j,36f
 Our group has currently focused on synthesis of variable valence oxido–
vanadium complexes that mimic the coordination environment of the metal ions in 
enzymes, as well as enhances the pharmacological activities.
36c,d,e,g,h
 Herein we have 
extended our study to the syntheses of three tridentate binegative ONO containing arylazo 
ligands coordinated to vanadium(IV) metal center, thereby forming complexes of 
coordination type [(VOL
1-3
)2(µ-OEt)][Et3NH]. It is relevant to mention that, although, 
there are numerous reports on transition metal complexes with azo ligand functionality, 
but rather limited attention has been focused on the synthesis of vanadium coordinated azo 
complexes.
37
 The novelty of our synthesized complexes lies in the fact that these represent 
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the first examples of structurally characterized fully reduced arylazo containing stable 
bridged divanadium (IV, IV) complexes. The complexes have been further studied by 
other spectroscopic techniques (IR, UV‒vis and ESI–MS) and their redox properties 
studied by cyclic voltammetry. 
It is noteworthy, that, despite the interesting magnetic properties exhibited by solvent 
derived bridging divanadium(IV, IV) complexes, there remains a gap in literature 
concerning the study of the magnetic behavior of similar alkoxido bridged arylazo ligand 
coordinated vanadium(IV, IV) systems, which needs to be scrutinized further. So, herein 
we have tried to probe the variable-temperature (2–300 K) magnetic susceptibility 
measurements of the synthesized ethoxido bridged arylazo V(IV, IV) complexes. 
Temperature dependent magnetic susceptibility measurements and corresponding 
theoretical simulations reveal strong antiferromagnetism for complex 1 (J = –53.4cm-1) 
and 3 (J = –52.2cm-1). The experimental and calculated exchange coupling constants of 
these complexes are found to be rather similar, with slight differences in antiferromagnetic 
coupling due to the structural differences of the bridging ethanolate moiety. 
In addition, the antiproliferative activity of the dinuclear vanadium(IV) complexes (1‒3) 
was probed against human colorectal adenocarcinoma (HT-29) and human cervical cell 
line (HeLa). 
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2.2. EXPERIMENTAL SECTION 
2.2.1. General Methods and Materials.  
Chemicals were purchased from commercial sources and used without further 
purification. VOSO4.5H2O, p-cresol and β-naphthol were purchased from Loba Chemie. 
Anthranalic acid and its derivatives were purchased from Sigma Aldrich. Dulbecco‟s 
Modified Eagle Media (DMEM), Dulbecco‟s phosphate buffer saline (DPBS), Trypsin 
EDTA solution, Fetal Bovine Serum (FBS), antibiotic-antimitotic solution and MTT assay 
kit were purchased from Himedia, Mumbai, India. TRITC-Phalloidin and DAPI were 
procured from Sigma-Aldrich, India. HeLa and HT-29 cell lines were procured from 
NCCS, Pune, India. Elemental analyses were performed on a Vario ELcube CHNS 
Elemental analyzer. IR spectra were recorded on a Perkin-Elmer Spectrum RXI 
spectrophotometer. 
1
H 
 
and
 13
C NMR spectra were recorded on a Bruker Ultrashield 400 
MHz spectrometer using SiMe4 as an internal standard. Electronic spectra were recorded 
on a Lamda25, PerkinElmer spectrophotometer. ESI-MS were obtained on a SQ–300 MS 
instrument operating in both positive and negative ion ESI mode. Electrochemical data 
were collected using a PAR electrochemical analyzer and a PC-controlled 
Potentiostat/Galvanostat (PAR 273A) at 298 K in a dry nitrogen atmosphere. Cyclic 
voltammetry experiments were carried out with Pt working and auxiliary electrodes, 
Ag/AgCl as the reference electrode and TEAP as the supporting electrolyte. 
2.2.2. Synthesis of Ligands (H2L
1‒3
). The 2–(2–carboxyphenylazo)phenol  ligands were 
prepared by coupling substituted diazotized anthranilic acid with p-cresol (H2L
1
 and 
H2L
2), or β–naphthol (H2L
3
).
38
 The resulting red compounds were filtered, washed with 
ethanol and dried over fused CaCl2.  
Elemental analysis, NMR (
1
H and 
13
C) and IR data of the ligands confirmed their 
structures. 
H2L
1
. Yield: 64%. Anal. calcd. for C14H12N2O3: C, 65.62; H, 4.72; N, 10.93. Found: C, 
65.65; H, 4.72; N, 10.90. IR (KBr pellet, cm
–1): 3542 ν(O–H)b;1700 ν(C=O); 1594 
ν(N=N); 1409 ν(C–O)phenolic. 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 8.24 – 6.97 (m, 7H, 
aromatic), 2.36 (s, 3H, CH3). 
13
C NMR (100 MHz, CDCl3): δ (ppm) = 168.82 (C=O), 
151.96 – 116.27 (12C, aromatic), 20.37 (–CH3). 
39 
 
H2L
2
. Yield: 66%. Anal. calcd. for C14H11N3O5: C, 55.82; H, 3.68; N, 13.95. Found: C, 
55.82; H, 3.66; N, 13.97. IR (KBr pellet, cm
–1): 3510 ν(O–H)b; 1699 ν(C=O); 1590 
ν(N=N); 1402 ν(C–O)phenolic.
 1
H NMR (400 MHz, CDCl3, ppm): δ 8.67‒6.90 (m, 6H, 
aromatic), 2.39 (s, 3H, CH3). 
13
C NMR (100 MHz, CDCl3, ppm): δ 166.39 (C=O), 
152.61–118.05 (12C, aromatic), 20.34 (–CH3). 
H2L
3
. Yield: 64%. Anal. calcd. for C17H11BrN2O3: C, 55.01; H, 2.99; N, 7.55. Found: C, 
55.04; H, 3.01; N, 7.55. IR (KBr pellet, cm
–1): 3337 ν(O–H)b ;1698 ν(C=O); 1549 
ν(N=N); 1402 ν(C–O)phenolic.
 1
H NMR (400 MHz, CDCl3, ppm): δ 11.8 (s, 1H, –COOH), 
8.33‒7.21 (m, 10H, aromatic). 13C NMR (100 MHz, CDCl3, ppm): δ 169.12 (C=O), 
156.40‒118.60 (16C, aromatic). 
2.2.3. Synthesis of complexes, [(–OEt)(VIVOL1-3)2][Et3NH] (1–3). Triethylamine          
(100 mg, 1 mmol) was added to a hot ethanolic solution of H2L (1 mmol), followed by 
VOSO4.5H2O (253 mg, 1 mmol). After refluxing for 64 h, greenish black X–ray quality 
crystals of 1 and 3 were obtained directly from the reaction medium. However, X-ray 
quality crystals of 2 have not been isolated. 
[(VOL
1
)2(µ-OEt)][Et3NH] (1). Yield: 62%. Anal. calcd. for C36H41N5O9V2: C, 54.75; H, 
5.23; N, 8.86. Found: C, 54.75; H, 5.21; N, 8.82. IR (KBr pellet, cm
-1
): 1664 ν(C=O); 
1493 ν(N=N); 1373 ν(C−O)phenolic; 980, 966 ν(V=O)s; 829 ν(V–O–V). ESI–MS (CH3CN): 
m/z 811.58 [M ‒ Na]+; 827.59 [M + K]+.  
[(VOL
2
)2(µ-OEt)][Et3NH] (2). Yield: 57%. Anal. Calcd. for C36H43N7O13V2: C, 48.93; H, 
4.90; N, 11.10. Found: C, 49.05; H, 4.86; N, 11.15. IR (KBr pellet, cm
-1): 1656 ν(C=O) s; 
1589 ν(N=N); 1356 ν(C−O)phenolic; 985, 970 ν(V=O)s; 831 ν(V–O–V). ESI–MS (CH3CN): 
m/z 859.54 [M ‒ Na]‒; 880.56 [M ‒ 2H]‒. 
[(VOL
3
)2(µ-OEt)][Et3NH] (3). Yield: 66%. Anal. calcd. for C42H39Br2N5O9V2: C, 49.48; 
H, 3.85; N, 6.87. Found: C, 49.90; H, 3.87; N, 6.83. IR (KBr pellet, cm
-1
): 1677 ν(C=O)s; 
1502 ν(N=N); 1349 ν(C−O)phenolic; 992, 973 ν(V=O)s; 832 ν(V–O–V). ESI–MS (CH3CN): 
m/z 1019.60 (75%, [M
+
]); m/z 998.35(68%, [M – Na + 4H]+). 
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2.2.4. X-ray Crystallography. 
[(VOL
1
)2(µ-OEt)][Et3NH] (1): A suitable single–crystal was selected using a polarizing 
microscope and mounted on a 50 μm MicroMesh MiTeGen MicromountTM using 
FROMBLIN Y perfluoropolyether (LVAC 16/6, Aldrich) before centering on a standard 
Bruker Kappa APEX II CCD-based 4-circle X-ray diffractometer using graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) of a fine focus molybdenum-target X-
ray tube operating at 50 kV and 30 mA. Crystal was cooled to 100(2) K with a Kryoflex 
low temperature device. 
Initial unit cell parameters were obtained by least-squares refinement of the xyz centroids 
of strong reflections harvested from a series of 12 frames in each of three orthogonally 
related regions of the reciprocal space using the Evaluate routine of the APEX software 
suite.
39
 Final unit cell parameters were calculated at the end of intensity measurements 
from xyz centroids of 9664 well-centred reflections of the complete data set. Intensity 
data were collected via ω– and φ–scans in a range up to 2θ = 56° with scan widths of 0.5° 
and scan speeds of 3 sec/frame at a crystal to detector distance of 40 mm. Collecting 
strategy was optimized by use of the Collect routine of the APEX software suite in order 
to reach an average data redundancy of 10 or better in about 24 h. Information about 
crystal mosaicity, as well as its scattering behavior at higher θ values was derived from 
prescans for unit cell determination. Integrated intensities were obtained with the Bruker 
SAINT
40
 software package using a narrow-frame algorithm performing spatial corrections 
of frames, background subtractions, Lorentz and polarization corrections, profile fittings 
and error analyses. Semi-empirical absorption corrections based on equivalent reflections 
were made by use of the program SADABS.
41
 Details of the data collection parameters 
applied on the individual crystals are summarized in Table 2.1 with Rint = Σ|Fo
2
-
Fo
2(mean)|/Σ[Fo
2
] and Rsigma = Σ[(Fo
2)]/Σ[Fo
2
]. 
The centrosymmetric triclinic space group
42
 was determined from E-value statistics 
evaluated by the examine data routine of the APEX program suite and confirmed by 
successful refinement. Structure was solved by Direct Methods and subsequent difference 
Fourier syntheses of the program SHELXS
43
 and refined by full-matrix least-squares 
techniques on F
2
 with SHELXL.
44 
Atomic scattering factors were taken from International 
Tables for Crystallography.
45
 No extinction corrections were applied. Final agreement 
41 
 
indices: R1 = Σ||Fo| ‒ |Fc||/Σ|Fo| and wR2 = [Σ[w(Fo
2–Fc
2
)
2]/Σ(wFo
2
)
2
]]
1/2
. Weighting 
function used: w = 1/[2(Fo
2
) + (pP)
2
 + qP] with P = (Fo
2
 + 2Fc
2
)/3. Goof = [Σ[w(Fo
2–
Fc
2
)
2
]/(n–p)]1/2 where n is the number of reflections and p is the total number of 
parameters refined. All non-hydrogen atoms were refined with anisotropic displacement 
parameters, hydrogen atoms with common isotropic displacement parameters for 
chemically related groups of hydrogen atoms. 
Although the hydrogen atoms could be localised in difference Fourier syntheses, those of 
the organic groups were refined in geometrically optimized positions riding on the 
corresponding carbon atoms with C-H distances of 0.98 Å (–CH3), 0.99 Å (–CH2–),    
0.95 Å (CHarom) and 0.93 Å (R3N–H). Further details on the results of structure refinement 
are summarized in Table 2.1. 
Figures were drawn using DIAMOND
46
 and Mercury,
47
 respectively. In the ball- and stick 
models all atoms are drawn as thermal displacement ellipsoids of the 50% level with 
exception of the hydrogen atoms which are shown as spheres of arbitrary radii. Hydrogen 
bridging bonds are drawn in red as dashed sticks.  
[(–OEt)(VIVOL3)2][Et3NH] (3): Suitable single crystals were chosen for X-ray 
diffraction studies. Crystallographic data and details of refinement are given in Table 2.1. 
Data was collected at 22
o
C on a Nonius Kappa CCD FR590 single crystal X-ray 
diffractometer, Mo–radiation. Data collection was 98.9% complete to 25o in . A total of 
16045 partial and complete reflections were collected covering the indices, h = –11 to 11, 
k = –23 to 21, l = –20 to 23. The data was integrated and scaled using hkl-
SCALEPACK.
48
 This program applies a multiplicative correction factor (S) to the 
observed intensities (I) and has the following form:
2 22 (sin ) /S = ( ) / scaleBe    
S was calculated from the scale and the B factor determined for each frame and was then 
applied to I to give the corrected intensity (Icorr). The solution was achieved by direct 
methods (SHELXS, SIR97
49
) to produce a complete heavy atom phasing model that was 
consistent with the proposed structure. The structure was completed by difference Fourier 
synthesis with SHELXL97.
50,51
 Scattering factors were from Waasmair and Kirfel.
52
 
Hydrogen atoms were placed in geometrically idealized positions and constrained to ride 
on their parent atoms with C---H distances in the range 0.95–1.00 Å. Isotropic thermal 
parameters Ueq were fixed such that they were 1.2Ueq of their parent atom Ueq for CH's 
42 
 
and 1.5Ueq of their parent atom Ueq in case of methyl groups. All non-hydrogen atoms 
were refined anisotropically by full-matrix least-squares. 
 
Table 2.1. Crystal data and refinement details for [(VOL
1,3
)2(µ-OEt)][Et3NH] (1 and 3) 
Complex 1 3 
 
Formula 
 
C36H41N5O9V2 
 
C42H39Br2N5O9V2 
M (g mol
-1
) 789.62 1019.48 
crystal system Triclinic Triclinic 
space group P-1 P-1 
a (Å) 11.3507(7) 11.0675(5) 
b (Å) 12.1801(8) 12.2101(6)   
c (Å) 13.2000(8) 16.9540(8)   
 (°) 89.234(3) 93.516(2)° 
β (°) 89.231(3) 107.485(3)° 
γ (°) 89.799(3) 95.750(2)° 
V(Å
3
) 1824.6(2) 2164.12(18)   
Z 2 2 
dcalc (gcm
-3
) 1.437 1.565  
absorption coefficient (mm
-1
) 0.573   2.338   
Ɵ range for data collection (°) 2.87 to 28.00 2.20 to 25.35° 
F(000) 820 1028 
crystal size (mm
3
) 0.13 x 0.24 x 0.29 0.50 x 0.30 x 0.20 
max./min. transmittance 0.9019/0.8648 0.9875/ 0.8953 
2max (
o
) 28 30.5 
reflections collected 168645 16045 
unique reflections 8784 [Rint = 0.0738] 7824 [Rint = 0.0630] 
R1[I>2(I)], wR2   0.0308, 0.0783   0.0590, 0.1207 
R1[all data], wR2    0.0362, 0.0814 0.1419, 0.1535 
S[goodness of fit] 1.047 0.985 
peak, hole (e.Å
-3
) 0.447, -0.357 0.677, -0.653 
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2.2.5. Magnetic Susceptibility Study. Magnetic susceptibilities‟ data were obtained from 
powdered samples in gelatin capsules at 1000 Oe and 2000 Oe using a Quantum-Design 
MPMS-5 SQUID magnetometer equipped with a 5 Tesla magnet in the range from 2 to     
300 K. The data is corrected for the sample holder and the diamagnetic moment of the 
sample. The data was simulated using the MagProp package of DAVE (Data Analysis and 
Visualization Environment, www.ncnr.nist.gov/dave). For data calculation and graphics 
OriginPro 8.5 (OriginLab, Northampton, MA) was used. 
 
2.2.6. Computational details. The quantum chemical calculations were performed with 
the Turbomole package of programs (version 6.6).
53
 Geometries were taken from the 
crystallographic structures for which the position of the hydrogen atoms were energy 
optimized prior to single-point calculations. These optimizations were carried out using 
the gradient-corrected BP86 functional
54,55 
in combination with single-δ def2-SVP basis 
sets
56
 and the resolution of identity (RI) approximation.
57
 The magnetic exchange 
coupling constants were calculated within the model of a phenomenological Heisenberg-
Dirac-van Vleck Hamiltonian HHDVV = –J12S1S2 utilizing the broken-symmetry (BS) 
approach with the spin projection procedure suggested by Yamaguchi.
58
 Within this 
theory the coupling constant can be derived by Eq. 2.1. 
      
   BS   HS 
〈 HS
 〉 〈 BS
 〉
    Eq. 2.1 
Single-point calculations for the high-spin (HS) and broken-symmetry (BS) states 
have been performed with Becke‟s three-parameter hybrid functional54,59 for the exchange 
part and the correlation functional of Lee-Yang-Parr,
60
 together denoted as B3LYP. 
Additional BS-DFT calculations were employed with the meta-GGA hybrid functional 
proposed by Tao, Perdew, Staroverov, and Scuseria
61
 (denoted as TPSSh). In all 
calculations the triple-δ def2-TZVPP basis sets56 were used together with a tight SCF 
energy convergence criterion (10
–8
 a.u.).  
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2.2.7. Cytotoxicity  
Anticancer properties of vanadium(IV) complexes (1‒3) was tested against two different 
human cancerous cell lines namely HeLa (cervical cancer) and HT-29 (colon cancer) in 
vitro by MTT assay. Cells cultured in DMEM media with 10% FBS in a humidified (95% 
humidity) CO2 incubator (5% CO2) at 37 
o
C were harvested by trypsinization and were 
seeded into a 96-well plate at a concentration of 1 x 10
4
 cells/well. After 12 h of initial 
seeding, cells were treated with compounds (1‒3) for 48 h. For this purpose, five different 
concentrations (250, 100, 50, 10 and 5 μg/ml) of each compound prepared in complete 
DMEM media were used. Tissue culture plate (TCP) was taken as control. After 48 h, 
MTT assay was performed using a MTT assay kit following the manufacture's instruction. 
The relative viability of the cells after treatment was reported in terms of cell viability 
index as per Eq. 2.2 given below. All the experiments were performed in quadruplets and 
the data were expressed as mean ± S.D. Statistical significance of the data was evaluated 
using single variance ANOVA under 95 % confidence interval. 
 
                      
                                  
                                   
                                        Eq. 2.2 
 
IC50 value of the compounds was calculated from the absorbance-concentration plot 
following standard procedure.
62
 
Distribution of F-actin (cytoskeletal organization), shape of the nucleus and its structural 
integrity were examined using fluorescence microscopy (Olympus). In brief, at the end of 
the treatment, cells were washed gently with PBS and were fixed with 4% 
paraformaldehyde for 15 min. Cells were then subjected for permeabilization (0.25% 
Triton X-100 in PBS, 10 min exposure) and subsequently stained with TRITC-Phalloidin 
and DAPI.
63
 For this study, cells were treated with the compounds at a concentration of 
100 μg/ml for 36 h. 
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2.3. RESULTS AND DISSCUSSION 
2.3.1. Synthesis.  
Three 2–(2–carboxyphenylazo)phenol ligands have been employed in the present study 
for the synthesis of ethoxido bridged V(IV) dimeric complexes. Reactions of the azo dyes 
with VOSO4.5H2O proceeded smoothly in refluxing ethanol, and did not require dried 
solvents or an inert atmosphere. Complexes 1 and 3 are obtained directly from the 
reaction medium as greenish black color crystalline compounds in good yields, but single 
crystals of 2 have not been isolated. 
The synthesis of the complexes is summarised in Scheme 2.1. Elemental analysis 
confirmed the purity of the synthesized complexes. All the three complexes are highly 
soluble in aprotic solvents, viz. CH3CN, DMF or DMSO, while complex 1 and 2 are also 
partially soluble in protic solvents, viz., EtOH, CH2Cl2, and CHCl3 and sparingly soluble 
(1: 50% , 2, 40%; 3: 20%) in H2O. The complexes are stable in the solid as well as in the 
solution state for 24 h. The solution state stability was confirmed by time-dependent UV-
vis (Figure 2.1) spectroscopy.  
 
OHY
N N
O OH
X
R
VOSO4.5H2O
EtOH, Et3N
[(VIVOL1-3)2(µ-OEt)][Et3NH] (1-3)
(H2L
1, X = H, Y = Me, R = --)
(H2L
2, X = NO2, Y= Me, R = --)
(H2L
3, X = Br Y= --, R = Ph)
N
O
N
V
O
C
O
O
O
V
O
O
O N
N
C
O
H2C
CH3
NEt3
H
X
Y
X
Y
R
R
 
Scheme 2.1. Schematic representation for the synthesis of [(V
IV
OL
1-3
)2(-OEt)]
 
[Et3NH]    
(1‒3). 
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Figure 2.1. Time dependent UV–vis spectra of [(VIVOL1)2(-OEt)][Et3NH] (1) in DMSO. 
 
2.3.2. Spectral Characteristics 
2.3.2.1. IR Spectroscopy. The IR spectra of complexes (1−3) showed similar shift in 
wavenumbers compared to those of their respective ligands. Three bands are observed at 
~1700, ~1594 and ~1409 cm
-1
; these bands are attributed to the carboxylate (C=O), azo  
(–N=N) and C–O phenolic fragments, respectively, of the ligands.64 The observed shift in 
(ν(C=O)carboxylate) of the complexes below 1678 cm
-1
, as compared to the ligand 
(ν(C=O)carboxylate > 1697 cm
-1
) is attributed to complexation. The bands shift to lower 
frequency upon coordination to the metal center. The vanadium complexes show two 
additional strong and sharp bands of ν(V=O) in the 992–966 cm-1 region, which suggests 
presence of two V=O bonds in the complex, while the presence of a bridging O atom is 
indicated by a ν(V–O–V) stretching vibration at ~831 cm-1 in all the three 
complexes.
36a,b,65 
The representative FT-IR spectrum of [(V
IV
OL
3
)2(-OEt)][Et3NH] (3) is 
elucidated in Figure 2.2. 
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Figure 2.2. IR spectrum of [(V
IV
OL
3
)2(-OEt)][Et3NH] (3). 
 
2.3.2.2. UV–vis Spectroscopy. Electronic absorption spectra of complexes 1–3 were 
recorded in DMSO (Table 2.2) and a representative spectrum of 3 is shown in Figure 2.3. 
Three strong absorptions are observed in the wavelength range of 510–258 nm in the 
complexes. The lower energy absorption in the visible range, λmax = 510–503 nm in the 
complexes is assigned to ligand to metal charge transfer transitions,
36b
 while the bands in 
the higher energy UV absorption region (376–258 nm) are likely to be due to ligand 
centered transitions. The low intensity band in the near IR range (869–828 nm) is 
assigned to a d–d transition in the complexes. 
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Figure 2.3. UV‒vis spectrum of [(-OEt)(VIVOL3)2]
 
[Et3NH] (3). in DMSO. 
 
Table 2.2. UV–vis spectral data for [(-OEt)(VIVOL1‒3)2]
 
[Et3NH] (1–3) in DMSO 
 
Complex Wavelength (nm) (εmax (M
-1
cm
-1
)) 
 
[(-OEt)(VIVOL1)2][Et3NH] (1) 
 
275(11540) 
 
376(1560) 
 
510(7650), 
 
866(72) 
[(-OEt)(VIVOL2)2][Et3NH] (2) 258(11580) 356(1582), 509(7600), 828(70) 
[(-OEt)(VIVOL3)2][Et3NH] (3)  271(11531) 358(1500) 503(7000) 869(75) 
 
2.3.3. ESI–MS. ESI-MS of the complexes (1–3) were recorded in acetonitrile solution. 
ESI-MS of complex 1 shows major peaks at m/z 811.58 [M + Na]
+
 and 827.59 [M + K]
+ 
in the positive ion mode. Complex 2 exhibits two prominent peaks at m/z 859.54            
[M ‒ Na]‒ and 880.56 [M ‒ 2H]‒ whereas complex 3 shows the characteristic molecular 
ion peak [M]
+
 at m/z 1019.60 and another peak at m/z 998.35 [M ‒ Na + 4H] +. in the 
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negative ion mode. The ESI–MS data are summarized in the Experimental Section. ESI–
MS of the complexes (1–3) is depicted in Figure 2.4‒2.6.  
 
Figure 2.4. ESI–MS of [(VIVOL1)2(-OEt)][Et3NH] (1) in CH3CN. 
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Figure 2.5. ESI–MS of [(VIVOL2)2(-OEt)][Et3NH] (2) in CH3CN.  
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Figure 2.6. ESI–MS of [(VIVOL3)2(-OEt)][Et3NH] (3). 
 
2.3.4. Electrochemical Properties. The Cyclic Voltammetry (CV) of 1 and 2 were 
examined in CH2Cl2 solution and that of 3 in DMF (0.1 M TEAP) at a scan rate of 100 
mV s
–1
. The CVs are similar for 1–3, which include two oxidation and two reduction 
peaks corresponding to one electron transfer (Table 2.3). A representative CV of 1 is 
depicted in Figure 2.7. The anodic region of 1 shows one reversible and one quasi-
reversible single-electron wave at E
a
1/2 values 0.46 and 1.09 V, which are assigned to the 
V(IV)/V(V) oxidation of the individual metal centers.
66
 In the cathodic region each V(IV) 
is reduced to V(III) showing two quasi-reversible single-electron waves at E
c
1/2 values      
-0.59 and -1.36 V.
67
 In the anodic region of Figure 2.7 two quasi-reversible oxidation 
waves at E
a
1/2 1.26 and 0.82 V and a quasi-reversible wave in the cathodic region at E
c
1/2   
-0.94 V were observed due to ligand oxidation and reduction processes, respectively. The 
corresponding cyclic voltammogram of ligand, H2L
1
 is shown in Figure 2.8. 
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Table 2.3. Cyclic voltammetric results for [(V
IV
OL
1-3
)2(-OEt)][Et3NH] (1–3) at 298 K.
[a] 
 
Complex E
a
1/2(V) ΔE
a
P (mV) E
c
1/2(V) ΔE
c
P(mV) 
     
[(V
IV
OL
1
)2(-OEt)][Et3NH] (1) 0.46, 1.09 236, 70 -0.59, -1.36 220, 420 
[(V
IV
OL
2
)2(-OEt)][Et3NH] (2)  0.42, 1.05 240, 71 -0.56, -1.30 222, 418 
[(V
IV
OL
3
)2(-OEt)][Et3NH] (3) 0.45, 1.07 232, 73 -0.60, -1.32 225, 417 
 
[a]
1 and 2 in CH2Cl2 and 3 in DMF at a scan rate of 100 mV s
–1
. E1/2 = (Ep
a
 + Ep
c
)/2, where 
Ep
a
 and Ep
c are anodic and cathodic peak potentials vs. Ag/AgCl, respectively. ΔEP = Ep
a
 – 
Ep
c
. 
 
 
Figure 2.7. Cyclic voltammogram of [(V
IV
OL
1
)2(-OEt)][Et3NH] (1) in CH2Cl2. 
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Figure 2.8. Cyclic Voltammogram of H2L
1
. 
 
2.3.5. Description of X–ray crystallographic structure of                                            
[(-OEt)(VIVOL1,3)2][Et3NH] (1 and 3) 
Single crystal X–ray structure determinations revealed similar geometry and coordination 
environments for complexes 1 and 3. The ball and stick model of 1 and the ORTEP 
representation with atom numbering schemes of 3 are depicted in Figures 2.9 and 2.10, 
respectively. The selected bond parameters are given in Table 2.4. The asymmetric unit of 
both structures comprises of a dinuclear, monovalent anion, the charge of which is being 
balanced by a triethylammonium cation. The common feature of both anions is the 
presence of two five-fold coordinated vanadium atoms linked via the oxygen atom O(9) 
of an ethoxido ligand with bond angles of 104.04(4)° for 1 and 108.3(2)° for 3. 
Asymmetry of this bridge arises from the fact that the corresponding bond lengths fall into 
two categories: a short one to V2 (d(V–O) = 1.977(1) Å, 1; 1.961(4) Å, 3) and a longer 
one to V1 (d(V–O) = 2.023(1) Å, 1; 2.019(3) Å, 3). In each case, the coordination sphere 
of the vanadium atoms is completed by a tridentate ligand with a 2- charge ([O(1)/O(5) of 
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carboxyl group, [N(1)/N(3)] of azo group and [O(3)/O(7)] from phenoxido group) and a 
double bonded [O(4)/O(8)] oxygen atom resulting, to a first extent, in a square-pyramidal  
(τ(V1) = 0.15, τ(V2) = 0.25, 1; τ(V1) = 0.14, τ(V2) = 0.32, 3; with τ = 0 for a square-
pyramidal coordinated atom and τ = 1 for a trigonal-bipyramidal coordinated atom,68 
{VO4N}–coordination of these metal atoms with the double bonded oxygen atom in an 
apical position, a typical coordination geometry of vanadium(IV).
69 
While the vanadium 
oxygen distances to the apical oxygen atoms (d(V=O) = 1.594(1)/1.597(1) Å, 1; 
1.589(4)/1.587(5) Å, 3) correspond to vanadium oxygen double bonds, vanadium bonds 
to the organic ligand via single bonds of different strength. The strongest (shortest) ones 
are observed in case of the V(2)–O(7)phenoxide bond (d(V–Ophenoxido) = 1.922(1) Å, 1; 
1.919(4) Å, 3) while the corresponding bonds in case of V(1) are significantly longer 
(weaker) [d(V–Ophenoxide) = 1.945(1) Å, 1; 1.966(5) Å, 3]. In contrast, vanadium-oxygen 
bonds to the carboxylato groups are of similar length for both vanadium atoms (mean 
value of d(V–O)carboxylato = 1.963(6) Å) and of similar strength like the V(2)–Ophenoxide 
bonds. With the weakest bonds in the coordination sphere of the vanadium atoms found in 
case of the coordination of the azo group (N(1)/N(3): 2.050(6) Å, 3 – 2.096(1) Å, 1) and 
taking the vanadium ethoxido bonds into account the following order of bond lengths is 
realized: d(V–Oapical) < d(V(2) –Ophenoxide) < d(V(1)–Ophenoxide) ~ d(V–Ocarboxylate) < d(V–
Oethoxide) < d(V–Nazo).  
Due to a weak (d(V···O) = 2.344(1) Å, 1; 2.367(4) Å, 3) bonding interaction (Figure 2.11) 
of O(5) and V(1), the coordination sphere of V1 is expanded from five, square-pyramidal 
to six, distorted octahedral, generating a pseudo four˗membered, butterfly˗shaped 
(dihedral angle between V(1)–O(9)–O(5) and V(2)–O(9)–O(5) planes: 34.29(4)°, 1; 
31.1(2)°, 3) ring, responsible for the rectangular (96.20(8)°, 1; 85.5(2)°, 3) orientation of 
the two apical oxygen atoms, O(4) and O(8). In case of V2, a similar interaction seems 
possible to O3, but distance between both atoms is rather long (d(V···O) = 2.808(1) Å, 1; 
3.106(4) Å, 3). 
In the solid state, anion and cation are linked via a hydrogen bond between the 
carboxylate atom O(2) as acceptor and Et3NH as donor (Figure 2.11 and 2.12). In case of 
1, the corresponding donor acceptor distance of 2.752(2) Å and the angle of 173.8° at the 
hydrogen atom are in good agreement with a hydrogen bond of medium strength. It is 
interesting to see that these hydrogen bonded ion pairs interact with each other in a way 
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that the cation moiety of one ion pair is sandwiched in the pocket of the anion of a 
neighboring ion pair. The anions exist in a V-shaped conformation with the tridentate 
organic ligands forming both sides of the opening and the vanadium–oxido–ethoxido 
moiety as linking unit on the opposite side (Figure 2.13). There are, however, no other 
interactions between neighboring ion pairs than van–der–Waals ones (Figure 2.14). 
 
 
Figure 2.9. Asymmetric unit in the crystal structure of [(-OEt)(VIVOL1)2][Et3NH] (1) 
with the atom numbering scheme used. 
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Figure 2.10. ORTEP representation of [(V
IV
OL
3
)2(-OEt)][Et3NH] (3) with atom 
numbering. 
 
 
 
 
 
 
 
 
Figure 2.11. Central part of the anion of [(V
IV
OL
1
)2(-OEt)][Et3NH] (1) visualizing the 
weak interaction [broken stick] of O(5) with V(1) and the hydrogen bond between O(2) of 
the anion with the donor function of the ammonium ion [broken, red stick]. 
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Figure 2.12. Space-filling model of the hydrogen bonded ion-pairs found in the crystal 
structure of [(V
IV
OL
1
)2(-OEt)][Et3NH] (1). 
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Figure 2.13. Space-filling model representing the anion-cation interaction between two 
neighboring ion pairs in [(V
IV
OL
1
)2(-OEt)][Et3NH] (1); only the interacting parts of both 
ion pairs are shown. 
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Figure 2.14. Packing of ion pairs in the crystal structure of [(V
IV
OL
1
)2(-OEt)][Et3NH] 
(1) looking down the a axis; for a better understanding some ion pairs are drawn 
incompletely so that hydrogen bonds between the cation and anion become visible. 
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Table 2.4. Selected geometric parameters for [(V
IV
OL
1,3
)2(-OEt)][Et3NH] (1 and 3) 
 
 1 3 
Bond lengths(Å) 
V(1)‒O(9)/V(2)‒O(9) 2.023(1)/1.977(1) 2.019(3)/1.961(4) 
V(1)‒N(1)/V(2)‒N(3) 2.096(1)/2.089(1) 2.086(4)/2.050(6) 
V(1)‒O(1)/V(2)‒O(5) 1.970(1)/1.959(1) 1.965(4)/1.957(4) 
V(1)‒O(3)/V(2)‒O(7) 1.945(1)/1.922(1) 1.966(5)/1.919(4) 
V(1)‒O(4)/V(2)-O(8) 1.594(1)/1.597(1) 1.589(4)/1.587(5) 
O(5)‒V(1) 2.344(1) 2.367(4) 
 
Bond Angles(
o
) 
V(2)‒O(9)‒V(1)/V(2)‒O(5)‒V(1) 104.04(4)/93.82(4) 108.3(2)/96.0(2) 
O(4)‒V(1)‒O(1)/O(8)‒V(2)‒O(5) 103.87(5)/109.86(5) 101.8(2)/114.4(2) 
O(4)‒V(1)‒O(3)/O(8)‒V(2)‒O(7) 104.09(5)/110.02(5) 104.1(2)/110.9(2) 
O(4)‒V(1)‒N(1)/O(8)‒V(2)‒N(3) 96.36(5)/99.08(5) 97.1(2)/100.3(2) 
O(4)‒V(1)‒O(9)/O(8)‒V(2)‒O(9) 102.13(5)/104.72(5) 99.9(2)/105.3(2) 
O(1)‒V(1)‒O(9)/O(5)‒V(2)‒O(9) 89.09(4)/79.41(4) 91.6(2)/79.7(2) 
O(1)‒V(1)‒O(3)/O(5)‒V(2)‒O(7) 152.02(5)/140.12(5) 154.0(2)/134.6(2) 
O(1)‒V(1)‒N(1)/O(5)‒V(2)‒N(3) 89.65(4)/86.27(5) 88.7(2)/85.0(2) 
O(3)‒V(1)‒O(9)/O(7)‒V(2)‒O(9) 84.02(4)/90.49(4) 86.1(2)/90.9(2) 
O(3)‒V(1)‒N(1)/O(7)‒V(2)‒N(3) 88.37(5)/87.67(5) 86.2(2)/84.9(2) 
O(9)‒V(1)‒N(1)/O(9)‒V(2)‒N(3) 161.22(5)/155.25(5) 162.6(2)/153.8(2) 
O(1)‒V(1)‒O(5) 77.50(4) 78.5(1) 
O(4)‒V(1)‒O(5) 171.93(5) 169.2(2) 
O(3)‒V(1)‒O(5) 74.66(5) 76.5(1) 
O(9)‒V(1)‒O(5) 69.85(4) 69.3(1) 
N(1)‒V(1)‒O(5) 91.59(4) 93.7(2) 
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2.3.6. Magnetic Susceptibility Study. The magnetic properties of 1 and 3 were measured 
in the temperature range from 300 to 2 K (Figure 2.15). In case of complex 1 (Figure 
2.15(a)), at higher temperatures the χT value reaches 0.65 emu K mol  1, which is slightly 
lower than the spin only value for two independent S = 1/2 species with g = 2, as expected 
for early transition metals with g-values typically smaller than 2. With decreasing 
temperature the χT value decreases and reaches a plateau below 10 K. The data could be 
simulated using spin hamiltonian Ĥ =‒JŜ1Ŝ2 for two coupled S = 1/2 ions with an isotropic 
g = 1.935 and 6.5% of a mononuclear impurity with S = 1/2. Refinement of all parameters 
gives an antiferromagnetic coupling of J = ‒53.4 cm-1. While in case of complex 3 (Figure 
2.15(b)), at high temperatures the χT still has a constant slope which could be simulated as 
a temperature independent contribution (tic). With decreasing temperature the χT value 
decreases and reaches a plateau below 10 K. By fitting the data with the same model as for 
1 we obtain g = 1.932, J = ‒52.2 cm  1, 4.9% of a mononuclear impurity with S = 1/2 and a 
tic = 219 
.
10
-5 
emu/mol. However, the magnetic properties of 2 did not give convincing 
results. 
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(a) 
 
(b) 
Figure 2.15. (a) Magnetic behavior of complex 1. The data could be simulated with g = 
1.935, J = ‒53.4 cm  1 and 6.5% mononuclear impurity. (b) Magnetic behavior of complex 
3. The data could be simulated with g = 1.932, J = ‒52.2 cm  1, 4.9% mononuclear 
impurity and a tic = 219 10
  5
 emu/mol. In both (a) and (b) black squares: measured data 
(solid: T, open:), red line: simulation. 
 
2.3.7. Computational studies. Computational studies based on broken-symmetry density 
functional theory (BS-DFT) were performed to further investigate the magnetic properties 
of the dinuclear complexes 1 and 3. The structural parameters used for these calculations 
were derived from the crystallographic data. In these calculations two common density 
functionals (B3LYP and TPSSh) were employed, as they are known to reproduce 
properties of transition metal complexes.
70
 The energies of the high-spin (HS) and 
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broken-symmetry (BS) states together with their corresponding spin expectation values 
<S
2
> and the exchange coupling constants J12 derived from Eq. 2.1 for both complexes 1 
and 3 are summarized in Table 2.5. For 1 both BS-DFT calculated coupling constants of  
–55.1 cm-1 (B3LYP) and –55.9 cm-1 (TPSSh) are in good agreement with the 
experimental value of –53.4 cm-1. The situation is different for complex 3. The coupling 
constant of 3 derived from BS-DFT/B3LYP calculation is found to be –50.7 cm-1, which 
is in good accordance to the experimental value of –52.2 cm-1, whereas the calculations 
with the TPSSh functional gave a value of –41.5 cm-1, which significantly underestimates 
the experimental coupling constant. The latter result is somewhat unexpected, as the 
TPSSh density functional is reported to show promising performance in bioinorganic 
applications, including the prediction of the energy sequence of spin states.
71
 However, at 
least for the cases reported here, the B3LYP functional provides the better description for 
the energy splitting of the spin states, which might be due to the difference in the amount 
of exact Hartree-Fock exchange implemented in the B3LYP (20%) and TPSSh (10%) 
functional. Nevertheless, the experimental trend of a stronger antiferromagnetic coupling 
in case of 1 compared to 3 is reproduced with both functionals.  
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Table 2.5. Results of BS-DFT calculations for [(V
IV
OL
1,3
)2(-OEt)][Et3NH] (1 and 3) 
Complex Density Functional 
J12 
(cm
-1
) 
 State 
 Energy 
(a.u.) 
<S
2
> 
1 B3LYP –55.1 
 HS  –3942.247718 2.023310 
 BS  –3942.247844 1.020910 
1 TPSSh –55.9 
 HS  –3943.673995 2.021577 
 BS  –3943.674123 1.018236 
3 B3LYP –50.7 
 HS  –9317.717246 2.023223 
 BS  –9317.717362 1.020538 
3 TPSSh –41.5 
 HS  –9319.347309 2.021780 
 BS  –9319.347404 1.018305 
 
The classification of the geometry of the [VO(μ−OR)2VO]
2+
 core in dinuclear 
vanadium(IV) complex, which is based on the orientation of the V=O groups, generally 
allows at least for a qualitative assignment of the magnetic properties.
20a
 Although this 
classification was strictly proposed for dinuclear complexes with six-coordinate vanadium 
centers, it can also be basically applied for dinuclear complexes with five-coordinate 
metal centers in a square-pyramidal environment.
72
 Interestingly, for the complexes 1 and 
3 a mixed situation is observed as one of the centers is six-coordinate (V1) whereas the 
other shows a square-pyramidal coordination (V2). At first glance it might be tempting to 
assign for both complexes a twist configuration of the bridging [VO(μ−OR)2VO]
2+
 core, 
which could be expected to lead to an accidental orthogonality of the magnetic orbitals. 
However, this would clearly disagree with the antiferromagnetic coupling observed for 
both complexes. In fact, the tilting angles between the two V=O bonds significantly 
deviate from the accidental orthogonality with values of 59.3° for 1 and 68.0° for 3. This 
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is consistent with the spin density distribution calculated for the high-spin states of both 
complexes depicted in Figure 2.16 and 2.17. 
 
Figure 2.16. Spin density (green surface, iso value = 0.04) of the high-spin state of        
[(V
IV
OL
1
)2(-OEt)][Et3NH] (1) obtained with DFT/B3LYP. 
 
 
Figure 2.17. Spin density (green surface, iso value = 0.04) of the high-spin state of      
[(V
IV
OL
3
)2(-OEt)][Et3NH] (3) obtained with DFT/B3LYP. 
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On the other hand, a quantitative magneto-structural correlation reported for 
systems with so-called orthogonal configurations of the bridging [VO(μ−OR)2VO]
2+
 core 
(J = –A exp(–εR) with A = 2.22×10–11, ε = 6.9 and R given in Å)73 leads to predicted 
coupling constants of –79 and –47 cm-1 for complexes 1 and 3, respectively. This is in 
surprisingly good agreement with the observed experimental values, although a super 
exchange pathway via the bridging ethanolate oxygen atom is operative in 1 and 3 rather 
than a direct exchange between the magnetic orbitals at the vanadium centers. 
To further investigate the possible exchange mechanism we performed a natural 
population analysis (NPA)
74
 for complexes 1 and 3. Selected total density NPA charges of 
the two vanadium atoms V1 and V2 as well as the bridging ethanolate oxygen atoms 
O(Et) and O(Bz) can be found in Table 2.6. In addition, the corresponding NPA spin 
densities for 1 and 3 are summarized in Table 2.7. The following discussion solely refers 
to the values obtained from the BS-DFT/B3LYP calculations, as their results are in better 
agreement with the experiment and their counterparts derived from BS-DFT/TPSSh 
calculations show similar trends. Not surprisingly, in all cases the square-pyramidal 
coordinated vanadium center V2 shows the higher total charge due to its lower 
coordination number. For the bridging oxygen atoms O(Et) and O(Bz) no significant 
differences in total NPA charges are observed between 1 and 3 as well as between HS and 
BS states. The situation is different as the NPA spin densities for 1 and 3 are compared. 
For 1 a clear difference in spin density at oxygen atom O(Bz) is observed between HS 
(0.0079) and BS (–0.0107) states, whereas for the oxygen atom O(Et) rather similar 
values are found in both states (HS: 0.0092; BS: 0.0102). On the other hand, for 3 a 
generally larger distribution of spin density onto the bridging oxygen atom O(Et) in both 
spin states is observed, which goes along with a lower spin density on the vanadium(IV) 
centers. Moreover, there is an additional considerable increase of spin density at the 
bridging ethanolate oxygen atom O(Et) in 3 when going from the HS (0.0126) to the BS 
(0.0337) state, which is accompanied by a significant decrease of spin density at 
vanadium center V1 (HS: 1.0699; BS: 1.0226). On the contrary, only a slight change in 
spin density at oxygen atom O(Bz) is observed for 3 when both spin states are compared 
(HS: 0.0055; BS: –0.0044). Therefore, it is tempting to conclude the presence of a better 
overlap of the magnetic orbitals at the bridging O(Et) in complex 3. However, the 
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experimental and calculated exchange coupling constants of 1 and 3 are rather similar, 
with a slight trend to a somewhat larger antiferromagnetic coupling in the case of 1. This 
might be related to structural differences of the bridging ethanolate moiety in 1 and 3, i.e. 
the V1–O(Et)–V2 bonding angle (1: 104°; 3: 108°) and the out-of-plane distortion of the 
alkyl substituent at the bridging oxygen atom O(Et) (1: τ = 31.0°; 3: τ = 4.9°). Both 
parameters are known to have a prominent influence on exchange coupling in such 
dinuclear vanadium(IV) complexes.
26 
In fact, the larger angle observed for 3 should lead 
to a decrease of the antiferromagnetic coupling, whereas the smaller out-of-plane 
distortion found for 3 is expected to result in the opposite trend. Overall, this leads to a 
situation where both structural effects counterbalance each other.  
 
Table 2.6. Selected total densities derived from natural population analysis (NPA) for       
[(V
IV
OL
1,3
)2(-OEt)][Et3NH] (1 and 3) 
Complex Density Functional State  V1 V2 O(Bz) O(Et) 
1 B3LYP HS  1.2708 1.3109 –0.6832 –0.6926 
BS  1.2700 1.3097 –0.6829 –0.6913 
3 B3LYP HS  1.2636 1.3064 –0.6894 –0.6963 
BS  1.2628 1.3053 –0.6891 –0.6951 
1 TPSSh HS  1.2165 1.2606 –0.6684 –0.6770 
BS  1.2154 1.2592 –0.6681 –0.6758 
3 TPSSh HS  1.2104 1.2564 –0.6747 –0.6801 
BS  1.2091 1.2551 –0.6743 –0.6794 
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Table 2.7. Selected spin densities derived from natural population analysis (NPA) for       
[(V
IV
OL
1,3
)2(-OEt)][Et3NH] (1 and 3) 
Complex Density Functional State  V1 V2 O(Bz) O(Et) 
1 B3LYP HS  1.2708 1.3109 –0.6832 –0.6926 
BS  1.2700 1.3097 –0.6829 –0.6913 
3 B3LYP HS  1.2636 1.3064 –0.6894 –0.6963 
BS  1.2628 1.3053 –0.6891 –0.6951 
1 TPSSh HS  1.2165 1.2606 –0.6684 –0.6770 
BS  1.2154 1.2592 –0.6681 –0.6758 
3 TPSSh HS  1.2104 1.2564 –0.6747 –0.6801 
BS  1.2091 1.2551 –0.6743 –0.6794 
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2.3.8. Cytotoxicity Study 
Analysis of the in vitro cytotoxicity study clearly showed that all the three complexes are 
cytotoxic and can kill cancer cells effectively. The ligands and metal precursor showed 
significantly lower toxicity (IC50 values >100 µM) in both HeLa and HT-29 cancer cells, 
as compared to the divanadium(IV) arylazo complexes, 1‒3 (IC50 values: 1.92‒9.39 µM 
and 25.93‒28.77 µM against HeLa and HT-29 cells respectively, Table 2.8), indicating 
enhanced cytotoxicity upon complexation and the presence of the vanadium (IV) ion. The 
variation in potency was found prominent at very low concentration of the compound (up 
to 10 μg/ml). At relatively higher concentration of about 50 μg/ml, such variation become 
insignificant and there was 80% cell death with respect to the control for all the treatment 
sets irrespective of the cell type. No further increase in cell death was observed with an 
increase in concentration above 50 μg/ml. Among the three compounds, 1 showed 
maximum cytotoxicity (IC50 value 1.92 μM) followed by 3 (IC50 value 6.57 μM) and 2 
(IC50 value 9.39 μM) against HeLa cells. In the case of HT-29, although 3 showed highest 
cytotoxicity but the data was found statistically insignificant. Further analysis revealed 
that IC50 value of each complex was many fold less for HeLa cells in comparison to that 
of HT-29 cells, which indicates the specificity of a complex towards a particular cell type 
specific (Table 2.8).  
It is already known that during the course of their action on the cell, many of the cytotoxic 
agents disrupts nuclear integrity and cytoskeletal structure.
75,76 
These includes clinically 
active compounds like cisplatin
77
 (complexation of nucleic acid), doxorubicin
78
 
(intercalate nucleic acid), taxol
79
 (stabilize microtubule), vinblastin
80
 (prevent 
polymerization of microtubule), and other compounds like Jasplakinolide
81
 (enhance 
polymerization of actin) and cytochalacin
82
 (prevents polymerization of actin). Keeping 
this perspective in mind cells after treatment were stained with fluorescence dyes specific 
for nucleus (stained with DAPI, blue colored) and F˗actin (stained with TRITC 
Phalloidin, red colored) and investigated under fluorescence microscope and imaged 
(Figure 2.18). Preliminary inspection confirmed that for all the treatment sets, cell nuclei 
remain intact which ruled out the possibility of nuclear defragmentation. However, a 
critical analysis of the images revealed two very interesting points. In this study, we 
observed that although under the exposure of the compounds (100 μg/ml for 36 h) 
individual cells were able to maintain their cytoskeletal integrity, however, both HeLa and 
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HT-29 cells failed to form a colony. Such variation was more profound in the cells treated 
with 1 and 3. So far a number of cytotoxic compounds have been reported which 
effectively inhibit colony formation.
83‒85
 On the basis of this aforesaid fact, we 
hypothesize that these set of compound may possess similar property.
 
The higher potency of 1 can be explained in terms of relatively high π electron density of 
1 in comparison to 2 and 3. As 2 and 3 both are substituted with an electron withdrawing 
group (‒NO2 and ‒Br), it is expected that π electron density will be less for this molecule 
in comparison to 1 (substituted with ‒H). It is already well established that π electron 
density has a very important role in governing the interaction among physiologically 
relevant biomolecules.
86
 It is assumed that the higher π electron density of 1 is responsible 
for the greater receptor-ligand interaction and subsequent changes in cell physiology. 
However, π density factor does not play a role in the cytotoxicity in HT-29 cancer cells. 
Commonly used chemotherapeutic drugs like cisplatin, cyclophosphamide, tamoxifen and 
5-fluorouridine have shown comparable antiproliferative efficacy under similar 
conditions, against HT-29 and HeLa cells. The µ-ethoxido dinuclear arylazovanadium(IV) 
complexes (1‒3) have shown improved in vitro cytotoxicity results as compared to our 
earlier cytotoxicity reports on vanadium
36d,e,g,h
 and molybdenum hydrazone
87
 and copper 
thiosemicarbazone complexes
88
 (IC50: 10‒40 µM) against HeLa cells. The IC50 values of 
1‒3 are either lower or comparable to photocytotoxic oxidovanadium(IV) complexes of 
polypyridyl ligands
89
 (IC50 3.9‒16.2 µM) and curcuminoids
90
 (IC50 2.4‒10.9 µM). 
The cytotoxicity results of 1‒3 against HT-29 were comparatively lower as compared to 
the standard drug, cisplatin (IC50 12.2 μM), however their antiproliferative efficacy was 
better or comparable to other vanadium complexes (>47 µM against HT-29 for [VO(sal-
L-tryp)(acetylethTSC)].C2H5OH, [VO(sal-L-tryp)(Me-ATSC)] and [VO(salL-tryp)(N-
ethhymethohcarbthio)].H2O).
92 
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Figure 2.18. Cytotoxicity of [(V
IV
OL
1‒3
)2(-OEt)][Et3NH] (1‒3) against HeLa (A1) and 
HT-29 cells (B1) after 48 h exposure. The experiments were performed in quadruplets and 
the data were expressed as mean ± S.D. Morphology of HeLa (B1) and HT-29 (B2) cells 
treated with complexes (1‒3) for 36 h. Cells were stained with DAPI (Blue color – 
nucleus) and TRITC Phalloidin (Red color ‒ F-actin) and visualized under fluorescent 
microscope. 
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Table 2.8. IC50 values of [(V
IV
OL
1‒3
)2(-OEt)][Et3NH] (1‒3) and some reported drugs 
against HeLa and HT-29 cell lines 
 
IC50 (µM) 
Complex HeLa cells HT-29 cells 
[(V
IV
OL
1
)2(-OEt)][Et3NH] (1) 1.92 ± 0.26 28.77 ± 2.27 
[(V
IV
OL
2
)2(-OEt)][Et3NH] (2) 9.39 ± 0.95 27.28 ± 1.91 
[(V
IV
OL
3
)2(-OEt)][Et3NH] (3) 6.57 ± 0.55 25.93 ± 1.71 
Cisplastin 70 12.2 
Cyclophosphamide 21.5
 
 1689 
Tamoxifen  9.3 8.82 
5-Fluorouridine 0.3 2.85 
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2.4. CONCLUSION 
The following are the salient observations and findings of this work:  
(a) Three ethoxido bridged dimeric V(IV) complexes, [(VIVOL1‒3)2(‒OEt)][Et3NH] 
(1‒3), employing tridentate azo ligands (H2L
1‒3
) have been synthesized and characterized 
by various physicochemical techniques. Single crystal X–ray structures have been solved 
for 1 and 3.  
(b) Time dependent UV–vis spectroscopy studies in DMSO showed the presence of 
d–d transition peak even after 24 h, thus proving the stability of the compounds in the 
solution state. 
(c) Variable temperature magnetic susceptibility measurements and corresponding 
theoretical simulations of 1 and 3 show strong antiferromagnetic coupling, which are in 
good agreement with the theoretical values. However, magnetic properties of 2 did not 
give convincing results. 
(d) Cytotoxicity studies against human cancer cell lines, HeLa and HT-29, confirmed 
the antiproliferative effect of the complexes and their specificity over particular cell type. 
Even though all the complexes were found to be cytotoxic, complex 1 was the most potent 
amongst them.  
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Chapter 3 
 
Synthesis, structure and characterization of mono- and trinuclear 
oxidovanadium(IV) azo complexes: Study of antiproliferative and insulin‒mimetic 
activity 
 
ABSTRACT 
Three monooxidovanadium(IV), [V
IV
OL
1–3
2] (1–3), and two alkoxido bridged 
trioxidovanadium(IV) [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4,5
2] (4 and 5), complexes have been 
reported, which were obtained upon reaction of 2–{(2–X)–diazo)}–4–methylphenol 
(where X = benzo[1,3]dioxol–5–yl (HL1), phenyl (HL2) and 4-methoxyphenyl (HL3)), 1–
(2–(thiazol–2–yl)diazenyl)naphthalene–2–ol (HL4) and 2–(2–(thiazol–2–yl)diazenyl)–4–
methylphenol (HL
5
) with VOSO4.5H2O. The synthesized complexes were successfully 
characterized by elemental analysis, IR and UV–vis spectroscopy, ESI–MS and their 
redox properties studied by cyclic voltammetry. Molecular structure of 4 has been 
determined by single crystal X‒ray diffraction study. X‒ray structure showed the 
molecule to be composed of three slightly distorted octahedral vanadium atoms forming 
an almost butterfly-shaped V3O4 unit similar to the well-known 3Fe-4S iron sulfur cluster. 
The complexes were probed for their in vitro insulin-mimetic activity against insulin 
responsive L6 myoblast cells. The complexes (1−5) have been screened for their 
cytotoxicity in human breast adenocarcinoma cell line, MCF-7. The cyotoxicity of the 
complex is affected by the functional groups on the arylazo ligand backbone. IC50 values 
of the complexes were found to be comparable with some of the clinically referred 
chemotherapeutic drugs. The insulin-mimetic activity of 1−5 was probed on rat L6 
myoblast cells. The percent glucose uptake of the complexes was found to be significant 
as compared to insulin, where complex 2 (25 µM) proved to be most potent. In order to 
further confirm whether these compounds act via insulin signaling pathway, immunoblot 
analysis for IRS-1 was carried out.  
84 
 
3.1. INTRODUCTION 
Vanadium coordination chemistry with O−N oligodentate ligands has aroused continued 
interest ever since the presence of vanadium was unraveled in certain ascidians, Amanita 
mushrooms,
1
 and various enzymes,
2
 in addition to its interesting chemistry.  
Over the past few years, vanadium compounds have flourished as potent therapeutic 
agents for the treatment of malignancies.
3
 It is established that vanadium inhibits growth 
and the spread of tumors by suppressing the proliferation of tumor cells and inducing 
apoptosis, and also by limiting invasion and the metastatic potential of neoplastic cells.
4
 
Review of both the chemical and biological traits of the existing vanadoforms triggered 
the design of vanadium complexes to promote anticancer activity with effectiveness, 
selectivity and specificity.
5
 The ternary hybrid vanadium-peroxido-betaine species, 
{Na2[V2O2(O2)4{L}2]}n.4nH2O, L = Me3N(+)-CH2-COO(−), has been known to inhibit 
the Ras signaling pathway in a dose-dependent fashion and the downstream cancer marker 
MMP-2 in both MCF-7 and A549 cancer cell lines.
6
 
Moreover, the potential of inorganic vanadyl and vanadate, as well as some vanadium(IV) 
and (V) complexes as insulin mimics and possible alternative to insulin in the treatment of 
diabetes, is continuously being exploited.
7−20
 The discovery of the insulin mimesis of 
oxidovanadates(V),
21
 the oxidovanadium(IV) precursor, vanadyl sulphate,
22
 and the much 
more potent bis(ethylmaltolato)oxovanadium(IV) (BEOV) and 
bis(maltolato)oxovanadium(IV) (BMOV),
23
 which have completed phase II clinical 
trials,
24
 also stimulate the search for vanadium complexes which may have application in 
the treatment of type II diabetes.
25,26
 Attempts have been made to identify more potent 
and orally active organic vanadium complexes, and also to understand how structural 
differences in inhibitors for phosphatase translate to functional differences in alleviating 
the symptoms of diabetes.
27−30
 Although the said complexes have shown pharmacological 
advantages compared to the uncomplexed VOSO4.5H2O, further improvement in ligand 
design is needed, focusing on development of new vanadium complexes with increased 
potency and decreased toxicity.
31
 
In this respect, coordinating ligands with azo functionality could be utilized, considering 
the structural modifiability, the possibility of high environmental stability, and the 
diversity of electronic properties of azo transition metallic chelates.
32,33
 Furthermore, azo 
compounds are known to be involved in many biological reactions such as DNA and 
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RNA inhibition, and protein synthesis,
34,35
 in addition to its utility in the chemical 
industry.
36-39
 Besides the role of bis-azo compound, FP  21399, as potent anti-human 
immunodeficiency virus (HIV) agent,
40
 other pharmaceutical application of azo 
compounds, such as, site-specific drug delivery in colon diseases such as colitis and 
irritable bowel syndrome
41
 and antimicrobial activity against both gram positive and 
negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Proteus vulgaris, 
Staphylococcus aureus and Streptococcus pyogenes) and fungi species (Candida 
albicans)
42
 have also been explored. Interest in the synthesis of thiazole ring containing 
azo ligands stems from the extensive research of the pharmacological properties exhibited 
by compounds utilizing this heterocyclic moiety;
43
 for example, for the treatment of 
Parkinson's disease and also as anti-Alzheimer
44
 and anticonvulsant drugs.
45
 In addition, 
thiazole derivatives have also been explored for their antitumor and antidiabetic 
activities.
46,47
 -naphthol moieties are yet another important pharmacophoric cores of 
several anticancer, hypotensive and bradycardiac drugs.
48
 So, the combined effects of 
thiazole and -naphthol can be utilized to design new biological complexes of enhanced 
pharmacological utility. Again, while many azo complexes exhibit good biological 
activities, their aqueous solubility is still inadequate, which may restrict their application. 
Hence, synthesis of some new water–soluble transition metal complexes of azophenols 
appeared to be of interest, which may also have significant pharmacological effects.  
Considering the rarity in literature of alkoxido bridged V(IV) clusters using organic 
ligands, in addition to the possible applicability of vanadium(IV) and azo compounds in 
biology,
1-42
 as well as a continuation of our ongoing research on the study of 
pharmacological properties of transition metal complexes,
50
 herein we report the synthesis 
of some new water soluble vanadium(IV) mono-, [V
IV
OL
1–3
2] (13), and trinuclear, 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4,5
2] (4 and 5) complexes using bi- and tridentate azo ligands. 
It is noteworthy to mention that although coordination chemistry of the V
III51 
and mixed 
valence trinuclear vanadium cluster complexes
52
 are established, reports of structurally 
characterized homovalent trinuclear V
IV
 complexes remain limited.
53,54
 Though trinuclear 
V species with inorganic phosphonate and silsesquioxane bridging compounds have been 
isolated,
53
 fully reduced examples of such complexes using organic ligands remain 
scarce.
54
 The mono- and trioxidovanadium(IV) complexes were characterized by 
spectroscopic techniques, and further structural evidence for the formation of complex 4 
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was obtained by X-ray crystallography. The cytotoxicity of the complexes against MCF-7 
breast cancer cell line was assessed by the MTT assay. The insulin-mimetic activity of 
these complexes was investigated on immortalized rat skeletal L6 myoblast cell line and 
to further confirm whether these compounds act via insulin signaling pathway, the 
immunoblot analysis for IRS−1 molecule was also carried out.  
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3.2. EXPERIMENTAL SECTION 
3.2.1. General Methods and Materials  
Reagent grade solvents were dried and distilled prior to use. All other chemicals were 
reagent grade, available commercially and used as received. Commercially available 
TBAP (tetra butyl ammonium perchlorate) was properly dried and used as a supporting 
electrolyte for recording cyclic voltammograms of the complexes. MCF-7 (human breast 
adenocarcinoma cell line) was procured from NCCS, Pune. Penicillin, streptomycin, 
Dulbecco's modified Eagle's medium (DMEM), Fetal Bovine Serum (FBS) and insulin 
were purchased from Invitrogen (San Diago, CA, USA) and glucose estimation kit from 
Coral clinical systems. Rat L6 myoblast cell line was procured from NCCS, Pune. Anti˗β-
actin antibodies, HRP-conjugated secondary antibodies, bicinchoninic acid kit, ECL 
western blotting detection reagents and autoradiography films (Kodak) were purchased 
from Sigma. Anti-IRS1 antibody and phosphate buffered saline (PBS) were purchased 
from Life technologies.  
Elemental analyses were performed on a Vario ELcube CHNS Elemental analyzer. IR 
spectra were recorded on a Perkin−Elmer Spectrum RXI spectrometer. 1H NMR spectra 
were recorded with a Bruker Ultrashield 400 MHz spectrometer using SiMe4 as an 
internal standard. Electronic spectra were recorded on a Lamda25, PerkinElmer 
spectrophotometer. ESI‒MS were obtained on a SQ–300 MS and Thermo DSQ II 
instruments operating in both positive and negative ion ESI mode. Electrochemical data 
were collected using a PAR electrochemical analyzer and a PC−controlled 
Potentiostat/Galvanostat (PAR 273A) at 298 K in a dry nitrogen atmosphere. Cyclic 
voltammetry experiments were carried out with a Pt working electrode, Pt counter 
electrode and Ag/AgCl as reference electrode.  
3.2.2. Synthesis of Ligands (HL
1−5
) 
Azo ligands were prepared under stirring condition at a temperature below 5 
ο
C by diazo 
coupling of diazotized aniline or its substituted derivatives with p-cresol (HL
1‒3
) and 
coupling of diazotised 2-aminothiazole with β-naphthol (HL4) or p-cresol (HL5).55 The 
resulting compounds were washed with water and dried over fused CaCl2. Purified 
ligands were obtained by slow evaporation of the saturated ethanolic solution of the crude 
products.  
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HL
1
. Yield: 80%. Anal. Calc. for C14H12N2O3 (%): C, 65.62; H, 4.72; N, 10.93. Found: C, 
65.64; H, 4.70; N, 10.92. IR (KBr pellet, cm
–1
): 3542 υ(O‒H)b, 1549 υ(N=N).
1
H NMR 
(400 MHz, CDCl3, ppm): δ 12.56 (s, 1H, −OH), 7.70−6.06 (m, 6H, aromatic), 4.23 (s, 2H, 
‒O−CH2−O), 2.39 (s, 3H, −CH3). 
13
C NMR (100 MHz, CDCl3, ppm): δ 153.60−115.88 
(12C, aromatic), 101.02(−O−CH2−O), 24.30(−CH3). 
HL
2
. Yield: 88%. Anal. Calc. for C13H12N2O (%): C, 73.56; H, 5.70; N, 19.16. Found: C, 
54.77; H, 4.16; N, 19.20.
 
IR (KBr pellet, cm
–1
): 3337 υ(O‒H)b, 1544 υ(N=N). 
1
H NMR 
(400 MHz, CDCl3, ppm): δ 12.72 (s, 1H, −OH), 7.86−6.90 (m, 8H, aromatic), 2.37 (s, 3H, 
−CH3). 
13
C NMR (100 MHz, CDCl3, ppm): δ 150.63−117.86 (12C, aromatic), 20.32 
(−CH3). 
HL
3
. Yield: 85%. Anal. Calc. for C14H14N2O2 (%): C, 69.41; H, 5.82; N, 11.56. Found: C, 
69.45; H, 5.83; N, 11.58.
 
IR (KBr pellet, cm
–1
): 3330 υ(O‒H)b, 1542 υ(N=N). 
1
H NMR 
(400 MHz, CDCl3, ppm): δ 12.00 (s, 1H, −OH), 7.80−6.95 (m, 7H, aromatic), 2.50 (s, 3H, 
−OCH3), 2.32 (s, 3H, −CH3). 
13
C NMR (100 MHz, CDCl3, ppm): δ 162.90−115.88 (12C, 
aromatic), 55.00 (−OCH3), 19.91 (−CH3). 
HL
4
. Yield: 88%. Anal. calc. for C13H9N3OS: C, 61.16; H, 3.55; N, 16.46. Found: C, 
61.18; H, 3.58; N, 16.48. IR (KBr pellet, cm
–1): 3510 ν(O–H)b; 1504 ν(N=N); 1412 ν(C–
O)phenolic.
1
H NMR (400 MHz, CDCl3, ppm): δ 14.87 (s, 1H, OH), 8.55−6.97 (m, 8H, 
aromatic). 
13
C NMR (100 MHz, CDCl3, ppm): δ 172.82−109.50 (13C, aromatic). 
HL
5
. Yield: 70%. Anal. calc. for C10H9N3OS: C, 54.78; H, 4.14; N, 19.16. Found: C, 
54.77; H, 4.16; N, 19.15. IR (KBr pellet, cm
–1): 3337 ν(O–H)b, 1532 ν(N=N); 1419 ν(C–
O)phenolic.
 1
H NMR (400 MHz, CDCl3, ppm): δ 10.50 (s, 1H, OH), 8.05−6.97 (m, 5H, 
aromatic), 2.23 (s, 3H, −CH3). 
13
C NMR (100 MHz, CDCl3, ppm): δ 155.06−118.95 (9C, 
aromatic), 20.34 (−CH3). 
3.2.3. Synthesis of the complexes (1−5) 
 [VOL
1
2 ] (1): Triethylamine (100 mg, 1 mmol) was added to 15 ml methanolic solution of 
the ligand, HL
1 
(156 mg, 1 mmol) under refluxing condition. The reddish yellow turbid 
solution became clear upon addition of base, triethylamine. 1 mmol VOSO4.5H2O       
(252 mg, 1 mmol) was then added to the refluxing solution. The color changed to greenish  
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black after an hour of reflux. Reflux continued for 68 h. Greenish black amorphous 
residue was isolated upon filtration. Yield: 62%. Elemental analyses are satisfactory with 
the general formula C28H22N4O7V. Anal. Calc. for C28H22N4O7V (%): C, 58.24; H, 3.84; 
N, 9.70. Found: C, 58.23; H, 3.83; N, 9.71. IR (KBr pellet, cm
-1
): 1472 ν(N=N); 972 
ν(V=O). ESI−MS (CH3CN): m/z 577.52 [M]
+
. 
 
[VOL
2
2] (2): This complex was obtained as a greenish black amorphous residue, 
following the same reaction conditions as adopted for 1 using ligand, HL
2 
(212 mg,           
1 mmol). Yield: 60%. Elemental analyses are satisfactory with the general formula 
C26H22N4O3V. Anal. Calc. for C26H22N4O3V (%): C, 63.81; H, 4.53; N, 11.45. Found: C, 
63.80; H, 4.54; N, 11.44.
 
IR (KBr pellet, cm
-1
): 1481 ν(N=N); 980 ν(V=O). ESI−MS 
(CH3CN): m/z 489.11 [M]
+
. 
 
[VOL
3
2] (3): This complex was obtained as greenish black amorphous product following 
the procedure adopted for 1 using ligand, HL
3 
(242 mg, 1 mmol). Yield: 58%. Elemental 
analyses are satisfactory with the general formula C28H26N4O5V. Anal. Calc. for 
C28H26N4O5V (%): C, 61.20; H, 4.77; N, 10.20. Found: C, 61.21; H, 4.78; N, 10.21.
 
IR 
(KBr pellet, cm
-1
): 1482 ν(N=N); 984 ν(V=O). ESI−MS (CH3CN): m/z 549.51 [M]
+
. 
 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4): Dirty green crystalline residue was isolated upon 
filtration, following the procedure adopted for 1 using ligand, HL
4 
(255 mg, 1 mmol). 
Yield: 65%. Elemental analyses are satisfactory with the general formula 
C30H28N6O9S2V3. Anal. calc. for C30H28N6O9S2V3: C, 43.23; H, 3.39; N, 10.08. Found: C, 
43.26; H, 3.46; N, 10.02. IR (KBr pellet, cm
-1
): 1494 ν(N=N); 935, 916 ν(V=O), 837 
ν(V−O−V). ESI−MS (CH3CN): m/z 832.87 [M ‒ H]
+
. 
 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
5
2] (5): This complex was obtained as black amorphous 
product following the same synthetic procedure adopted for 1 using ligand, HL
2
 (1 mmol, 
219 mg). Yield: 61%. Elemental analyses are satisfactory with the general formula 
C20H16N6O6S2V2. Anal. calc. for C24H28N6O9S2V3: C, 37.86; H, 3.71; N, 11.04. Found: C, 
37.93; H, 3.79; N, 11.09.
 
IR (KBr pellet, cm
-1
): 1485 ν(N=N); 972, 933 ν(V=O); 854 
ν(V−O−V). ESI−MS (CH3CN): m/z 763.11 [M + 2H]
+
. 
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3.2.4. X-Ray Crystallography 
A black prism of complex 4 measuring 0.04 x 0.02 x 0.02 mm
3
, was mounted on a loop 
with oil. Data was collected at -173
o
C on a Bruker APEX II single crystal X-ray 
diffractometer, Mo-radiation. 
Crystal-to-detector distance was 40 mm and exposure time was 180 seconds per frame for 
all sets. The scan width was 0.5
o
. Data collection was 100 % complete to 25
o
 in . A total 
of 38402 reflections were collected covering the indices, -21<=h<=21, -27<=k<=27,         
-10<=l<=10. 6100 reflections were symmetry independent and the Rint = 0.1879 reflects 
the small sample size. Indexing and unit cell refinement indicated a primitive monoclinic 
lattice. The space group was found to be P 21/c (No. 14).  
The data was integrated and scaled using SAINT, SADABS within the APEX2 software 
package by Bruker.
56 
Solution by direct methods (SHELXS, SIR97)
57 
produced a complete heavy atom phasing 
model consistent with the proposed structure. The structure was completed by difference 
Fourier synthesis with SHELXL97.
58,59
 Scattering factors are from Waasmair and Kirfel.
60
 
Hydrogen atoms were placed in geometrically idealised positions and constrained to ride 
on their parent atoms with C---H distances in the range 0.95‒1.00 Angstrom. Isotropic 
thermal parameters Ueq were fixed such that they were 1.2Ueq of their parent atom Ueq for 
CH's and 1.5Ueq of their parent atom Ueq in case of methyl groups. All non-hydrogen 
atoms were refined anisotropically by full-matrix least-squares. Table 3.1 summarizes the 
data collection details. 
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Table 3.1. Crystal data and refinement details for [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4) 
Complex 4 
Empirical formula C30H28N6O9S2V3 
Formula weight 833.52 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P 21/c 
a (Å) 17.723(2) Å 
b (Å) 22.825(3) Å 
c (Å) 8.3250(12) Å 
 (°) 90° 
β (°) 100.411(10)° 
γ (°) 90° 
Volume 3312.2(7) Å3 
Z 4 
Density (calculated) 1.671 Mg/m3 
Absorption coefficient 1.019 mm-1 
F(000) 1692 
Crystal size 0.04 x 0.02 x 0.02 mm3 
Theta range for data collection 1.47 to 25.49° 
Index ranges -21<=h<=21, -27<=k<=27, -10<=l<=10 
Reflections collected 38402 
Independent reflections 6100 [R(int) = 0.1879] 
Completeness to theta = 25.00° 100.0 % 
Max. and min. transmission 0.9799 and 0.9604 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6100 / 0 / 455 
Goodness-of-fit on F2 1.008 
Final R indices [I>2sigma(I)] R1 = 0.0790, wR2 = 0.1517 
92 
 
R indices (all data) R1 = 0.1834, wR2 = 0.1898 
Largest diff. peak and hole 0.964 and -0.430 e.Å-3 
 
 
3.2.5. Cytotoxicity studies 
3.2.5.1. MTT assay 
MCF-7 cells were cultured in DMEM containing 10% FBS and penicillin (100 U/ml) and 
streptomycin (100 µg/ml) in a humidified 5% CO2 incubator at 37 
◦
C. The cytotoxicity 
was assayed by determining the viability of MCF-7 cells after treatment by MTT assay. 
Briefly, MCF-7 cells (10
5 
cells/well) were seeded in 96-well plates in DMEM containing 
10% FBS. After cells reached confluency, treatment was given with varying 
concentrations (5, 10, 25 and 50 µM) of the vanadium compounds. The compounds were 
dissolved in DMSO and working solutions were prepared by diluting the stock of 5 mM 
of each compound with plain DMEM. Final working concentration of DMSO in assay 
was less than 2%. Untreated cells were taken as 100% survival. After the treatment, 
medium was removed and cells were incubated with MTT (5 mg/ml) for 4 h. The crystals 
formed were dissolved in DMSO and absorbance was noted at 595 nm. IC50 was 
calculated for each compound by treating the cells for 48 h. 
 
3.2.5.2. Nuclear Morphology study using DAPI Staining 
DAPI (4,6-diamidino-2-phenylindole dihydrochloride) staining was performed to see the 
morphology of the nuclei after treatment. The cells were grown in the 96-well plate. After 
reaching approximately 90% confluency, the cells were treated with vanadium complexes 
at different concentrations (5, 10, 25 and 50 µM) and were incubated for 48 h. The cells 
were washed with PBS and fixed in 3.7% of formaldehyde for 15 min. Then the cells 
were treated with 0.2% triton−X 100 and 2% BSA in PBS for 30 s. The cells were stained 
with DAPI for 30 min in dark and imaged under fluorescence microscope (FLoid, Life 
technologies).  
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3.2.6. In Vitro Insulin-Mimetic Activity 
L6 myoblast were cultured in DMEM containing 10% FBS and penicillin (100 U/ml) and 
streptomycin (100 µg/ml) in a humidified 5% CO2 incubator at 37 
º
C. To differentiate 
myotubes, the myoblast cells (5 x 10
4
) were seeded in 24 well plates in DMEM containing 
2% FBS. The myoblast cells (5 x 10
4
) were grown for 11 days in 0.4 ml of 2% 
FBS/DMEM to allow the formation of myotubes. The medium was changed in every 2 
days. On the 10
th
 day cells were washed and incubated with plain DMEM containing      
25 mM glucose overnight to induce hyperglycemia.
61
 On the 11
th
 day, cells were 
incubated in Kreb‟s bicarbonate buffer (KRBB) for 2 h. Myotubes were further cultured 
in KRBB along with 25 mM glucose and 10, 25 and 50 µM of vanadium compounds 
(1−5) and VOSO4.5H2O for 4 h. The insulin (100 nM) was taken as positive control.
62
 
The buffer aliquots were collected at time 0 and 240 min. The residual glucose in the 
buffer aliquots remaining in each well after 4 h was estimated using glucose estimation kit 
(Coral systems, GOD/POD method). 
 
3.2.7. Immunoblot analysis 
3.2.7.1. Analysis of accumulation of IRS-1 in L6 myotubes in presence of vanadium 
complexes 
To confirm that the vanadium complexes exert their effect via activation of insulin 
signaling pathway, the immunoblot for IRS-1 was carried out in the cells. Briefly, L6 
myotubes were treated with 25 μM of 2, 10 μM of 5 or 100 nM insulin in presence of 
glucose. The cells were harvested at 0, 30, 60, 120, 180 and 240 min. After each time 
point, L6 myotubes were harvested and lysed in a lysis buffer (10 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate (SDS), 0.5 mM dithiothreitol, 1 mM PMSF) for 30 min at 4°C. The lysates were 
then sonicated for 10 s and centrifuged at 12,000 g for 15 min at 4°C. The protein 
concentrations of the supernatants were estimated using BCA assay and further used for 
immunoblotting. 
 
3.2.7.2. Immunoblot analysis for IRS-1  
Equal amounts of protein (25 μg/lane) and pre−stained molecular weight markers (life 
technologies) were separated onto 12% SDS−PAGE and transferred to nitrocellulose 
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membranes. The membranes were then incubated for blocking in 1% BSA in 
phosphate−buffered saline (PBS) for 1 h. After the incubation, the membranes were 
washed in PBS containing 0.1% Tween−20 and incubated with anti−IRS−1 or anti−actin 
antibodies overnight at 4°C respectively. The membranes were then washed in PBS 
containing 0.1% (v/v) Tween−20 for three times and incubated with 
horseradish−peroxidase−conjugated anti−rabbit IgG antibodies at a dilution of 1:5000 for 
1 h at room temperature. Immunoreactive bands were visualized using ECL Plus™ 
Western blotting detection reagents. 
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3.3. RESULTS AND DISCUSSION 
3.3.1. Synthesis.  
Herein we have reported the synthesis of three monooxidovanadium(IV) complexes (1‒3) 
and two discrete –OCH3 bridged trivanadium(IV) complexes (4 and 5) synthesized by 
the reaction of 2–{(2–X)–diazo)}–4–methylphenol (where X = benzo[1,3]dioxol–5–yl 
(HL
1
), phenyl (HL
2
) and 4-methoxyphenyl (HL
3
), 1‒(2‒(thiazol‒2‒
yl)diazenyl)naphthalene‒2‒ol (HL4) and 2‒(2‒(thiazol‒2‒yl)diazenyl)‒4‒methylphenol 
(HL
5
) with VOSO4.5H2O in equimolar ratios in methanolic medium. Schematic 
representation for the synthesis of the complexes is shown in Scheme 3.1 and 3.2. The 
compounds are soluble in CH3CN, DMF and DMSO and partially soluble in water, 
MeOH and EtOH. The structural formula of the complexes is based on elemental 
analyses, IR and UV–vis spectroscopy and ESI-MS, and single crystal X-ray diffraction 
analyses of 4. Complexes 1 and 3‒5 (1, 45%; 3, 60%; 4, 30% and 5, 80% H2O‒DMSO 
solution) were moderately soluble in H2O, while complex 2 was completely soluble. All 
the complexes were stable in both solid and solution phases. The solution phase stability 
of the complexes was confirmed by electronic absorption study. Time-dependent UV˗vis 
study of the complexes showed them to be stable in the solvent medium over a period of 
72 h. The representative time˗dependent electronic spectrum of (d−d transition peak) of 5 
in CH3CN is given in Figure 3.1.  
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Scheme 3.1. Schematic diagram of the synthesis of monooxidovanadium(IV) complexes, 
[V
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1-3
2] (1‒3). 
 
O
N
N
V
O
X
N
S
O
V
O
O
X
N
N
S
N
O
V
O
O
O
HO
N
N
N
S VOSO4.5H2O
Et3N, MeOH
[VIV3O3(µ-OMe)3(µ3-OMe)L
4,5
2]
(HL4; X = --, R = Ph)
(HL5; X = Me, R = --)
R
R
XR
 
Scheme 3.2. Schematic diagram of the synthesis of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4,5
2] (4 
and 5) 
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Figure 3.1. Time-dependent UV-vis spectra (d  d transition peak) of [VIVOL12] (1) in 
CH3CN solution. 
 
3.3.2. Spectral Characteristics 
3.3.2.1. IR spectroscopy. IR stretching frequencies of the ligands observed in the range 
of 1549−1504cm-1 is attributed to the presence of the azo(N=N) functional group,32,33 
which shifts to a lower frequency range of 1494−1472 cm-1 upon complexation (1−5). The 
presence of a strong band in the range 984−972 cm-1 for complexes 1−3 is attributed to 
V=O stretching which implies formation of a monooxidovanadium complex,
4
 while the 
presence of two strong and sharp peaks in the IR spectrum of 4 and 5 in the range 
972−916 cm-1 are consistent with a typical V=O stretching frequency, which indicates 
presence of symmetry in the molecule.
50b-e 
 A medium intensity stretching peak 854‒837 
cm
-1 
in the IR spectra of 4 and 5 could possibly be due to the V−O−V stretching in these 
complexes.
63 
Representative IR spectrum of 4 is presented in Figure 3.2. 
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Figure 3.2. IR spectrum of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4). 
 
3.3.2.2. UV-vis spectroscopy. The electronic spectra of the complexes were recorded in 
CH3CN medium. The main features of all the spectra are quite similar. The spectral data 
are summarized in Table 3.2 and the representative spectrum of 3 is shown in Figure 3.3. 
Three strong absorptions are observed in the wavelength range 378–216 nm. The lower 
energy absorption in this range
 
are possibly due to ligand to metal charge transfer 
(LMCT) transitions
64
 whereas the higher energy absorptions are likely to be ligand 
centered transitions.
65 
Low intensity peaks observed in the higher wavelength region, 
872−635 nm, are due to d−d transition in the complexes.64 
 
Table 3.2. UV–vis spectral data for complex 1–5 in CH3CN solution. 
 
Complex max (nm) (εmax (M
−1
cm
−1
)) 
[V
IV
OL
1
2] (1)  253(11540) 281(9853) 365(8542) 866(823) 
[V
IV
OL
2
2] (2)  259(11531) 284(10120) 380(9580) 864(767) 
[V
IV
OL
3
2] (3)  216(15030) 244(10420) 378(9920) 862(694) 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4)  260(11580) 390(7600) 635(700) 872(1582) 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
5
2] (5) 255(11531) 384(7500) 645(705) 857 (1500) 
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Figure 3.3. UV–vis spectrum of [VIVOL32] (3) in CH3CN solution. 
 
3.3.3. ESI–MS  
ESI–MS of complexes 1–5 have been recorded in acetonitrile solution in the positive ion 
mode. The base peak observed in the ESI–MS of 1, 2 and 3 is the characteristic molecular 
ion peak ([M]
+
) at m/z 577.52, 489.11 and 549.51 respectively. Mass spectral analysis for 
4 and 5, shows predominant peaks at m/z 832.87 and 763.11, which correspond to         
[4    H]+ and [5 + 2H]+ respectively. Results of mass spectrometry give strong evidence in 
favor of the formation of monooxidovanadium(IV) arylazo (1‒3) and µ-methoxido 
bridged trivanadium(IV) azo species (4 and 5), as proposed in Scheme 3.1 and 3.2. 
ESI−MS data are summarized in the „Materials and Methods‟ section. ESI−MS of 
complexes 1‒5 are shown in Figures 3.4‒3.7 respectively and their corresponding data are 
summarized in the Experimental Section.  
100 
 
0 
Figure 3.4. ESI-MS of [V
IV
OL
1
2] (1) in CH3CN: m/z 577.52 (100%, [M]
+
, MW = 
577.44). 
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Figure 3.5. ESI-MS of [V
IV
OL
2
2] (2) in CH3CN: m/z 489.11 (100%, [M]
+
, MW = 
489.42). 
 
 
 
Figure 3.6. ESI-MS of [V
IV
OL
3
2] (3) in CH3CN: m/z 549.51 (100%, [M]
+
, MW = 549.47). 
102 
 
 
 
Figure 3.7. ESI-MS of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4) in CH3CN: m/z 832.87 (100 , 
[M    H]+, MW = 833.52). 
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Figure 3.8. ESI-MS of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
5
2] (5) in CH3CN: m/z 763.11 (100%, 
[M + 2H]
+
, MW = 761.47). 
 
3.3.4. Electrochemical properties 
The cyclic voltammetry of 1–3 were recorded in CH3CN solution and that of 4 and 5 were 
performed in DMF solution (0.1 M TBAP) at a scan rate of 50 mV s
–1
 for 1–3 and 100 
mV s
–1
 for 4 and 5. The voltammogram pattern is similar for 1–3, which exhibits a single 
electron transfer reversible oxidation wave (V(IV)/V(V)) in the anodic region in the E
a
1/2 
range +0.21 to +0.18 V
66
 and one quasi-reversible reduction wave in the cathodic region 
at E
c
1/2 = –0.31 to –0.34 V ((V(IV)/V(III)).
67
 The CVs for 4 and 5 are similar, which 
include the three different redox couple corresponding to single-electron transfer in the 
three vanadium centers of the trinuclear complexes. The anodic region of 4 and 5 show 
104 
 
one quasi-reversible oxidation wave at E
a
1/2 value 0.26 and 0.22 V, respectively, which is 
assigned to the V(IV)/V(V) redox couple of one of the metal centers,
 
while the cathodic 
region depicts one quasi-reversible and another reversible V(IV)/V(III) couple at E
c
1/2 –
0.62 V and –1.50 V respectively.68  An irreversible oxidation wave for all the complexes 
is located in the +0.58 to +0.55 V range, which is attributed to a ligand centered process. 
The representative voltammogram of 1 and 4 are depicted in Figure 3.9 and 3.10 
respectively. The results are summarized in Table 3.3. The one–electron nature of this 
oxidation was verified by comparing its current height with that of the standard 
ferrocene–ferrocenium couple under identical experimental conditions.  
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(a) 
 
(b) 
Figure 3.9. Cyclic voltammogram of [V
IV
OL
1
2] (1) showing (a) oxidation (V(IV)→V(V)) 
and (b) reduction (V(IV)→V(III)) of the vanadium(IV) centre. 
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Figure 3.10. Cyclic voltammogram of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4) showing three 
redox couples for oxidation (V(IV) →V(V)) and reduction (V(IV) →V(III)) of the three 
vanadium(IV) centre. 
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Table 3.3. Cyclic voltammetric results for oxidovanadium(IV) complexes (1−5) at       
298 K.
[a] 
Complex E
a
1/2 (V) ΔEp
a
 
(mV) 
E
c
1/2 (V) ΔEp
c
 
(mV) 
 
[V
IV
OL
1
2] (1) 0.20 60 −0.34 110 
[V
IV
OL
2
2] (2) 0.18 70 −0.34 160 
[V
IV
OL)2] (3)  0.21 50 −0.31 120 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4) 0.26 470 −0.62, −1.50 134, 64 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
5
2] (5)  0.22 468 −0.63, −1.52 135, 65 
 
[a]
1‒3 in CH3CN at a scan rate of 50 mV s
-1
, 4 and 5 in DMF at a scan rate of 100 mV s
–1
. 
E1/2 = (Ep
a
 + Ep
c
)/2, where Ep
a
 and Ep
c
 are anodic and cathodic peak potentials vs. 
Ag/AgCl, respectively. ΔEP = Ep
a
 − Ep
c
. 
 
3.3.5. Description of X-ray crystallographic structure of                                  
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4)  
The trimeric structure of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4) has been demonstrated by X-
ray diffraction analysis. The selected bond lengths and angles of 4 are enlisted in Table 
3.4 and an ORTEP plot
69
 of the complex is shown in Figure 3.11. The molecule is 
composed of three slightly distorted octahedral vanadium atoms forming an almost 
butterfly-shaped V3O4 unit similar to the well-known 3Fe-4S iron sulfur cluster
70
 (Figure 
3.12a) where four alternate corners are occupied by four oxygen atoms of the ligands and 
other three alternate corners are occupied by the three V(IV) atoms (Scheme 3.12b). The 
linkage between the three vanadium atoms is obtained by four bridging methoxido 
groups. Three methoxides work as conventional three-center bridged (µ-OMe) ligands 
with oxygen donor atom bonding two metal centers. The VO distances formed with the 
apical and basal vanadium atoms are rather similar (ranging from 1.958(5) to 2.001(5) Å) 
and compare well with those observed earlier. The remaining methoxido group adopted a 
"tridentate" bonding mode (µ3-OMe) with the oxygen atom bridging the three metal 
centers [V1O4 = 2.124(5) Å, V2O4 = 2.192(5) Å and V3O4 = 2.206(5) Å].  
108 
 
All three vanadium atoms contain an oxido oxygen atom with an average V=O bond 
distance of 1.605 Å. The coordination of the apical vanadium atom (V1) is fulfilled by 
two iminyl nitrogen atoms (N1 and N4) of the two ligands, apart from the oxygen atoms 
of the oxido (O1) and bridging methoxido (O4, O5 and O7) groups, whereas for the 
terminal vanadium atoms (V2 and V3), the coordination is completed by the phenolic 
oxygen (O9/O8) and the azo nitrogen atoms (N5/N2) of each ligand separately (average 
V‒N distance 2.084 Å). The large bite angle of the bridging methoxido groups results in a 
basal to apical vanadium-vanadium (V1ˑˑˑˑV2 and V1ˑˑˑˑV3) distance of ~ 3.191(3) Å and 
basal to basal vanadium-vanadium (V2ˑˑˑˑV3) distance of ~ 3.303(3) Å, outside of the 
range for any possible metal-metal bonding. 
 
 
Figure 3.11. ORTEP diagram of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4) with atom 
numbering scheme. 
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      (a)                (b)  
Figure 3.12. Core structure of (a) 3Fe-4S cluster and (b) V3O4 unit of                
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4). 
 
Table 3.4. Selected bond parameters of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4) 
 
Bond lengths (Å) 
N(1)-V(1) 2.147(6) O(6)-V(3) 2.004(5) 
N(2)-V(3) 2.080(7) O(7)-V(1) 1.958(5) 
N(4)-V(1) 2.154(6) O(7)-V(2) 2.000(5) 
N(5)-V(2) 2.088(6) O(8)-V(3) 2.002(5) 
O(4)-V(2) 2.192(5) O(9)-V(2) 1.996(5) 
O(4)-V(3) 2.206(5) O(1)-V(1) 1.602(5) 
O(5)-V(1) 1.970(5) O(2)-V(2) 1.600(5) 
O(5)-V(3) 2.001(5) O(3)-V(3) 1.602(5) 
O(6)-V(2) 1.992(5) O(4)-V(1) 2.124(5) 
Bond angles () 
O(1)-V(1)-O(4) 172.5(3) O(7)-V(1)-O(4) 79.6(2) 
O(5)-V(1)-O(4) 80.2(2) O(1)-V(1)-N(1) 93.4(3) 
O(7)-V(1)-N(1) 160.0(2) O(5)-V(1)-N(1) 84.3(2) 
O(4)-V(1)-N(1) 81.1(2) O(1)-V(1)-N(4) 92.0(3) 
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O(7)-V(1)-N(4) 82.7(2) O(5)-V(1)-N(4) 162.6(2) 
O(4)-V(1)-N(4) 84.0(2) N(1)-V(1)-N(4) 100.6(2) 
O(2)-V(2)-O(6) 104.8(2) O(2)-V(2)-O(9) 97.5(3) 
O(6)-V(2)-O(9) 90.9(2) O(2)-V(2)-O(7) 95.8(2) 
O(6)-V(2)-O(7) 91.1(2) O(9)-V(2)-O(7) 165.5(2) 
O(2)-V(2)-N(5) 100.3(2) O(6)-V(2)-N(5) 154.7(2) 
O(9)-V(2)-N(5) 82.6(2) O(7)-V(2)-N(5) 89.5(2) 
O(2)-V(2)-O(4) 172.9(2) O(6)-V(2)-O(4) 75.73(19) 
O(9)-V(2)-O(4) 89.5(2) O(7)-V(2)-O(4) 77.1(2) 
N(5)-V(2)-O(4) 79.8(2) O(3)-V(3)-O(5) 96.1(2) 
O(3)-V(3)-O(8) 97.2(2) O(5)-V(3)-O(8) 165.2(2) 
O(3)-V(3)-O(6) 105.3(2) O(5)-V(3)-O(6) 92.3(2) 
O(8)-V(3)-O(6) 90.4(2) O(3)-V(3)-N(2) 99.5(3) 
O(5)-V(3)-N(2) 88.6(2) O(8)-V(3)-N(2) 82.9(2) 
O(6)-V(3)-N(2) 155.0(2) O(3)-V(3)-O(4) 173.7(2) 
O(5)-V(3)-O(4) 77.57(19) O(8)-V(3)-O(4) 89.0(2) 
O(6)-V(3)-O(4) 75.2(2) N(2)-V(3)-O(4) 80.6(2) 
 
 
3.3.6. Cytotoxicity studies 
3.3.6.1. MTT assay 
In the present study, antiproliferative efficacy of vanadium complexes with ON and ONN 
coordinating azo ligands (1−5) was assayed by determining the viability of MCF-7 cells 
using the MTT assay. The ligands HL
1−5 
and
 
VOSO4.5H2O gave high IC50 values of >200 
μM, whereas corresponding complexes 1−5 gave values in the range of ~51−14 μM after 
48 h of incubation period (Table 3.5). The standard anticancer drug, cisplatin, has been 
reported to have an IC50 value of 7.8 µM against MCF-7 cell line under similar 
conditions.
4,71
 The significant decrease in the inhibitory concentration for the ligands 
compared to the metal complexes clearly indicates that incorporation of vanadium in the 
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ligand environment has a marked effect on cytotoxicity. A possible explanation is that by 
coordination, the polarity of the ligand and the central metal ion are reduced through 
charge equilibration, which favors permeation of the complexes through the lipid layer of 
the cell membrane.
72,73
 The present results are consistent with the observation that metal 
complexes can exhibit greater biological activities than the free ligands.
74
  
 
Table 3.5. IC50 (µM) values of 1–5 and clinically referred drugs. 
 
 
 
 
 
 
 
 
 
 
The cytotoxic activity of the three complexes (1−5) follows the order 2  4> 5 > 3 > 1, 
which is reflected from their IC50 values (48 h) with dose dependency as illustrated in 
Figure 3.13. The graphical representation showing the percent cell viability of MCF-7 
cells after 24 h of treatment with increasing concentrations (5, 10, 25 and 50 µM) of 
vanadium complexes (1–5) is shown in Figure 3.14. The lower IC50 values of 2 as 
compared to the other complexes after 48 h may be attributed to its higher solubility in 
aqueous medium.
75
  
 
 
 
 
 
Complex 
 
IC50 (µM) 
48h 
[V
IV
OL
1
2] (1) 50.64 ± 2.45 
[V
IV
OL
2
2] (2) 13.82 ± 1.32 
[V
IV
OL
3
2] (3) 29.89 ± 1.94 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4)         13.90 ± 3.44 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
5
2] (5)         22.85 ± 2.48 
Cisplatin 7.8 
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Figure 3.13. Graph showing the percent cell viability of MCF-7 cells after 48 h of 
treatment with increasing concentrations (5, 10, 25 and 50 µM) of vanadium complexes 
(1–5). 
 
The IC50 values for complexes 2‒5 were smaller against MCF-7 cell lines as compared to 
some other oxidovanadium(IV) complexes reported (>50 M against MCF-7 for [VO(sal-
Gly)(bipy)], [VO(sal-Gly)(phen)], [VO(sal-L-Phe)(H2O)], [VO(sal-LPhe)(bipy)] and 
[VO(sal-L-Phe)(phen)],
67
 [VO(pyphen)(acac)](ClO4) reported in both light and dark 
conditions
75
 and vanadium complexes of di-2-pyridyl ketones.
76
 The solution stability of 
complexes 15 is of interest considering recent exploration by Reytmann et. al. on HT-29, 
ovarian OVCAR-1 cell, A2780 and A2780cis cell lines wherein they showed the high 
cytotoxicity of hydrolytically stable oxidovanadium compounds with ON donor 
ligands.
77,78
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Figure. 3.14. Graph showing the percent cell viability of MCF-7 cells after 24 h of 
treatment with increasing concentrations (5, 10, 25 and 50 µM) of vanadium complexes 
(1–5) and VOSO4.5H2O, in comparison to control. 
 
3.3.6.2. Nuclear Morphology study using DAPI Staining 
The effect of complexes on the nuclear morphology of MCF-7 cells was determined by 
staining dying cells with DAPI. The density of the DAPI stained nuclei was used to check 
the live cells in different treatment groups. Figures 3.15 and 3.16 show images taken after 
DAPI staining in blue fluorescence at different concentrations of 2 and 4. It can be seen 
from Figures 3.15 and 3.16 that the number of DAPI stained nuclei was reduced in treated 
wells with increasing concentrations of the complexes indicating the dose dependent cell 
death. Control cells hardly showed any sort of condensation in comparison to the test 
compounds‟ activity (as shown in Figure 3.17) when the cells were examined under a 
fluorescent microscope, with a DAPI filter. Figures 3.15 and 3.16 also show the grey scale 
images at 48 h of the representative complex 2 and 4, respectively, after the treatment 
with increasing concentrations of the complexes. All images clearly demonstrate the 
brightly condensed chromatin bodies and the nuclear blebbings (indicated by arrows in 
Figures 3.15 and 3.16) in treated cells compared to control cells. Besides showing nuclear 
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changes, the drug treated groups also revealed a shrinking morphology, which is another 
important hallmark of apoptosis.  
 
5M     10M   25M   50M 
    
 
     
 
Figure 3.15. Images taken after DAPI staining in blue fluorescence and the corresponding 
grey scale images at 48 h at different concentrations of [V
IV
OL
2
2] (2). Arrows showing 
the morphological changes in nuclei of MCF-7 cells observed on applying increasing 
concentrations (5, 10, 25 and 50 µM) of [V
IV
OL
2
2] (2) in comparison to control. 
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5M     10M                25M             50M 
    
    
Figure 3.16. Images taken after DAPI staining in blue fluorescence and the corresponding 
grey scale images at 48 h at different concentrations of [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] 
(4). Arrows showing the morphological changes in nuclei of MCF-7 cells observed on 
applying increasing concentrations (5, 10, 25 and 50 µM) of 4 in comparison to control. 
 
 
       
Figure 3.17. Images taken after DAPI staining in blue fluorescence and the corresponding 
grey scale image at 48 h after the treatment with control. 
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3.3.7. In Vitro Insulin-Mimetic Activity  
In this study, 1−5 were tested for their insulin-mimetic potential in an in vitro glucose 
uptake assay. In L6 myotubes, a cell line of skeletal muscle origin, glucose uptake in 
response to insulin stimulation plays a key role in whole body glucose homeostasis. 
GLUT4 is the major glucose transporter of muscle exquisitely regulated by insulin 
through post−translational events.79 The L6 myotubes differentiated from the L6 myoblast 
have the ability to respond to insulin via insulin receptor signaling and translocation of 
GLUT4 to the plasma membrane. 
In the present study, the hyperglycemic condition was created in cell culture by incubating 
the cells in 25 mM glucose. Table 3.6 summarizes the percent glucose uptake at 10, 25 
and 50 µM concentrations of 1−5 while the graphical presentation is shown in Figure 
3.18. The glucose uptake induced by insulin (100 nM) was considered as 100%. Complex 
2 (25 µM) was found to have considerable insulin-mimetic activity (256.14%). The        
10 µM concentrations of all the complexes showed insulin-mimetic activity comparable to 
that of insulin taken as positive control (1: 122.10%; 2:132.63%; 3:167.36%, 4: 135.44%; 
5: 197.89%; VOSO4.5H2O: 138.94%). Therefore it can be concluded that all the 
compounds have good insulin-mimetic property at 10 µM concentration. D. Rehder et al. 
have also reported some ON ligated vanadium compounds which are as effective as or 
more potent than insulin at concentrations of 10 µM and below.
9
 It has also been observed 
in the case of 1, 3‒5 and VOSO4, that with increasing complex concentration (10 to         
50 μM), there is a decrease in percent glucose uptake, while in case of 2 it increases from 
10 to 25 μM but again decreases upon increasing the concentration to 50 μM. There are 
literature evidences wherein it has been reported that in many species the linearity of 
percent glucose uptake is not maintained with increasing concentration.
80 
In the case of 2 
and 5 at 25 µM concentration, the enhancement of the insulin-mimetic activity with 
respect to the other synthesized complexes might be related to their different structural 
characteristics and extent of solubility in aqueous medium. The mechanism of insulin-
mimetic activity of the complexes has to be determined further. However, for vanadium it 
has been proposed that it can enhance insulin signaling most likely closely to its potent 
inhibition of PTPases of the insulin regulatory cascade. It has been reported that the 
exposure of cells to VOSO4 resulted in an increase in glucose uptake, insulin receptor (IR) 
and protein kinase B (Akt) phosphorylation and intracellular ROS generation.
81
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Our observed results are comparable or better than some of the recent reports on in vitro 
antidiabetic results of vanadium(IV) complexes.
82 
The glucose uptake activity of our 
reported complexes are comparable to bis(maltolato)vanadium(III)-polypyridyl 
complexes
14
 and also the nonoxidovanadium(IV) aroylhydrazone complexes
50a
 reported 
earlier. The difference in values may be attributed to the nature of compounds synthesized 
with different ligands. Thus it can be concluded that the reported vanadium complexes 
(15) have profound insulin-mimetic activity and can be considered as a possible 
treatment option for diabetes. 
 
Table 3.6. Percent glucose uptake at concentrations (10, 25 and 50 M) of 1–5, 
VOSO4.5H2O and Control as compared to 100% glucose uptake of insulin (100 nm). 
Complex Glucose Uptake (%) 
 
 10 M 
 
25 M 50 M 
[V
IV
OL
1
2] (1) 122.10 ± 0 
 
111.58 ± 7.27 76.49 ± 3.94 
[V
IV
OL
2
2] (2) 132.63 ± 7.87 
 
256.14 ± 1.88 73.68 ± 0.90 
[V
IV
OL
3
2] (3) 167.36 ± 9.54 
 
119.30 ± 0.30 112.28 ± 1.36 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
4
2] (4)         135.44 ± 2.81  
 
72.98 ± 4.65 55.79 ± 1.96 
[V
IV
3O3(µ-OMe)3(µ3-OMe)L
5
2] (5)         197.89 ± 4.54 
 
86.31 ± 2.11 67.37 ± 4.51 
VOSO4.5H2O 138.94 ± 5.50 
 
126.32 ± 2.42 20.34 ± 3.21 
Control 7.02 ± 10.29 
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Figure 3.18. Effect of vanadium complexes on glucose uptake in cultured L6 myotubes 
under high glucose conditions (25 mM Glucose). Three concentrations 10, 25 and 50 µM 
were tested for each complex. The data is represented as mean ± SD (n = 3).  
 
3.3.8. Immunoblot analysis 
From the glucose uptake study, it was found that complexes 2 (25 µM) and 5 (10 µM) 
have considerable hypoglycemic activity. Further the mechanism of action of 2 and 5 was 
studied in differentiated L6 myotubes. Thus to determine whether these compounds act 
via insulin signaling pathway, immunoblot analysis for Insulin receptor substrate-1 (IRS-
1) was carried out. IRS-1 is a cytoplasmic substrate molecule which is phosphorylated by 
insulin receptor when activated by insulin or insulin like molecules. It may mediate the 
control of various cellular processes by insulin. There was an increase in IRS-1 protein 
after the treatment with insulin as revealed by immunoblot. In presence of 2 and 5, it was 
found that IRS  1 accumulation was maintained at a constant level in the cytoplasm even 
after 240 min of treatment. The data indicates that complex 2 (25 µM) and 5 (10 µM) 
exerts their effect via the activation of insulin receptor. Thus, the immunoblot analysis 
shows that complexes 2 and 5 have considerable insulin-mimetic activity. Figure 3.19 
depicts the immunoblot analysis of IRS-1 after the treatment of differentiated L6 
myotubes with 2 (25 µM), 5 (10 µM) and insulin (100 nM). 
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Figure 3.19. Effect of vanadium complexes treatment on IRS-1 accumulation. The 
immunoblot analysis of IRS-1 after the treatment of differentiated L6 myotubes with A) 
Complex 5 (25µM); B) Insulin (100 nM); and C) Complex 3 (10µM). Lanes 1–6 show 
IRS-1 accumulations at 0, 30, 60, 120, 180 and 240 min after compound or insulin 
treatment respectively.  
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3.4. CONCLUSION  
Synthetic approach to monooxidovanadium(IV), [V
IV
OL
1–3
2] (1‒3) and trinuclear 
alkoxido bridged vanadium(IV), [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4,5
2] (4 and 5) complexes 
using azo ligands have been presented. The synthesized complexes were fully 
characterized by elemental analysis, IR and UV-vis spectroscopy and cyclic voltammetry. 
Further support for the formation of the trinuclear species was obtained from single 
crystal X-ray diffraction study, which revealed the molecule to be composed of three 
slightly distorted octahedral vanadium atoms forming an almost butterfly-shaped V3O4 
unit similar to the well-known 3Fe-4S iron sulfur cluster. The in vitro antiproliferative 
activity of the complexes against MCF-7 cancer cell line was assayed. The cytotoxicity of 
the complexes is affected by varying the substituent of the ligands, whereby 2 and 4 was 
particularly potent against the cells tested. The cyotoxicity of the complexes is affected by 
the functional groups attached to the thiazolylazo derivative. The results reported herein 
will inspire further work on oxidovanadium(IV)−azo complexes for the development of 
metal-based anti-cancer agents and future drugs for diabetes. IC50 values of the complexes 
were found to be comparable with some of the clinically referred chemotherapeutic drugs. 
In addition, the complexes were probed for their in vitro insulin-mimetic activity against 
insulin responsive L6 myoblast cells. The percent glucose uptake of the complexes was 
found to be significant as compared to insulin, where complex 2 (25 µM) and 5 (10 µM) 
proved to be more potent, possibly due to their greater aqueous solubility. Considering the 
high values of glucose uptake, the insulin signaling mechanism of 2 and 5 was studied by 
immunoblot analysis for IRS-1 molecule. Our observed results are comparable or better 
than some of the recent reports on in vitro antidiabetic results of vanadium(IV) 
complexes. 
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ABSTRACT 
________________________________________________________________________ 
Reaction of 2-(arylazo)phenols (HL) with [Ru(PPh3)3Cl2] in ethanolic medium under 
basic conditions affords two organometallic Ru(II) complexes, [Ru(PPh3)2L(CO)] (1)and 
[Ru(PPh3)2L(CH3CN)] (2). A similar reaction of HL with [Ir(PPh3)3Cl] results in 
formation of the organometallic Ir(III) complex, [IrL(PPh3)2(H)] (3). The 2-
(arylazo)phenolate ligand is coordinated to the metal center in each complex (1‒3) as a 
tridentate C, N, O-donor via C‒H activation of the ligand. The sixth coordination site in 
the equatorial plane of 1‒3 is occupied by CO, CH3CN and H
‒
, respectively. The 
plausible solvent assisted mechanistic pathway for the unprecedented CO coordination to 
the Ru(II) center in the case of 1 has been explained. The synthesized complexes have 
been characterized by various spectroscopic techniques (viz., IR, UV-vis and NMR 
spectroscopy), ESI-MS and their electrochemical behavior studied by cyclic voltammetry. 
Molecular structures of 1‒3 have been determined by X-ray crystallography. 
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4.1. INTRODUCTION 
Azo group is one of the most versatile active units, which depending on the chemical 
constitution in the molecule might be photochromic,
1
 proton-responsive,
2
 and redox 
active. Azo functionalized metal complexes have been designed, targeted at adjusting the 
properties by external stimuli to which the azo function responds.
3
 Being highly selective 
and sensitive toward the incorporation of various metal ions, the azo-type ligand is one of 
the most flexible ligands studied in coordination chemistry.  
Azo complexes of platinum group metals have largely been explored.
4
 The platinum 
group metal complexes of 2-(arylazo)pyridine ligand system have been the subject of 
substantial interest because of their rich redox and spectroscopic behavior, catalytic 
activities and isomerization reactions.
5,6,7
 Among the platinum group metals, ruthenium 
demonstrates versatile chemistry, considering the largest range of oxidation states from 
−II to +VIII shown by Ru, with most of the inorganic chemistry taking place in the +II 
and +III states.
8
 Ruthenium-based catalytic systems are found to be effective in the 
hydrogenation of ketones for the synthesis of chiral alcohols.
9 
Studies by Noyori and 
coworkers have shown that the transfer hydrogenation of prochiral ketones can be attained 
in high enantiomeric excess by tailoring the chiral ruthenium catalysts.
10
 On the other 
hand, complexes of iridium are also widely studied due to their application in different 
fields, viz. photocatalysis, photo-electrochemistry,
 
biological labeling and 
electroluminescence (EL).
11
  
C‒H and C‒C activation of ligands is an interesting feature observed in case of platinum 
group metal complexes.
12
 The C‒H activation of 2-arylazophenols by Wilkinson‟s 
catalyst, encouraged chemists to explore more platinum group metal azo complexes.
13
 
Therefore, in order to have further insight into the chemistry of arylazo complexes, we 
have herein reported the synthesis of some azo functionalized organoruthenium(II) (1 and 
2) and iridium(III) (3) complexes and characterized them using several physico-chemical 
techniques (elemental analyses, IR, NMR and UV-vis spectroscopy, ESI-MS and cyclic 
voltammetry), including single crystal X-ray diffraction study and have also compared 
their varying chemistry. Ru(II) complexes, 1 and 2, represent the major and minor 
products respectively, obtained from the same reaction. In addition to the C‒H activation 
in 1, another interesting feature is the unprecedented CO coordination to the Ru center. A 
suitable mechanism based on the decomposition of Grubbs metathesis catalysts and 
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alcohol dehydrogenation
14
 is proposed to understand the formation of the carbonyl 
coordinated bivalent ruthenium complexes as a major product. The source of CO group in 
previous literature evidences on CO coordinated Ru(II) arylazo complexes, was either the 
CO contained in the metal precursor,
12d,15
 or that obtained by the oxidation of the 
substituted alkyl groups.
16 
However to the best of our knowledge, there are no proposed 
mechanistic reports of organometallic CO coordinated arylazo ruthenium products 
wherein the CO generation could have been attributed to Ru(II) assisted solvent oxidation.  
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4.2. EXPERIMENTAL SECTION 
4.2.1. General Methods and Materials. Chemicals were purchased from commercial 
sources and used without further purification. Ruthenium trichloride and iridium 
trichloride was obtained from Arora Matthey, Kolkata, India. [Ru(PPh3)3Cl2]
17
 and 
[Ir(PPh3)3Cl]
4a
 were synthesized according to previously reported procedure. The 
synthesis of the ligand is reported as HL
1
 in Section. 3.2.2. Reagent grade solvents were 
dried and distilled prior to use. Elemental analyses were performed on a Vario ELcube 
CHNS Elemental analyzer. IR spectra were recorded on a Perkin-Elmer Spectrum RXI 
spectrophotometer. 
1
H and 
31
P NMR spectra were recorded on a Bruker Ultrashield 400 
MHz spectrometer using SiMe4 as an internal standard. Electronic spectra were recorded 
on a Lamda25, PerkinElmer spectrophotometer. Mass spectra were obtained on a SQ–300 
MS instrument operating in positive ion ESI mode. A CH-Instruments (Model No. 
CHI6003E) electrochemical analyzer was used for cyclic voltammetric experiments with 
CH3CN solutions of the complexes containing TBAP (tetra butyl ammonium perchlorate) 
as the supporting electrolyte. The three electrode measurements were carried out at 298 K 
with a platinum working electrode, platinum auxiliary electrode and SCE as a reference 
electrode. Caution: Although no problems were encountered during the course of this 
work, attention is drawn to the potentially explosive nature of perchlorates.  
 
4.2.2. Synthesis of complexes (1‒3) 
Synthesis of [RuL(PPh3)2(CO)] and [RuL(PPh3)2(CH3CN)] (1 and 2) 
2˗{(2˗benzo[1,3]dioxol˗5˗yl)˗diazo)}˗4˗methylphenol (100 mg, 0.1 mmol) was dissolved 
in ethanol (50 mL) and refluxed for 10 min, followed by addition of triethylamine (22 mg, 
0.22 mmol) and [Ru(PPh3)3Cl2] (100 mg, 0.1 mmol). The resulting solution was refluxed 
in a nitrogen atmosphere for 24 h to yield a brown solution. The solvent was evaporated, 
and the solid mass, thus obtained, was subjected to purification by thin-layer 
chromatography on a silica plate. With 10:1.5 benzene-acetonitrile as the eluent, two 
prominent bands, a dark green and a brown band separated, and the corresponding 
materials were extracted separately with acetonitrile. Evaporation of these acetonitrile 
extracts gave [RuL(PPh3)2(CO)] (1) and [RuL(PPh3)2(CH3CN)] (2) as green and brown 
colored crystalline solids respectively. 
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[RuL(PPh3)2CO] (1): Yield: 40%. Anal. calc. for: C, 66.30; H, 4.58; N, 4.55. Found: C, 
66.36; H, 4.53; N, 4.61. Main IR peaks (KBr, υ/cm–1): 1936 υ(CO); 1478 υ(N=N); 1238 
ν(C‒O)phenolic, 750, 691, 519 υ(3P‒Ph). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 7.71 and 
7.15‒6.91 (m, 5H, Ar‒H); 7.36‒7.18 (2PPh3); 6.09 (s, 2H, O‒CH2‒O); 2.39 (s, 3H, 
ArCH3). 
31
P NMR (CDCl3) δ (ppm): 33.97.  
 
[RuL(PPh3)2(CH3CN)] (2): Yield: 20%. Anal. calc. for: C, 67.82; H, 4.71; N, 4.56. Found: 
C, 67.78; H, 4.73; N, 4.51. Main IR peaks (KBr, υ/cm–1): 2212 υ(CH3CN); 1487 υ(N=N); 
1245 υ(C‒O)phenolic; 749, 690, 516 υ(3P‒Ph). 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.59‒
6.81 (m, 35H, aromatic); 5.90 (s, 2H, O‒CH2‒O); 2.35 (s, 3H, ArCH3); 1.96 (s, 3H, 
CH3CN). 
31
P NMR, δ (ppm): 33.93.  
 
Synthesis of [IrL(PPh3)2(H)] (3) 
2˗{(2˗benzo[1,3]dioxol˗5˗yl)˗diazo)}˗4˗methylphenol (100mg, 0.1 mmol) was dissolved 
in ethanol (50 mL) and refluxed for 10 min, followed by addition of triethylamine (22 mg, 
0.22 mol) and [Ir(PPh3)3Cl] (100 mg, 0.1 mmol). The resulting solution was refluxed in a 
nitrogen atmosphere for 32 h to yield a green solution. The solvent was evaporated, and 
the solid mass, thus obtained, was subjected to purification by thin-layer chromatography 
on a silica plate. With 1:1 benzene-toluene as the eluent, a dark blue band separated, and 
the corresponding material was extracted separately with acetonitrile. Evaporation of this 
acetonitrile extract gave [IrL(PPh3)2(H)] (3), as blue crystalline solid. 
[IrL(PPh3)2(H)] (2): Yield: 45%. Anal. calc. for: C, 61.78; H, 4.25; N, 2.88. Found: C, 
61.73; H, 4.20; N, 2.93. Main IR peaks (KBr, υ/cm–1): 2050 υ(Ir‒H); 1480 υ(N=N); 1237 
υ(C‒O)phenolic; 746, 694, 515 υ(3P‒Ph). 
1
H NMR (DMSO–d6, 400 MHz) δ (ppm): 7.36‒
7.23 (m, 15H, PPh3); 6.79‒5.95 (m, 5H, Ar‒H); 1.88 (s, 3H, ArCH3); ˗12.54 (t, hydride, 
Ir‒H). 31P NMR, δ (ppm): 11.90, 9.89.  
 
4.2.3. X–ray Crystallography. 
Single crystals of complexes were mounted on a Bruker Smart Apex CCD diffractometer 
equipped with a graphite monochromator and a Mo K radiator (λ) 0.71073 Å. 
Crystallographic data and details of refinement are given in Table 4.1. The unit cell 
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dimensions and intensity data were measured at 293(2) K for 1 and 3 and 297(2) K for 2. 
Integrated intensities were obtained with the Bruker SAINT 
18 
software package using a 
narrow frame logarithm. The intensity data were corrected for Lorentz, polarization and 
absorption effects. Absorption corrections were applied using SADABS
19
 and the 
structures were solved by direct methods using the program SHELXS‒9720 and refined 
using least squares with the SHELXL‒9720 software program. Hydrogens were either 
found or placed in calculated positions and isotropically refined using a riding model. The 
non‒hydrogen atoms were refined anisotropically. Figures were drawn using DIAMOND 
and MERCURY. In the ball-and-stick models all atoms are drawn as thermal 
displacement ellipsoids of the 40% level with exception of the hydrogen atoms which are 
shown as spheres of arbitrary radii.  
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Table 4.1.  Crystal data and refinement details for 1‒3 
 
 
 
Complex 1∙CH3CN 2 3 
Empirical 
formula 
C53H42N3O4P2Ru C52H43N3O3P2Ru C50H41IrN2O3P2 
Formula 
weight 
947.90 920.90 971.99 
Temperature 293(2) K 297(2) 297(2) K 
Radiation MoKα MoKα MoKα 
Crystal 
system 
monoclinic monoclinic triclinic 
Space group C1m1 P 21/n P-1 
Unit cell 
dimensions 
a =  18.2828(2)  Å 
b =  14.6228(2)  Å 
c =  9.68930(10) Å 
α = 90° 
β = 120.7910(4)° 
γ = 90° 
a = 12.0619(2)  Å 
b = 17.3951(2)  Å 
c =  20.5496(3)  Å 
α = 90° 
β = 96.0240(6) 
γ = 90° 
a = 11.1808(2) Å 
b = 12.0131(3) Å 
c = 19.2103(4) Å 
α = 101.2930(7)° 
 = 90.9690(7)° 
γ  = 111.4660(6)° 
Volume 2225.25(5) Å
3
 4287.87(11) 2343.66(9) Å
3
 
Z 2 4 2 
Density 
(calculated) 
1.415 g/cm
3
 1.427 g/cm
3
 1.377 g/cm
3
 
Absorption 
coefficient 
0.475 mm
-1
 0.489 mm
-1
 2.958 mm
-1
 
F(000) 974 1896 972 
Crystal size 
0.250 x 0.350 x 0.600 
mm 
0.025 x 0.100 x 0.200 
mm 
0.050 x 0.080 x 
0.150 mm 
Theta range 
for data 
collection 
1.90 to 28.34° 1.876 to 28.346°   1.95 to 30.77° 
Reflections 
collected 
32606 104119 71547 
Reflections 
unique 
5305 10676 14045 
Final 
R1/wR2 
[I>2sigma(I)] 
 
R1 = 0.0233, wR2 = 
0.0550 
 
R1 = 0.0456, wR2 = 
0.0954 
R1 = 0.0319, wR2 
= 0.0991 
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4.3. RESULTS AND DISCUSSION 
4.3.1. Synthesis of complexes (1‒3)  
Reaction of equimolar mixture of 2-(arylazo)phenol, HL, with [Ru(PPh3)2Cl2] in ethanol 
medium under basic condition, afforded two types of complexes under refluxing 
conditions in a nitrogen atmosphere, with distinctly different colors, viz. green and brown, 
having the stoichiometry, [RuL(PPh3)2(CO)] (1) and [RuL(PPh3)2(CH3CN)] (2), 
respectively, while under the same condition, reaction of HL with [Ir(PPh3)3Cl] resulted in 
the formation of blue crystalline compound of [IrL(PPh3)2(H)] (3). The synthetic 
methodology of 1‒3 is illustrated in Scheme 4.1. Elemental analyses, IR and NMR spectra 
and ESI-MS of 1‒3 gave some idea about their compositions, but could not point to a 
definite formulation. For an unambiguous identification of the complexes, their X-ray 
structures were solved, which was consistent with their preliminary characterization. The 
complexes were slightly soluble in ethanol and methanol, but completely soluble in other 
protic and aprotic solvents.  
OH
N N
O
O
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O
H3C
N
N
O
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Scheme 4.1. Schematic representation of the synthesis of [RuL(PPh3)2(CO)] (1), 
[RuL(PPh3)2(CH3CN)] (2) and [IrL(PPh3)2(H)] (3). 
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The ligand coordinates to the metal center in the case of all the three complexes as a 
tridentate C, N, O˗donor via metal assisted C‒H activation, which is well documented in 
literature.
4a,12d,f-h,15a,16
 In the case of [RuL(PPh3)2(CH3CN)] (2), the acetonitrile used for 
extraction, coordinates to the Ru center at the sixth coordination site, while the hydride 
generated from C‒H activation of the ligand coordinates at the sixth coordination site, in 
[IrL(PPh3)2(H)] (3). But, the coordination of a carbonyl group to the Ru(II) center in the 
case of [RuL(PPh3)2(CO)] (1) was unexpected since the metal precursor, [Ru(PPh3)3Cl2], 
used for synthesis of 1 cannot serve as a source of CO. Earlier reports on unprecedented 
CO coordination in the case of arylazo ruthenium(II) complexes in ethanolic medium was 
rationalized by the migration of an alkyl group in the ligand backbone and its subsequent 
oxidation to CO, resulting in ligand modification.
16 
However in the case of complex 1, 
similar explanation was not possible since the substituted methyl group in the ligand 
remained intact even after complex formation. The formation of Ru–CO complexes, by 
heating Ru(II) and Ru(III) compounds in the presence of primary alcohols, has earlier 
been established by C. Yi et al.
 
and Jayanthi et al.
14a
 Taking these literature reports into 
consideration, the source of CO was assumed to be the solvent (ethanol) used for 
synthesis. In order to ascertain whether ethanol served as the source of CO, reaction of 
HL with [Ru(PPh3)3Cl2] was carried out in toluene and acetonitrile, in basic medium. 
However, preliminary characterization (IR) of the products obtained from toluene and 
acetonitrile did not show any trace of CO generation in the reaction medium, thereby 
clearly indicating EtOH as the source of CO. A. Chakravorty et al. had previously 
reported the synthesis of Os and Ru complexes, wherein decarbonylation of the 
diformylphenol Schiff base ligand had occurred resulting in the formation of CO 
coordinated organometallic complexes.
21
 In their case however the CO coordination was 
indifferent to the variation of solvent. Based on the above discussion, a mechanistic 
scheme for the formation of 1 is exemplified in Scheme 4.2. 
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Scheme 4.2. Proposed mechanism for the formation of [RuL(PPh3)2(CO)] (1). 
 
4.3.2. Spectral Characteristics 
4.3.2.1. IR spectroscopy. A broad band at ~3450 cm
-1
 was observed for HL, which 
disappears upon complex formation of 1−3. IR stretching frequency of HL observed at 
1549 cm
-1 
is attributed to the presence of the azo(N=N) functional group.
22
 The 
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corresponding peak shifts to a lower frequency range of ~1481 cm
-1
 upon complexation 
(1−3). The presence of a coordinated CO in the case of 1 is evident from the characteristic 
peak of CO, observed at 1936 cm
-1
,
16
 while an extra peak at 2212 cm
-1
 in the IR spectra of 
2,
 
as compared to the
 
ligand, could be attributed to the CN stretching frequency in the 
complex.
 
Besides the difference in the CO and CN stretch, the infrared spectrum of 1 and 
2 are very similar. The presence of three strong absorption bands (~515, 694, 746 cm
-1
)
 
in 
1, 2 and 3 is due to the coordinated PPh3 ligands to the metal centers and the peak at 2050 
cm
-1 
is assigned to the Ir‒H stretching frequency.12g Figures 4.1 and 4.2 represent the IR 
spectra of 1 and 3 respectively.
 
 
Figure 4.1. IR spectra of [RuL(PPh3)2(CO)] (1). 
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Figure 4.2. IR spectra of [IrL(PPh3)2(H)] (3). 
4.3.2.2. UV-vis spectroscopy. The electronic spectra of [RuL(PPh3)2(CO)] (1), 
[RuL(PPh3)2(CH3CN)] (2) and [IrL(PPh3)2(H)] (3) was recorded in dichloromethane 
solution. The strong transitions in the UV region of 1, 2 and 3 are attributable to intra-
ligand charge transfer transitions whereas the transitions of higher intensities in the lower 
energy region of the spectra are presumably due to metal to ligand charge transfer 
transition (MLCT).
23 
The weaker absorption tails exhibited by the [IrL(PPh3)2 (H)], 3, in 
the lower energy region may be ascribed to forbidden MLCT (dπ(Ir)–π*(ligand)) 
transitions.
24
 Representative UV-vis spectra of 1 and 3 is given in Figures 4.3 and 4.4 
respectively and the values are tabulated in Table 4.2. 
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Table 4.2. Electronic spectra for complexes 1–3 in dichloromethane solution. 
Complex λmax/nm (εmax/M
–1
 cm
–1
) 
[RuL(PPh3)2(CO)] (1)  207 (26533), 224 (16000), 262 (5000), 348 (1666), 449 
(1333), 642 (1200) 
[RuL(PPh3)2(CH3CN)] (2) 278 (45121), 230 (25000), 258 (8500), 385 (27637), 457 
(9500), 668 (1400) 
[IrL(PPh3)2(H)] (3) 210 (26666), 258 (10133), 336 (2333), 433 (1466), 598 
(2533) 
 
 
Figure 4.3. UV-vis spectrum of [RuL(PPh3)2(CO)] (1). 
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Figure 4.4. UV-vis spectrum of [IrL(PPh3)2(H)] (3). 
4.3.2.3. NMR spectroscopy. The complexes [RuL(PPh3)2(CO)] (1), 
[RuL(PPh3)2(CH3CN)] (2) and [IrL(PPh3)2(H)] (3) are diamagnetic, which corresponds to 
+2 oxidation state of 1 and 2 and +3 oxidation state of 3 (low spin d
6
, S = 0). 
1
H NMR 
spectra of 1 and 2 have been recorded in CDCl3, while that of 3 in
 
DMSO-d6.
 
The 
1
H 
NMR spectra of 1 and 2 are qualitatively similar. 
1
H NMR spectra of 1 shows broad 
signals in the range 7.36‒7.18 ppm for the two coordinated PPh3 ligands. The signals for 
the other aromatic protons in the ligand moiety of complex 1 are observed in the range 
7.15‒6.91 and 7.71 ppm. The expected signals from the aromatic protons of the 
coordinated 2-(arylazo)phenolate ligand of complex 2 could not be identified separately 
because of their overlap with the PPh3 signals. A singlet is observed at ~5.99 ppm for the 
CH2 group (O‒CH2‒O) in the ligand fragment for complex 1 and 2. The signals for the 
methyl protons of the phenolate fragment of 2-(arylazo)phenolate ligand in 1 and 2 is 
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observed at ~2.37 ppm, while an extra three proton singlet is observed in 2 due to the 
methyl group of the coordinated CH3CN. The protons of the coordinated PPh3 in complex 
3 resonate at ~7.36‒7.23 ppm. The signals for the aromatic protons of the coordinated     
2-(arylazo)phenolate ligand of 3 was observed in the ~6.79‒5.95 ppm range while the 
peak for the CH2 group (O‒CH2‒O) is observed at 5.68 ppm. The methyl protons of 
complex 3 resonate in the upfield region of ~1.88 ppm. In addition 
1
H NMR spectrum of 
the complex 3 show a hydride signal near ~ ‒12.54 ppm. 
31
P NMR spectra of 1 and 2 show a single resonance within 33.97‒33.93 ppm, as 
expected, while two resonating signals are observed for 3, at 11.90 and 9.89 ppm for the 
two coordinated PPh3 ligands. The NMR spectral data of 1, 2 and 3 are therefore in 
agreement with their respective composition and stereochemistry. Representative 
1
H and 
31
P NMR spectra of 1 and 3 are given in Figures 4.5‒4.7, respectively.  
 
 
Figure 4.5. 
1
H NMR spectrum of [RuL(PPh3)2(CO)] (1). 
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Figure 4.6. 
1
H NMR spectrum of [IrL(PPh3)2(H)] (3). 
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            (a)                                                                         (b)  
Figure 4.7. 
31
P NMR spectrum of (a) [RuL(PPh3)2(CO)] (1) in CDCl3and 
[IrL(PPh3)2(H)] (3) in DMSO-d6.. 
 
4.3.3. ESI-MS.  
ESI-MS of 1−3 have been recorded in acetonitrile solution. ESI-MS of 1 shows a peak for 
[M + 2H ‒ CH3CN]
+ 
at m/z 908.70, whereas the ESI-MS for 2 and 3 displays molecular 
ion peaks, [M]
+
, at m/z 921.10 and 972.77 respectively. Figures 4.8 and 4.9 depict the 
representative ESI-MS spectra of 1 and 3 respectively. 
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Figure 4.8. 
 
ESI-MS of [RuL(PPh3)2(CO)] (1) in CH3CN. 
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Figure 4.9. 
 
ESI-MS of [IrL(PPh3)2(H)] (3). 
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4.3.4. Electrochemical Properties. The potential data of 1‒3 is tabulated in Table 4.2 and 
the representative cyclic voltammogram of 1 and 3 is given in Figures 4.10 and 4.11, 
respectively. The cyclic voltammagram pattern of 1 and 2 are similar; each exhibits a 
single electron transfer quasi-reversible oxidative wave Ru(II)/Ru(III) in the anodic region 
at E
a
1/2 value of +0.54 and +0.52 V, respectively, while 3 shows a reversible redox couple 
for (Ir(III)/Ir(IV)) at +0.50 V respectively. An irreversible ligand centered oxidation and 
reduction peak is observed at +1.25V and ‒1.4V in the anodic and cathodic region 
respectively. The one–electron nature of this oxidation was verified by comparing its 
current height with that of the standard ferrocene–ferrocenium couple under identical 
experimental conditions.  
 
Table 4.2. Cyclic voltammetric results for 1–3 at 298 K.[a] 
 
Complex E1/2(V) ΔEp (mV) 
[Ru(PPh3)2L(CO)] (1)  0.54  110 
[Ru(PPh3)2L(CH3CN)] (2) 0.52  100 
[Ir(PPh3)2L(H)] (3) 0.50  90 
 
[a]
 1–3 in CH3CN solution at a scan rate of 100 mV s
-1
. E½ = ½(Ep
a
 + Ep
c
), ΔEp = Epa ‒ 
Ep
c
 (Ep
a
 = anodic peak potential, Ep
c
= cathodic peak potential). 
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Figure 4.11. Cyclic Votammogram of [RuL(PPh3)2(CO)] (1).
 
Figure 4.12. Cyclic Votammogram of [IrL(PPh3)2(H)] (3). 
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4.3.5. Description of X-ray Structure of [RuL(PPh3)2CO] (1), [RuL(PPh3)2(CH3CN)] 
(2) and [IrL(PPh3)2(H)] (3) 
[RuL(PPh3)2CO] (1): The molecular structure and the atom numbering scheme for 
[RuL(PPh3)2CO] (1) is shown in Figure 4.12 and the relevant bond parameters are 
collected in Table 4.3. Structure of 1 shows that in this complex the 2-(arylazo)phenol is 
coordinated to the metal (via loss of the phenolic proton as well as another proton from 
one ortho position of the phenyl ring in the arylazo fragment) as a tridentate C, N, O-
donor, resulting in a distorted octahedral coordination geometry of 1. The remaining three 
coordination sites are occupied by two triphenylphosphines and a carbon monoxide 
molecule. The coordinated 2-(arylazo)phenolate ligand and CO share an equatorial plane 
with Ru at the center, where the CO is trans to the coordinated azo-nitrogen(N1). The 
PPh3 ligands occupy the axial positions and the Ru−PPh3 [Ru(1)‒P(1) = 2.3716(6) Å] 
distances are comparable to those found in similar complexes.
12d 
A CH3CN molecule is 
also present as the solvent of crystallisation in the crystal lattice of 1 (not shown in Figure 
below). 
 
 
Figure 4.12. ORTEP diagram of the asymmetric unit of [RuL(PPh3)2CO] (1). 
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Table 4.3. Selected geometric parameters for [RuL(PPh3)2CO] (1) 
 
Bond Distances(Å) 
Ru(1)‒C(15) 1.862(4) Ru(1)‒C(13) 2.042(5) 
Ru(1)‒N(1) 2.045(3) Ru(1)‒O(1) 2.195(3) 
Ru(1)‒P(1) 2.3716(6)   
Bond Angles(º) 
C(15)‒Ru(1)‒C(13) 95.5(2) C(15)‒Ru(1)‒N(1) 172.4(2) 
C(13)‒Ru(1)‒N(1) 76.9(2) C(15)‒Ru(1)‒O(1) 109.6(2) 
C(13)‒Ru(1)‒O(1) 154.9(1) N(1)‒Ru(1)‒O(1) 77.9(1) 
C(15)‒Ru(1)‒P(1) 89.0(2) C(13)‒Ru(1)‒P(1) 96.3(1) 
N(1)‒Ru(1)‒P(1) 91.8(1) O(1)‒Ru(1)‒P(1) 84.44(8) 
P(1)‒Ru(1)‒P(1) 167.36(3)   
 
[RuL(PPh3)2(CH3CN)] (2): The molecular structure and the atom numbering scheme for 
[RuL(PPh3)2(CH3CN)] (2) is shown in Figure 4.13 and the relevant bond parameters are 
tabulated in Table 4.4. The ligand is coordinated to the Ru center as a tridentate dianionic 
C, N, O donor as in the case of 1; however in 2 the fourth coordination site in the 
equatorial plane is occupied by CH3CN group instead of CO. Two five membered chelate 
rings define the equatorial plane with bite angles 77.0(1)º [C(13)‒Ru(1)‒N(1)] and 
79.47(9)º [O(1)‒Ru(1)‒N(1)]. The two triphenylphosphines are placed mutually trans to 
each other in the axial plane, the bond angle P(1)‒Ru(1)‒P(2), being 176.38(3)º. In case 
of [RuL(PPh3)2(CH3CN)] (2), there is a slight difference in the bond distance between 
Ru(1)‒P(1) (2.3610(6) Å) and Ru(1)‒P(2) (2.3834(8) Å), resulting in the formation of a 
distorted octahedral geometry, as compared to [RuL(PPh3)2(CO)] (1), where both the 
Ru(1)‒P(1) bonds are equidistant. Notably, the Ru(1)‒N(1) distance (1.989(2) Å) in 2 is 
shortened as compared to Ru(1)‒N(1) distance (2.045(3) Å) of 1 due to the lesser trans 
effect of CH3CN (in 3) than CO (in 1). 
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Figure 4.13. ORTEP diagram of [RuL(PPh3)2(CH3CN)] (2). 
 
Table 4.4. Selected geometric parameters for [RuL(PPh3)2(CH3CN)] (2) 
Bond Distances (Å) 
Ru(1)‒C(13) 2.026(3) Ru(1)‒N(3) 1.997(3) 
Ru(1)‒N(1) 1.989(2) Ru(1)‒O(1) 2.160(2) 
Ru(1)‒P(1) 2.3640(8) Ru(1)‒P(2) 2.3834(8) 
Bond Angles (º) 
P(1)‒Ru(1)‒P(2) 176.38(3) P(2)‒Ru(1)‒N(3) 88.43(9) 
P(1)‒Ru(1)‒O(1) 91.14(6) P(2)‒Ru(1)‒C(13) 92.19(8) 
P(1)‒Ru(1)‒N(1) 91.98(7) O(1)‒Ru(1)‒N(1) 79.47(9) 
P(1)‒Ru(1)‒N(3) 87.96(9) O(1)‒Ru(1)‒N(3) 99.3(1) 
P(1)‒Ru(1)‒C(13) 88.43(8) O(1)‒Ru(1)‒C(13) 156.4(1) 
P(2)‒Ru(1)‒O(1) 89.73(6) N(1)‒Ru(1)‒N(3) 178.7(1) 
P(2)‒Ru(1)‒N(1) 91.64(7) N(1)‒Ru(1)‒C(13) 77.0(1) 
N(3)‒Ru(1)‒C(13) 104.3(1)   
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[IrL(PPh3)2(H)] (3): The structure of the Ir(III) complex [IrL(PPh3)2H] (3) is illustrated in 
Figure 4.14 and selected bond parameters are tabulated in Table 4.5. Bond parameters 
reflect the distortion of the coordination geometry of the cyclometallated organometallic 
complex (3) from an ideal octahedron. The bond distances, Ir(1)–C(1), Ir(1)–N(1), Ir(1)–
O(1), Ir(1)–H(1), Ir(1)–P(1) and Ir(1)–P(2) within the C, N, O-chelated fragment of 3 are 
normal and comparable to previous evidences.
4a
 The equatorial plane in the complex is 
defined by two five membered rings formed by the coordination of the ligand as a 
tridentate C, N, O donor with bite angles of 77.91(8)º [C(1)–Ir(1)–N(1)] and 78.88(7)º 
[N(1)–Ir(1)–O(1)]. In addition, a hydride occupies the equatorial plane positioned trans to 
the N1 atom, while two PPh3 groups occupy the axial positions in complex 3.  
 
Figure 4.14. ORTEP diagram of [IrL(PPh3)2(H)] (3). 
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Table 4.5. Selected geometric parameters for [IrL(PPh3)2H] (3) 
 
Bond lengths (Å) 
Ir(1)‒C(1) 2.023(2) Ir(1)‒N(1) 2.033(2) 
Ir(1)‒O(1) 2.180(2) Ir(1)‒P(1) 2.3142(6) 
Ir(1)‒P(2) 2.3219(6) Ir(1)‒H(101) 1.51(2) 
Bond angles (º) 
C(1)–Ir(1)–N(1) 77.91(8) C(1)–Ir(1)–O(1) 156.68(8) 
N(1)–Ir(1)–O(1) 78.88(7) C(1)–Ir(1)–P(1) 95.47(6) 
N(1)–Ir(1)–P(1) 96.16(5) O(1)–Ir(1)–P(1) 89.21(5) 
C(1)–Ir(1)–P(2) 97.50(6) N(1)–Ir(1)–P(2) 96.10(5) 
O(1)–Ir(1)–P(2) 82.74(5) P(1)–Ir(1)–P(2) 163.75(2) 
C(1)–Ir(1)–H(101) 99.4(9) N(1)–Ir(1)–H(101) 177.3(9) 
O(1)–Ir(1)–H(101) 103.8(3) P(1)–Ir(1)–H(101) 84.0(9) 
P(2)–Ir(1)–H(101) 84.3(9)   
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4.4. CONCLUSION 
The chemistry of some new ruthenium(II) (1 and 2) and iridium(III) arylazo (3) 
complexes have been reported. The complexes (1‒3) were characterized by various 
analytical techniques (IR, UV-vis, 
1
H and
 31
P NMR spectroscopy, ESI-MS and cyclic 
voltammetry). The molecular structures of 1‒3 were also solved by single crystal X-ray 
diffraction analysis. The complexes have a distorted octahedral geometry. The two PPh3 
groups occupy the axial position and the sixth coordination site in the equatorial plane is 
occupied by the CO, CH3CN and H
‒
 in 1, 2 and 3 respectively. Metal (Ru and Ir) 
mediated C‒H activation of the ligand occurs in all the three complexes, resulting in 
coordination of the ligand as a tridentate binegative C, N, O-donor. In order to rationalize 
the unprecedented CO coordination to the Ru(II) center in the case 1, a suitable 
mechanism via alcohol dehydrogenation has been proposed.  
The ruthenium carbonyl complex, [RuL(PPh3)2CO] can act as a CO reservoir and may be 
utilized for hydroformylation reaction or as a catalyst precursor for the reduction of CO2 
or the water gas shift reaction. There is thus scope for further research in this regard.  
 
 
157 
 
4.5. REFERENCES 
(1) Rau, H. In Studies in Organic Chemistry 40: Photochromism, Molecules and 
Systems; Dürr, H.; Bouas-Laurent, H., Eds.; Elsevier: Amsterdam, 1990; pp 165‒192. (b) 
Feringa, B. L.; Jager, W. F.; de Lange, B. Tetrahedron 1993, 49, 8267‒8310. (c) Willner, 
I.; Rubin, S. Angew. Chem., Int. Ed. Engl. 1996, 35, 367‒385. (d) Makita, S.; Saito, A.; 
Hayashi, M.; Yamada, S.; Yoda, K.; Otsuki, J.; Takido, T.; Seno, M. Bull. Chem. Soc. 
Jpn. 2000, 73, 1525‒1533. 
(2) Ueno, A.; Kuwabara, T.; Nakamura, A.; Toda, F. Nature 1992, 356, 136‒137. 
(3) Screen, T. E. O.; Blake, I. M.; Rees, L. H.; Clegg, W.; Borwick, S. J.; Anderson, 
H. L. J. Chem. Soc., Perkin Trans. 2002, 1, 320‒329. (b) Hunter, C. A.; Sarson, L. D. 
Tetrahedron Lett. 1996, 37, 699‒702. (c) Autret, M.; LePlouzennec, M.; Moinet, C.; 
Simonneaux, G. J. Chem. Soc., Chem. Commun. 1994, 1169‒1170. (d) Tsuchiya, S. J. 
Am. Chem. Soc. 1999, 121, 48‒53. (e) Neuman, K. H.; Vӧgtle, F. J. Chem. Soc., Chem. 
Commun. 1988, 520‒522. (f) Reddy, D. R.; Maiya, B. G. Chem. Commun. 2001, 117‒
118. 
(4) (a) Acharyya, R.; Basuli, F.; Wang, R.-Z. ; Mak, T. C. W.; Bhattacharya, S. Inorg. 
Chem. 2004, 43, 704‒711. (b) Maiti, N.; Pal, S.; Chattopadhyay, S. Inorg. Chem. 2001, 
40, 2204‒2205. (c) Datta, P.; Sardar, D.; Saha, R.; Mondal, T. K.; Sinha, C. Polyhedron 
2013, 53, 193–201. 
(5) Krause, R. A.; Krause, K. Inorg. Chem. 1980, 19, 2600‒2603.  
(6) (a) Ghosh, P.; Pramanik, A.; Bag, N.; Chakravorty, A. J. Chem. Soc., Dalton 
Trans. 1992, 1883‒1886. (b) Lahiri, G. K.; Bhattacharya, S.; Goswami, S.; Chakravorty, 
A. J. Chem. Soc., Dalton Trans. 1990, 561‒565. (c) Ghosh, B. K.; Chakravorty, A. Coord. 
Chem. Rev. 1989, 95, 239‒294. (d) Wolfang, S.; Strekas, T. C.; Gafney, H. D.; Krause, A. 
R.; Krause, K. Inorg. Chem. 1984, 23, 2650‒2655. (e) Goswami, S.; Mukherjee, R. N.; 
Chakravorty, A. Inorg. Chem. 1983, 22, 2825‒2832. (f) Goswami, S.; Chakravarty, A. R.; 
Chakravorty, A. Inorg. Chem. 1983, 22, 602‒609. 
(7) (a) Ghosh, A. K.; Majumdar, P.; Falvello, L. R.; Mostafa, G.; Goswami, S. 
Organometallics 1999, 18, 5086‒5090. (b) Lahiri, G. K.; Goswami, S.; Falvello, L. R.; 
Chakravorty, A. Inorg. Chem. 1987, 26, 3365‒3370. (c) Goswami, S.; Chakravarty, A. R.; 
Chakravorty, A. J. Chem. Soc., Chem. Commun. 1982, 1288‒1289. (d) Goswami, S. 
Chakravarty, A. R.; Chakravorty, A. Inorg. Chem. 1982, 21, 2737‒2742. 
158 
 
(8) Sabo-Etienne, S.; Grellier, M. Ruthenium: Inorganic & Coordination Chemistry, 
Encyclopedia of Inorganic Chemistry [Online] John Wiley & Sons, Ltd, 2006. 
(9) Touge, T.; Hakamata, T.; Nara, H.; Kobayashi, T.; Sayo, N.; Saito, T.; Kayaki, Y.; 
Ikariya, T. J. Am. Chem. Soc. 2011, 133, 14960–14963. 
(10) Ohkuma, T.; Ooka, H.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. 
Soc. 1995, 117, 2675–2676. 
(11) (a) Lo, K. K; Chung, C. K.; Lee T. K.; Lui, L. H.; Tsang, K. H.; Zhu, N. Inorg 
Chem. 2003, 42, 6886‒6897. (b) Lo, K. K. -W.; Chung, C. -K.; N. Zhu, Chem. Eur. J. 
2003, 9, 475‒483. 
(12) (a) Arockiam, P. B.; Bruneau, C.; Dixneuf, P. H. Chem. Rev. 2012, 112, 5879–
5918. (b) Park, Y.; Heo, Joon; Baik, Mu-Hyun; Chang, Sukbok, J. Am. Chem. 
Soc. 2016, 138, 14020‒14029. (c) Labinger, J. A. Chem. Rev. 2016 DOI: 
10.1021/acs.chemrev.6b00583. (d) Gupta, P.; Dutta, S.; Basuli, F.; Peng, S. -M.; Lee, G. -
H.; Bhattacharya, S. Inorg. Chem. 2006, 45, 460‒467. (e) Pratihar, J. L.; Maiti, N.; 
Chattopadhyay, S. Inorg. Chem. 2005, 44, 6111‒6114. (f) Mandal, S.; Samanta, S.; 
Mondal, T. K.; Goswami S. Organometallics 2012, 31, 5282−5293. (g) Acharyya, R.; 
Basuli, F.; Peng, S. -M.; Lee, G.-H.; Wang, R. -Z.; Mak, T. C. W.; Bhattacharya, S. J. 
Organomet. Chem. 2005, 690, 3908‒3917. (h) Acharyya, R.; Peng, S. -M.; Lee, G.-H.; 
Bhattacharya, S. J. Chem. Sci. 2009, 121, 387‒395. (i) Ghosh, P.; Bag, N.; Chakravorty, 
A. Organometallics 1996, 15, 3042‒3047. 
(13) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624‒655.  
(14) (a) Jayanthi, E.; S. Kalaiselvi, V. V. Padma, N. S. P. Bhuvanesh, N. Dharmaraj, 
Dalton Trans. 2016, 45, 1693‒1707 and references therein. (b) Dinger, M. B.; Mol, J. C. 
Organometallics 2003, 22, 1089–1095. 
(15) (a) Nag, S.; Gupta, P.; Butcher, R. J.; Bhattacharya, S. Inorg. Chem. 2004, 43, 
4814‒4816. (b) Sarkar, S. K.; Jana, M. S.; Mondal, T. K.; Sinha, C. J. Organomet. Chem. 
2012, 716, 129‒137. 
(16) Acharyya, R.; Peng, S. -M.; Lee, G. H.; Bhattacharya, S. Inorg. Chem. 2003, 42, 
7378‒7380. 
(17) Hallman, P. S.; Stephenson, T. A.; Wilkinson, G., 
Tetrakis(triphenylphosphine)dichlororuthenium(II) and 
159 
 
Tris(triphenylphosphine)dichlororuthenium(II). In Inorganic Syntheses, John Wiley & 
Sons, Inc.: 2007; pp 237‒240. 
(18) SAINT. 2008, Bruker AXS Inc.: Madison, Wisconsin, USA. 
(19) SADABS. 2008, Bruker AXS Inc.: Madison, Wisconsin, USA. 
(20) Sheldrick, G. M.: SHELXS-97: Programs for Structure Determination, University 
of Gӧttingen, Gӧttingen, Germany 1997. 
(21) (a) Ghosh, P.; Bag, N.; Chakravorty, A. Organometallics 1996, 15, 3042‒3047. 
(b) Bag, N.; Choudhury, S. B.; Pramanik, A.; Lahiri, G. K.; Chakravorty, A. Inorg. Chem. 
1990, 29, 5013‒5014. 
(22) Halder, S.; Drew, M. G. B.; Bhattacharya, S. J. Chem. Sci. 2008, 120, 441−446. 
(23) Panda, M.; Paul, N. D.; Joy, S.; Hung, C. –H.; Goswami, S. Inorg. Chim. 
Acta 2011, 372, 168–174. 
(24) Lo, K. K. -W. Chung, C. -K. Zhu, N. Chem. Eur. J. 2003, 9, 475. 
160 
 
 
 
 
 
 
Chapter 5 
 
 
 
 
 
Synthesis, structure, DNA interaction and cytotoxicity of a series 
of dioxidomolybdenum(VI) complexes featuring salan ligands 
 
 
 
 
 
 
 
 
 
 
161 
 
Chapter 5 
 
Synthesis, structure, DNA interaction and cytotoxicity of a series of 
dioxidomolybdenum(VI) complexes featuring salan ligands 
 
ABSTRACT 
Seven hexacoordinated cis-dioxidomolybdenum(VI) complexes [MoO2L
17
] (17) 
derived from various substituted tetradentate diamino bis(phenolato) “salan” ligands, 
N,Nʹ-dimethyl-N,Nʹ-bis-(2-hydroxy-3-X-5-Y-6-Z-benzyl)-1,2-diaminoethane {(X = Br, Y 
= Me, Z = H (H2L
1
); X = Me, Y = Cl, Z = H (H2L
2
); X = 
i
Pr, Y = Cl, Z = Me (H2L
3
)} and 
N,Nʹ-bis-(2-hydroxy-3-X–5-Y-6-Z-benzyl)-1,2-diaminopropane {(X = Y = tBu, Z = H 
(H2L
4
); X = Y = Me, Z = H (H2L
5
); X = 
i
Pr, Y = Cl, Z = Me (H2L
6
); X = Y = Br, Z = H 
(H2L
7
)} containing ON donor atoms, have been isolated and structurally characterized. 
The formation of cis-dioxidomolybdenum(VI) complexes was confirmed by elemental 
analysis, IR, UV-vis and NMR spectroscopy, ESI-MS and cyclic voltammetry 
measurements. X-ray crystallography showed the O2N2 donor set to define an octahedral 
geometry in each case. The asymmetric unit of all the complexes consists of a complete 
formula unit with the exception of 2, which belongs to point group C2. [MoO2L
17
] (1‒7) 
showed moderate DNA binding propensity with binding constants ranging from 10
4−105 
M
-1
. The experimental results showed that the complexes 1‒7 effectively interact with 
CT-DNA by both minor and major groove binding mode, while complex 2 additionally 
interacts by partial intercalative mode of binding. The dioxidomolybdenum (VI) 
complexes (1‒3) showed moderate photo-induced cleavage of pUC19 supercoiled 
plasmid DNA. All the complexes (1–7) were tested for their in vitro antiproliferative 
activity against HT-29 and HeLa cell lines. IC50 values of the complexes in HT-29 follow 
the order 6 < 7 << 1 < 2 < 5 << 3 < 4 while the order is 6 < 7 < 5 < 1 << 3 < 4 < 2 in 
HeLa cells. Some of the complexes proved to be as active as the clinical referred drugs, 
and the greater potency of 6 and 7 (IC50 values of 6 are 2.62 and 10.74 µM and that of 7 is 
11.79 and 30.48 µM in HT-29 and HeLa cells, respectively) may be dependent on the 
substituents in the salan ligand environment coordinated to the metal. 
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5.1.  INTRODUCTION 
Metals, in particular transition metals provide potential advantages over the more 
common organic-based drugs, including a broad range of coordination numbers and 
geometries, accessible redox states, kinetics of ligand substitution and „tune-ability‟ of the 
thermodynamics, and a wide structural diversity.
1–13
 It was the discovery of cisplatin that 
gave momentum to metal-based drug research.
14
 Despite its tremendous success as an 
anticancer drug, its use is restricted due to serious side-effects, general toxicity, and 
acquired drug resistance.
15
 In order to overcome the challenges set forth by platinum 
based drugs, researchers in the field of medicinal inorganic chemistry are developing non-
platinum based chemotherapeutic agents that exhibit enhanced selectivity and non-
covalent DNA binding interaction modes.
16,17 
Investigation of DNA binding interactions 
with metal complexes have gained profound interest due to its medical applications and 
genomic research.
16,17
 
As compared to other transition metals, molybdenum gains advantages due to its low 
toxicity and its extensive and labile chemistry.
18
 Lack of molybdenum in nutrition may 
cause increased risk of developing esophageal cancer.
19
 Again, exploitation of 
molybdenum(VI) complexes seems relevant, due to its already proven versatility in 
biology,
20–23
 such as the presence of molybdenum(VI) center at the active centers of 
oxotransfer molybdoenzymes, nitrogen fixing enzymes - the nitrogenases
21
 as well as 
several oxotransferase enzymes like xanthine oxidase, sulphite oxidase and DMSO 
reductase.
20,22,23
  
Among the diverse class of molybdenum complexes utilized for their pharmaceutical 
applicability, their anti-cancer activities gained special attention.
24–27
 Significant anti-
tumoral effect of Mo(II) complexes was observed in organometallic complexes Cp2MoX2 
(X= Cl, Br, acido ligand) which presented favorable drug like characteristics.
24k,l
 
Researchers have further investigated the toxicity and specificity of other molybdocene 
complexes, for example in [CpMo(2,2′-biimidazole)2(CO)2](BF4), [Mo(ε
3
-
C3H5)X(CO)2(N-N)] (N-N= 1,10-phenanthroline or 2,2′-bipyridyl and X = CF3-SO3, Br, 
Cl) etc., on variable cancer cell lines.
25
 Remarkable cell-growth inhibition of various 
polyoxidomolybdates was observed in a dose dependent manner selectively on specific 
carcinoma cells.
26
 Most promising cytotoxicity results of molybdenum complexes 
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obtained so far have been with the Mo centre in +II oxidation state, but reports on similar 
potency of Mo(VI) complexes against cancer cells remain scarce.
27
 Anticancer activities 
of Mo(VI) complexes against human cancer cells, was shown to decrease with increasing 
chelation and this in vitro structure-cytotoxicity relationship have also been rationalized 
by theoretical calculations.
27c 
 
On the other hand, use of the salen ligand (Schiff bases (SB)) framework in transition-
metal chemistry is well-documented, especially in the area of asymmetric catalysis.
28
 Less 
common is the related salan (hydrogenated analogue of SB) complexes, which often 
display different structural conformation, due to greater flexibility as a consequence of 
C=N bond hydrogenation and increased N-basicity, which leads to different reactivity and 
selectivity.
29
 In contrast to the salen complexes, where the imine moiety is prone to 
decomposition in the presence of water, the higher resistance to hydrolytic decomposition 
of reduced SB compounds deserves special mention.
30
 It is noteworthy that though 
catalytic efficiency of metal complexes of tetradentate salan ligands have largely been 
investigated,
31
 their utility for the treatment of malignancies have only been exploited in 
the recent past.
32, 33
 Promising cytotoxicity results as compared to cisplatin, both in vitro 
and in vivo have been obtained for titanium(IV)
33a–h
 and vanadium(V)
29a,30,33j
 complexes, 
by tuning the steric and electronic effects of the salan ligand backbone. Though the 
synthesis, characterization and catalytic activity of analogues Mo(VI)-salan complexes 
have been reported previously,
29c‒h
 however, to the best of our knowledge, these 
complexes have never been probed for their antitumor activity, and thus demand further 
investigation. 
Recent reports from our laboratory have shown that variable valence nonoxido- and 
oxidovanadium complexes with varying aroylhydrazone ligands
34
 and some copper(I/II)-
thiosemicarbazone complexes
35
 are cytotoxic against the human cervical cancer cell line 
(HeLa) with IC50 values ranging from 9.90–44.96 M.
34,35
 It is noteworthy that evaluation 
of cell cytotoxicity of vanadium
36
 and copper
37
 have been studied extensively, but there 
are rather limited reports in the related field for cis-dioxidomolybdenum(VI) 
complexes.
38,39a,b
 Considering these facts and as a continuation of our ongoing research on 
the study of Mo(VI) complexes with multidentate ligands,
39
 especially those with 
pharmacological utility,
39a,b
 we have herein reported the synthesis of a series of cis-
dioxidomolybdenum(VI) complexes with various substituted tetradentate salan ligands. 
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These complexes were fully characterized by IR, UV-vis and NMR spectroscopy, ESI-
MS, cyclic voltammetry and X-ray crystallography. Furthermore, the DNA binding and 
cleavage activity of the complexes were probed and their cytotoxicity was surveyed by 
the MTT assay against the HeLa and HT-29 cell line. 
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5.2. EXPERIMENTAL SECTION 
5.2.1. General Methods and Materials  
[MoO2(acac)2] was prepared as described in the literature.
40
 Reagent grade solvents were 
dried and distilled prior to use. All other chemicals were reagent grade, available 
commercially and used as received. Dulbecco‟s Modified Eagle Media (DMEM), 
Dulbecco‟s phosphate buffer saline (DPBS), Trypsin EDTA solution, Fetal Bovine Serum 
(FBS), antibiotic-antimitotic solution and MTT assay kit were purchased from Himedia, 
Mumbai, India. TRITC-Phalloidin and DAPI were procured from Sigma-Aldrich, India. 
HeLa and HT-29 cell lines were procured from NCCS, Pune, India. The supercoiled (SC) 
pUC19 DNA from E. coli DH5α cells was purified by using GeneJET Plasmid Isolation 
Kit (Thermo Scientific, USA). Calf thymus (CT) DNA (biochemistry grade) and agarose 
(molecular biology grade) were purchased from SRL (India) and Sigma Aldrich (USA), 
respectively. 
Elemental analyses were performed on a VarioELcube CHNS Elemental analyzer. IR 
spectra were recorded on a Perkin-Elmer Spectrum RXI spectrometer. NMR spectra were 
recorded with a BrukerUltraShield 400 MHz spectrometer at 298 K room temperature 
using SiMe4 (
1
H and 
13
C) as an internal. Electronic spectra were recorded on a Lamda25, 
PerkinElmer spectrophotometer. Mass spectra were recorded on a SQ-300 MS instrument 
operating in positive ESI mode. Magnetic susceptibility was measured with a Sherwood 
Scientific AUTOMSB sample magnetometer. Conductivity was measured using Eutech 
CON 700 conductivity meter. A CH-Instruments (Model No. CHI6003E) electrochemical 
analyzer was used for cyclic voltammetric experiments with CH3CN solutions of the 
complexes containing TBAP (tetra butyl ammonium perchlorate) as the supporting 
electrolyte. The three electrode measurements were carried out at 298 K with a glassy 
carbon working electrode, platinum auxiliary electrode and SCE as a reference electrode. 
Caution: Although no problems were encountered during the course of this work, 
attention is drawn to the potentially explosive nature of perchlorates.  
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5.2.2. Synthesis of ligands (H2L
1–7
) 
Salan ligands, H2L
1–7
, were prepared by the one pot Mannich condensation of substituted 
phenols, formaldehyde and substituted amines in methanol medium following a standard 
procedure.
41
 The resulting white compounds were filtered, washed with ethanol and dried 
over fused CaCl2. 
H2L
1
: Yield: 0.13 g (65%). Anal. Calcd for C20H26N2O2Br2: C, 49.40; H, 5.39; N, 5.76. 
Found: C, 49.45; H, 5.40; N, 5.79%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
–1
): 2942 ν(O–H)H-bonded. 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 10.54 (s, 1H, 
OH), 7.25  6.72 (2H, aromatic), 3.68 (s, 2H, ArCH2), 2.71 (s, 2H, NCH2), 2.31 (s, 3H, 
ArCH3), 2.23 (s, 3H, NCH3). 
13
C NMR (100 MHz, DMSO-d6): δ (ppm) = 152.02, 132.44, 
129.57, 128.30, 122.23, 109.76, 61.57, 54.31, 41.84, 20.18.  
 
H2L
2
: Yield: 0.20 g (72%). Anal. Calcd for C20H26N2O2Cl2: C, 60.46; H, 6.60; N, 7.05 
Found: C, 60.42; H, 6.61; N, 7.05%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
–1
): 2900 ν(O–H)H-bonded. 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 10.87 (s, 1H, 
OH), 7.046.8 (m, 2H, aromatic), 3.64 (s, 2H, ArCH2), 2.65 (s, 2H, NCH2), 2.28(s, 3H,  
ArCH3), 2.19 (s, 3H,  NCH3).
13
C NMR (100 MHz, DMSO-d6): δ (ppm) = 154.48, 129.66, 
126.97, 125.69, 123.03, 122.12, 61.34, 53.78, 41.57, 15.62.  
 
H2L
3
: Yield: 0.15 g (66%). Anal. Calcd for C26H38N2O2Cl2: C, 64.86; H, 7.95; N, 5.82. 
Found: C, 64.86; H, 7.97; N, 5.81%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
–1
): 2956 ν(O–H)H-bonded
 1
H NMR (400 MHz, DMSO-d6): δ (ppm) = 11.47 (s, 1H, 
OH), 7.11 (m, 1H, aromatic), 3.75 (s, 2H, ArCH2), 3.26 (heptet, 1H, ArCH), 3.21(s, 2H, 
NCH2), 2.64 (s, 3H, ArCH3), 2.27 (3H, NCH3), 1.95 (m, 6H, CH(CH3)2). 
13
C NMR (100 
MHz, DMSO-d6): δ (ppm) = 154.19, 134.84, 130.76, 125.94, 124.56, 120.71, 58.18, 
53.53, 41.50, 41.49, 26.47, 22.46, 16.10. 
 
H2L
4
: Yield: 0.18 g (70%). Anal. Calcd for C33H54N2O2: C, 77.60; H, 10.66; N, 5.48. 
Found: C, 77.65; H, 10.67; N, 5.44%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
-1
): 2957 ν(O–H/ N–H)H-bonded.
 1
H NMR (400 MHz, DMSO-d6): δ (ppm) = 10.64 
(s, 2H, OH), 7.236.83 (m, 4H, aromatic), 4.193.45 (m, 6H, 3CH2), 3.03 (sextet, 1H, 
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CHCH3), 2.19 (s, 3H, CHCH3), 1.441.28 (m, 36H, 4C(CH3)3). 13C NMR (100 MHz, 
DMSO-d6): δ (ppm) = 154.07, 153.98, 140.71, 140.67, 135.69, 135.64, 123.26, 123.22, 
123.11, 123.05, 121.03, 120.71, 74.59, 59.77, 59.71, 59.42, 59.36, 59.18, 59.01, 58.02, 
34.88, 34.43, 34.14, 33.95, 31.66, 31.52, 30.96, 30.90, 29.60,  29.21, 29.10, 18.55, 15.01. 
 
H2L
5
: Yield: 0.13 g (65%). Anal. Calcd for C21H30N2O2: C, 73.65; H, 8.83; N, 8.18. 
Found: C, 73.61; H, 8.80; N, 8.18%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
–1
): 2957 ν(O–H/ N–H)H-bonded.
 1
H NMR (400 MHz, DMSO-d6): δ (ppm) = 10.80 
(s, 2H, OH), 6.93  6.52 (m, 4H, aromatic), 4.984.88 (m, 4H, ArCH2), 4.12  4.09 (sextet, 
1H, CHCH3), 3.24  3.20 (d, 2H, NCH2), 2.26 (s, 6H, p-ArCH3), 2.25 (s, 6H, o-ArCH3), 
1.00 (d, 3H, CHCH3). 
13
C NMR (100 MHz, DMSO-d6): δ (ppm) = 153.33, 149.22, 
131.60, 131.35, 130.87, 129.85, 129.64, 129.13, 128.38, 124.08, 120.83, 114.76, 59.36, 
53.09, 50.47, 48.77, 20.52, 20.38, 16.05, 15.57, 15.42.  
 
H2L
6
: Yield: 0.12g (58%). Anal. Calcd for C25H36N2O2Cl2: C, 64.23; H, 7.76; N, 5.99. 
Found: C, 64.23; H, 7.71; N, 5.96%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
–1
): 2966 ν(O–H/ N–H)H-bonded
 1
H NMR (400 MHz, DMSO-d6): δ (ppm) = 11.23 
(s, 2H, OH), 7.12‒7.11 (m, 2H, aromatic), 3.93‒3.37 (m, 4H, ArCH2), 3.32 (d, 2H, 
NCH2), 3.28‒3.01 (m, 2H, 2CH(CH3)), 2.47 (q, 1H, CHCH3), 2.29‒2.28 (m, 6H, 
2ArCH3), 1.33 (d, 3H, CH(CH3)), 1.23‒1.20 (m, 12H, 2CH(CH3)2).
 13
C NMR (100 MHz, 
DMSO-d6): δ (ppm) = 153.96, 153.79, 134.91, 134.85, 130.60, 130.55, 126.13, 126.07, 
124.86, 124.79, 120.71, 120.33, 74.72, 74.24, 59.70, 59.57, 54.41, 53.25, 26.51, 26.46, 
22.54, 22.39, 18.33, 16.17, 16.14 . 
 
H2L
7
: Yield: 0.13 g (65%). Anal. Calcd for C17H18N2O2Br4: C, 33.92; H, 3.01; N, 4.65. 
Found: C, 33.91; H, 3.05; N, 4.60%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
–1
): 2964 ν(O–H/ N–H)H-bonded
 1
H NMR (400 MHz, DMSO-d6): δ (ppm) = 10.71 
(s, 2H, OH), 6.856.62 (m, 4H, aromatic), 3.683.33 (s, 4H, ArCH2), 2.71 (m, 2H, NCH2) 
2.62 (q, 1H, CHCH3), 1.41 (d, 3H, CH(CH3)). 
13
C NMR (100 MHz, DMSO-d6): δ (ppm) 
= 154.09, 153.97, 135.79, 135.70, 127.25, 127.23, 126.86, 126.78, 126.67, 126.60, 
122.62, 122.30, 73.57, 59.25, 58.86, 57.73, 56.71, 34.74, 29.80, 20.85, 19.09.  
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5.2.3. Synthesis of complexes [MoO2L
17] (17) 
Triethylamine (1.0 mmol) was added to the methanolic solution of the ligand H2L
1–7
 (1.0 
mmol) and the resulting solution was refluxed for 0.5 h, followed by the addition of 
MoO2(acac)2 (1.0 mmol). Reflux was continued for 3 h. Yellow residue of complexes 
14, 6 and orange residue of complexes 5 and 7 were obtained immediately upon 
MoO2(acac)2 addition . Crystals suitable for X-ray analysis were isolated for [MoO2L
24
] 
(24) directly from the reaction medium. X-ray quality crystals of [MoO2L
1
] (1) were 
obtained by layer diffusion of DCM:n-hexane, [MoO2L
5
] (5) by recrystallizing in EtOH 
while that of  [MoO2L
6
] (6) by layer diffusion in DMF:EtOEt. 
 
[MoO2L
1
] (1): Yield: 57%. Anal. Calcd for C20H24N2O4Br2Mo: C, 39.24; H, 3.95; N, 
4.58. Found: C, 39.22; H, 3.98; N, 4.60%. Selected IR peaks with proposed assignments 
(KBr, νmax/cm
–1
): 923, 907 ν(Mo=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.34  6.80 
(m, 4H, aromatic), 3.56  3.51 (m, 4H, 2PhCH2), 3.02  3.00 (4H, 2NCH2), 2.74 (6H, 
2PhCH3), 2.27 (s, 6H, 2NCH3). 
13
C (100 MHz, CDCl3): δ (ppm) = 153.81, 153.21, 
133.22, 133.21, 131.06, 131.16, 129.32, 129.31, 122.93, 122.91, 113.43, 113.41, 64.83, 
64.77, 51.83, 51.82, 48.12, 48.10, 29.71, 20.23. ESI-MS: m/z 621.58 [M    CH3 + Na]
+
, 
612.94 [M]
+
, 533.81 [M    Br]+. 
 
[MoO2L
2
] (2): Yield: 65%. Anal. Calcd for C20H24N2O4Cl2Mo: C, 45.91; H, 4.62; N, 
5.35. Found: C, 45.92; H, 4.60; N, 5.38%. Selected IR peaks with proposed assignments 
(KBr, νmax/cm
–1
): 919, 897 ν(Mo=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.21–7.07 
(m, 2H, aromatic), 3.82  3.78 (d, 2H, ArCH2), 2.78 (s, 2H, NCH2), 2.50 (s, 3H, ArCH3), 
2.11 (s, 3H, NCH3). 
13
C NMR (100 MHz, CDCl3): δ (ppm) = 156.93, 129.82, 128.94, 
127.33, 124.41, 123.72, 63.12, 52.06, 47.71, 16.44. ESI-MS: m/z 523.31 [M]
+
. 
 
[MoO2L
3
] (3): Yield: 60%. Anal. Calcd for C26H36N2O4Cl2Mo: C, 51.41; H, 5.97; N, 
4.61. Found: C, 51.41; H, 5.99; N, 4.59%. Selected IR peaks with proposed assignments 
(KBr, νmax/cm
–1
): 913, 901 ν(Mo=O). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 7.17 (s, 
2H, aromatic), 3.34–3.32 (m, 4H, 2ArCH2), 3.21–3.17 (m, 2H, 2ArCH), 2.80‒2.78 (m, 
4H, 2NCH2), 2.54–2.49 (m, 6H, 2Ar-CH3), 2.29 (m, 6H, 2NCH3), 1.16–1.10 (m, 12H, 
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2CH(CH3)2). 
13
C NMR (100 MHz, CDCl3): δ (ppm) = 156.31, 155.98, 136.17, 136.48, 
131.92, 131.86, 128.42, 127.93, 125.54, 125.01, 123.29, 122.86, 60.51, 60.22, 48.34, 
48.12, 40.19, 39.98, 26.76, 26.73, 23.59, 23.51, 22.66, 22.62, 16.59, 16.40. ESI-MS: m/z 
607.42 [M]
+
. 
 
[MoO2L
4
] (4): Yield: 62%. Anal. Calcd for C33H52N2O4Mo: C, 62.25; H, 8.23; N, 4.40. 
Found: C, 62.21; H, 8.24; N, 4.43%. Selected IR peaks with proposed assignments (KBr, 
νmax/cm
–1
): 918, 905 ν(Mo=O). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 7.14–6.84 (m, 
4H, aromatic), 4.10–3.36 (m, 6H, 3CH2), 3.55 (m, 1H, CHCH3), 2.83 (s, 3H, CHCH3), 
1.35–1.19 (m, 36H, 4C(CH3)3). 
13
C NMR (100 MHz, DMSO-d6): δ (ppm) = 154.01, 
153.98, 141.41, 140.25, 134.98, 133.41, 123.56, 123.34, 122.52, 122.91, 121.63, 121.42, 
75.41, 59.26, 58.96, 57.23, 40.57, 40.36, 35.25, 35.33, 34.86, 34.38, 34.33, 34.21, 33.50, 
31.96, 31.92, 30.48, 30.33, 29.88, 29.86, 18.96, 14.74. ESI-MS: m/z 636.72 [M]
+
. 
 
[MoO2L
5]∙EtOH (5): Yield: 70%. Anal. Calcd for C23H34N2O5Mo: C, 53.70; H, 6.66; N, 
5.45. Found: C, 53.71; H, 6.68; N, 5.41%. Selected IR peaks with proposed assignments 
(KBr, νmax/cm
–1
): 920, 892 ν(Mo=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.92  6.70 
(m, 4H, aromatic), 4.16‒3.96 (s, 4H, 2ArCH2), 2.90  2.83 (m, 1H, CHCH3), 2.54  2.48 (m, 
2H, NCH2), 2.25  2.20 (m, 12H, 4ArCH3), 1.16 (d, 3H, CHCH3). 
13
C NMR (100 MHz, 
CDCl3): δ (ppm) = 156.81, 156.67, 130.18, 129.85, 128.23, 128.19, 127.98, 127.82, 
127.71, 126.39, 121.29, 121.19, 53.05, 52.89, 50.24, 49.84, 49.05, 20.58, 20.55, 17.31, 
17.25, 14.20. ESI-MS: m/z 468.46 [M ‒ EtOH]+. 
 
[MoO2L
6
]∙DMF (6): Yield: 70%. Anal. Calcd for C28H41Cl2MoN3O5: C, 50.46; H, 6.20; 
N, 6.30. Found: C, 50.41; H, 6.24; N, 6.33%. Selected IR peaks with proposed 
assignments (KBr, νmax/cm
–1
): 904, 882 ν(Mo=O). 1H NMR (400 MHz, DMSO-d6): δ 
(ppm) = 7.17‒6.90 (m, 2H, aromatic), 4.25‒3.93 (m, 4H, 2PhCH2), 3.57 (m, 1H, CHCH3), 
3.20–3.15 (m, 2H, 2ArCH), 2.77 (d, 2H, NCH2), 2.312.09 (m, 6H, 2ArCH3), 1.23‒1.12 
(m, 12H, 2CH(CH3)2), 1.10 (d, 3H, NCHCH3). 
13
C NMR (100 MHz, DMSO-d6): δ (ppm) 
= 157.32, 156.86, 136.91, 136.84, 131.25, 131.09, 126.39, 126.37, 125.52, 125.07, 
120.23, 120.05, 53.64, 51.41, 50.92, 50.40, 47.51, 27.42, 22.72, 22.60, 22.48, 22.42, 
16.30, 16.23, 16.09. ESI-MS: m/z 592.48 [M ‒ DMF ‒ H]+. 
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[MoO2L
7
] (7): Yield: 68%. Anal. Calcd for C17H16N2O4Br4Mo: C, 28.05; H, 2.22; N, 
3.85. Found: C, 28.05; H, 2.24; N, 3.87%. Selected IR peaks with proposed assignments 
(KBr, νmax/cm
–1
): 931, 833 ν(Mo=O). 1H NMR (400 MHz, DMSO-d6):δ (ppm) = 7.24‒
7.00 (m, 4H, aromatic), 3.82‒3.81 (m, 4H, ArCH2), 3.03 (m, 1H, CHCH3), 2.76 (d, 2H, 
NCH2), 1.47 (d, 3H, CH(CH3)). 
13
C NMR (100 MHz, DMSO-d6): δ (ppm) = 156.80, 
156.65, 130.18, 129.84, 128.23, 128.33, 128.19, 127.99, 127.71, 126.39, 121.29, 121.19, 
56.48, 52.88, 49.83, 17.27, 14.19. ESI-MS: m/z 727.12 [M]
+
. 
 
5.2.4. X-ray crystallography 
General handling and description of equipment 
Suitable single-crystals were either gathered from solution or selected from solid samples. 
Inherent impurities of other crystals were removed carefully and appropriate size was 
achieved by cutting. Therefore, crystal shape and size given in the table of 
crystallographic data only approximate the properties of the crystal measured and not of 
the naturally grown crystals. The data for complex 1 was collected on SuperNova AS2 
using high intensity of SuperNova microfocus Cu source (λ = 1.54184 Å) and a highly 
sensitive Atlas CCD detector at ~ 100 K. Single crystals of 2 were mounted on a Bruker 
Smart Apex CCD diffractometer, equipped with a graphite monochromator and a Mo K 
radiator (λ = 0.71073 Å) at 150 K. Crystals of complexes (3 – 6 ∙ DMSO) were mounted 
on a 50 μm MicroMeshMiTeGenMicromountTM using FROMBLIN Y perfluoropolyether 
(LVAC 16/6, Aldrich) before they were centred on a Bruker Kappa APEX II CCD-based 
4-circle X-ray diffractometer using graphite monochromated Mo Kα radiation (λ = 
0.71073 Å) of a fine focus molybdenum-target X-ray tube operating at 50 kV and 30 mA. 
In case crystals were cooled this was achieved with a Kryoflex low temperature device. 
Data collection and handling 
Integrated intensities were obtained with the Bruker SAINT
42
 software package using a 
narrow-frame algorithm performing spatial corrections of frames, background 
subtractions, Lorentz and polarization corrections, profile fittings and error analyses. 
Semi-empirical absorption corrections based on equivalent reflections were made by use 
of the program SADABS.
43
  Details on the data collection parameters applied on the 
individual crystals are summarized in Table 5.1 with Rint = Σ|Fo
2
-Fo
2(mean)|/Σ[Fo
2
] and 
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Rsigma = Σ[(Fo
2)]/Σ[Fo
2
]. Space groups
44
 were determined from systematic absences and 
E-value statistics evaluated by the examine data routine of the APEX program suite.  
General information on structure solution and refinement 
Structures were solved by direct methods or Patterson methods and subsequent difference 
Fourier syntheses of the program SHELXS
45
 and refined by full-matrix least-squares 
techniques on F
2
 with SHELXL,
45
 applying anisotropic displacement factors for all non-
hydrogen atoms. Atomic scattering factors were taken from International Tables for 
Crystallography.
46
 No extinction corrections were applied.  
In all cases, final agreement indices were defined as following: R1 = Σ||Fo| - |Fc||/Σ|Fo| and 
wR2 = [Σ[w(Fo
2
-Fc
2
)
2]/Σ(Fo
2
)
2
]]
1/2
. Weighting function used: w = 1/[2(Fo
2
) + (pP)
2
 + qP] 
with P= (Fo
2
 + 2Fc
2)/3. Goof = [Σ[w(Fo
2
-Fc
2
)
2
]/(n-p]
1/2
 where n is the number of 
reflections and p is the total number of parameters refined. All non-hydrogen atoms were 
refined with anisotropic displacement parameters and hydrogen atoms with common 
isotropic displacement parameters for chemically related groups of hydrogen atoms. 
Although most of the hydrogen atoms could be localised in difference Fourier syntheses, 
those of the organic groups were refined in geometrically optimized positions riding on 
the corresponding carbon atoms with C-H distances of 0.98 Å (-CH3), 0.99 Å (-CH2-) 
1.00 Å (-CH=) and 0.95 Å (CHarom). Hydrogen atoms bonded to oxygen were refined with 
respect to a common O-H distance of 0.96 Å before they were fixed and allowed to ride 
on the corresponding oxygen atoms. Further details on the results of structure refinement 
are summarized in Table 5.1. 
With the exception of complex 2 all other compounds crystallize in centrosymmetric 
space groups. Complex 2 crystallizes in the non-centrosymmetric space group Fdd2 with 
a Flack-Parameter of 0.020(9). 
Disorder was only observed in case of one t-butyl group of complex 4, the methyl groups 
of which adopt two different positions of occupancy 0.646/0.354. The positions of these 
carbon atoms were refined without constrains in contrast to the anisotropic displacement 
parameters which were set equal for neighboring atoms. 
Figures were drawn using DIAMOND
47
 and Mercury,
48
 respectively. In the ball-and stick 
models all atoms are drawn as thermal displacement ellipsoids of the 40% level with 
exception of the hydrogen atoms which are shown as spheres of arbitrary radii. Hydrogen 
bonds are drawn in red as dashed sticks.  
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Table 5.1. Crystal data and refinement details for [MoO2L
1-6
] (1‒6) 
Complex 1 2 3 4 5  6  
Empirical 
formula 
C20H24Br2
MoN2O4 
C20H24Cl2
MoN2O4 
C26H36Cl2
MoN2O4 
C33H52Mo
N2O4 
C23H34Mo
N2O5 
C28H41Cl2
MoN3O5 
Formula 
weight 
612.17 523.25 607.41 636.71 514.46 666.48 
Temperat
ure 
293(2) K 150(2) K 200(2) K 100(2) K 100(2) K 100(2) K 
Radiation CuKα MoKα MoKα MoKα MoKα MoKα 
Crystal 
system 
triclinic 
orthorhom
bic 
orthorhom
bic 
orthorhom
bic 
monoclini
c 
monoclinic 
Space 
group 
P-1 Fdd2 Pbca Pbca P21/c P21/n 
Unit cell 
dimensio
ns 
a =    
7.2058(2) 
Å 
b =    
7.6148(3) 
Å 
c =  
20.9813 
(7) Å 
α =   
92.634(3)° 
β =   
90.386(2)° 
γ = 
111.985 
(3)° 
a = 
35.1333(8
) Å 
b = 
10.1735(2
) Å 
c = 
11.8528 
(3) Å 
α = 90°  
 = 90° 
γ  = 90° 
a = 
13.6828(6
) Å 
b = 
11.2862(5
) Å 
c = 
34.5755 
(14) Å 
α = 90°  
 = 90° 
γ  = 90° 
a = 
12.4692(3
) Å 
b = 
15.6244(5
)  Å 
c = 
34.2618 
(9) Å 
α = 90° 
 = 90° 
γ = 90° 
a =   
8.0902(3) 
Å 
b= 
11.3676(4
) Å 
c = 
26.5906 
(9) Å 
α = 90° 
= 
95.336(2)
° 
γ = 90° 
a = 
14.9920(5) 
Å  
b =   
8.5462(3) 
Å 
c = 
23.5139 (8) 
Å 
α = 90 
 = 
92.040(2) 
γ = 90 
Volume 
(Å
3
) 
1066.1(1) 4236.5(2)   5339.4(4)  6675.0(3)  2434.8(2)  3010.8(2)  
Z 2 8 8 8 4 4 
Density 
(calculate
d) 
1.907 
Mg/m
3
 
1.641  
Mg/m
3
 
1.511 
Mg/m
3
 
1.267 
Mg/m
3
 
1.403 
Mg/m
3
 
1.470 
Mg/m
3
 
Absorptio
n 
coefficien
t 
9.676  
mm
-1
 
0.901  
mm
–1
 
0.726 
mm
–1
 
0.429 
mm
–1
 
0.573 
mm
–1
 
0.654 mm
–1
 
F(000) 604 2128 2512 2704 1072 1384 
Crystal 
size 
0.794 x 
0.1196 x 
0.1486 
mm 
0.60 x 
0.60 x 
0.15 mm 
0.34  
0.08  
0.05 mm
 
0.24  
0.15  
0.11 mm 
0.29  
0.29  
0.18 mm 
0.22  0.15 
 0.12 mm 
Theta 4.22° to 2.32° to 2.79° to 2.67° to 2.53° to 2.74° to 
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5.2.5. DNA binding experiments 
Absorption spectral studies The binding of the dioxidomolybdenum (VI) complexes to 
calf thymus DNA (CT-DNA) was carried out using a Perkin-Elmer Lambda35 
spectrophotometer as described previously.
34b,d
 UV-vis spectroscopy was used to perform 
the titration experiments with variable CT-DNA concentrations ranging from 0 to 70 µM 
against a fixed concentration of dioxidomolybdenum (VI) complex (25 µM) in 10 mM 
Tris–HCl buffer (pH 8.0) containing 1% DMF. Binding of the ligands to CT-DNA was 
also studied with the aid of UV-vis spectroscopy. For this, the concentration of ligand was 
fixed at 25 µM and was titrated with variable CT-DNA concentration ranging from 0 to 
70 µM in 10 mM Tris–HCl buffer (pH 8.0) containing 1% DMF. For both complexes and 
ligands, the spectra were recorded after each addition of CT-DNA (5 µM). The data 
obtained from the titration experiments were then fit to Eq. 5.1 to obtain binding constant 
Kb.
34b,d 
     
     
  
     
     
  
 
         
                                 Eq. 5.1 
where [DNA] is the concentration of DNA base pairs, εa, εf, and εb correspond to apparent 
extinction coefficient for the complex i.e. Abs/[complex] in the presence of DNA, in 
absence of DNA and to fully bound DNA, respectively. A plot of [DNA]/(εa – εf) vs 
[DNA] gave a slope and intercept equal to 1/(εb – εf) and 1/Kb(εb – εf), respectively; Kb is 
calculated from the ratio of the slope to the intercept.  
range for 
data 
collection 
67.00° 30.03° 28.00° 28.00° 28.00 ° 28.00° 
Reflectio
ns 
collected 
5531 15517 91268 264860 89947 120330 
Reflectio
ns unique 
3424 2334 6403  8062 5826  7243 
Final 
R1/wR2 
[I>2sigm
a(I)] 
0.0315/0.0
828 
0.0152/0.0
427 
0.0393/0.0
717 
0.0324/0.0
717 
0.0507/0.
1127 
0.0472/0.1
019 
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Thermal denaturation studies Thermal denaturation studies were carried out in 
absorbance mode using a Chirascan CD spectropolarimeter (Applied Photophysics, UK) 
equipped with a peltier temperature controller. The thermal denaturation of 100 µM CT-
DNA in the absence and presence of 25 µM complexes were carried out by monitoring 
the absorbance at 260 nm in the temperature range of 30–90 oC in 10 mM Tris-HCl buffer 
(pH 8.0) containing 1% DMF. The ramp rate for each of the denaturation experiment was 
0.50 
o
C/min. The melting temperature (Tm) was calculated from the derivative plot 
(dA260/dT vs T) of the melting profile.
49
 
Circular dichroism studies. Chirascan CD spectropolarimeter (Applied Photophysics, 
UK) equipped with a peltier temperature controller was used to perform the circular 
dichroism (CD) spectroscopic studies. All the CD studies were done at 25 ºC. The CD 
spectra of 100 µM CT-DNA in the absence and presence of 25 µM complexes were 
obtained in the wavelength range of 240–400 nm in 10 mM Tris-HCl buffer (pH 8.0) 
containing 1% DMF using quartz cell with 10 mm path length.
34b,d
 
Competitive DNA binding fluorescence measurements The competitive binding 
experiments were done as described previously.
35
 Briefly, each of the DNA binding probe 
i.e. 4′,6-diamidino-2-phenylindole (DAPI), methyl green (MG) and ethidium bromide 
(EB), 2 µM each, was separately incubated with 50 µM of CT-DNA for 1 h at 25 ºC. 
Thereafter, the competitive binding of the dioxidomolybdenum (VI) complex (1‒7) with 
DAPI, MG and EB bound CT-DNA was studied by measuring the fluorescence intensities 
of the DAPI, MG and EB bound CT-DNA with increasing concentration of the complexes 
(0-90 µM). The fluorescence emission intensities of DAPI, MG and EB at 455 nm 
(excitation 358 nm), 672 nm (excitation 633 nm) and 597 nm (excitation 510 nm) 
respectively, was monitored with the aid of Fluoromax 4P spectrofluorimeter (Horiba 
Jobin Mayer, USA). 
5.2.6. DNA cleavage experiments 
For DNA cleavage experiments, 300 ng supercoiled (SC) pUC19 DNA was used and all 
experiments were carried out in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. 
Chemical-induced DNA cleavage. For chemical nuclease studies, the cleavage 
experiments were carried out in dark using 0.5 mM hydrogen peroxide as the oxidising 
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agent in the absence and presence of 1–100 µM complexes. The reactions were incubated 
at 37 ºC for 3 h and analysed for DNA cleaved products by agarose gel electrophoresis. 
Photo-induced DNA cleavage. The photo-induced DNA cleavage studies were done as 
described previously.
34b,d 
Briefly, the photolytic DNA cleavage experiments were carried 
out on supercoiled (SC) pUC19 DNA (300 ng) with varying concentration from 1 to 100 
µM of complexes in 50 mM Tris HCl buffer (pH 8.0) containing 1% DMF. The extent of 
DNA cleavage was measured from the intensities of the bands using the UVP Gel 
Documentation System (Gel Doc It
2
). The observed error in measuring the band 
intensities ranged between 2–5%. The mechanistic aspect behind the DNA cleavage was 
studied using four different additives: two singlet oxygen quenchers (sodium azide and L-
histidine) and other two hydroxyl radical quenchers (KI and D-mannitol). These additives 
were added to the reaction mixture prior to the addition of the complex. The concentration 
of each additive was 0.5 mM. 
 
5.2.7. Cytotoxic Activity 
Cytotoxicity of dioxidomolybdenum(VI) complexes (1‒7) was evaluated in vitro against 
two different human cancerous cell lines namely HeLa (cervical cancer) and HT-29 
(colon cancer) by MTT assay. Prior to the experiment, cells were maintained in DMEM 
with 10% FBS in a humidified (95% humidity) CO2 incubator (5% CO2) at 37 
o
C with 
regular passages at 70‒80 % cell confluence. For the cytotoxicity study, cells were seeded 
into 96 well plate at a concentration of 1 x 10
4
 cells/ well. Aqueous suspensions of the 
compounds (1‒7) of four different concentrations (100, 50, 10 and 5 μg/ml) were prepared 
in complete DMEM media. After 12 h of initial seeding, cells were treated with 
compounds (1‒7) for 48h. Tissue culture plate (TCP) was taken as controls. After 48 h, 
MTT assay was performed using a MTT assay kit following the manufacturer's 
instruction. The absorbance of the final product was measured at 595 nm. The experiment 
was performed in quadruplets. The cytotoxicity index of the compounds was calculated 
using the equation Eq. 5.2 given below, expressed as mean ± S.D. Statistical significance 
of the data was evaluated using single variance ANOVA under 95 % confidence interval.     
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                       Eq. 5.2 
 
IC50 value of the compounds was calculated from the absorbance-concentration plot 
following standard procedure.
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Cytoskeletal organization and the integrity of the nucleus were examined using 
fluorescence microscopy (Olympus). For this purpose, cells were fixed with 4 % 
paraformaldehyde for 15 min, permeabilized for 10 min with 0.25% Triton X-100 in PBS 
and stained with TRITC-Phalloidin and DAPI.
51
 For this study, cells were treated with the 
compounds at a concentration of 100 μg/ml for 36 h.  
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5.3. RESULTS AND DISCUSSION 
5.3.1. Synthesis. 
The synthetic methods of all the complexes are illustrated in Scheme 5.1. Reaction of 
MoO2(acac)2 with tetradentate diamino bis(phenolato) (ONNO) “salan” ligands (H2L
1‒7
) 
in the molar ratio of 1:1 in MeOH formed a yellow for 1–4 and 6 and an orange 
precipitate for 5 and 7, of stoichiometry [MoO2L
1‒7
]. The purity of these compounds was 
further confirmed by elemental analyses. NMR spectra and ESI-MS were consistent with 
the X-ray structures. The complexes were soluble in aprotic solvents, DMF and DMSO, 
and sparingly soluble in protic solvents. It was determined that the complexes are 
diamagnetic, indicating the presence of molybdenum in the +VI oxidation state and are 
non-conducting in solution. 
All the complexes were stable in both solid and solution phases. The solution phase 
stability of the complexes was confirmed by NMR spectral studies (Figure 5.1). 
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Scheme 5.1. Schematic representation of ligands (H2L
1-7
) and synthesis of complexes, 
[MoO2L
1-7
]
 
(1–7)  
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Figure 5.1. Time dependent 
1
H NMR spectrum of MoO2L
5
. EtOH (5) in CDCl3. 
 
5.3.2. Spectral characteristics 
Infrared spectra of these complexes in the 940–833 cm−1 region display a strong two-band 
pattern characteristic of a cis-dioxidomolybdenum(VI) center.
39
 Their IR spectra also 
contain all the characteristic bands of the coordinated tetradentate ligands. Absence of a 
broad peak in the 3600‒3400 cm-1 range as compared to the ligand indicates the 
deprotonation of the two phenolic OH groups of the ligand. 
The electronic spectra of all the complexes (Table 5.2) were recorded in DMF solutions. 
Two strong absorptions are observed in the wavelength range 388–275 nm. The lower 
energy medium intensity absorptions at around 388–330 nm are ascribable to LMo(dπ) 
LMCT transitions whereas the higher energy absorptions are likely to be due to ligand 
centered transitions.
39
 A representative spectrum of 1 is shown in Figure 5.2. 
 
179 
 
Table 5.2. Electronic spectra for complexes [MoO2L
1‒7
] (1–7) in DMF solution. 
Complex                                                   λmax/nm (εmax/M
–1
cm
–1
) 
[MoO2L
1
] (1)                                             277(51814), 345(26982) 
[MoO2L
2
] (2)                                             278(45121), 385(27637) 
[MoO2L
3
] (3)                                             277(23258), 388(15223) 
[MoO2L
4
] (4)                                             279(25123), 365(15921) 
[MoO2L
5
].EtOH (5)                                   277(26126), 355(15711) 
[MoO2L
6
].DMF (6)                                   276(23470), 330(16352) 
[MoO2L
7
] (7)                                             275(22768), 346(16939) 
 
 
Figure 5.2. Electronic absorption spectrum of [MoO2L
1
] (1). 
 
The NMR spectra (
1
H and 
13
C) of 1–3, 5 were recorded using CDCl3 and 4 and 7 with 
DMSO–d6. The 
1H NMR spectra of the free ligands exhibit resonance in the range δ = 
11.47–10.54 ppm due to phenolic OH, but upon complex formation the peak disappears. 
The aromatic peaks for the complexes appear in the region δ = 7.34‒6.80 ppm, while the 
aliphatic protons ( –CH, –CH2 and CH3) are observed in δ = 4.25‒1.10 ppm region. The 
detailed NMR data has been included in the experimental section. The representative 
1
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NMR spectrum of complex 2 is shown in Figure 5.3. The peaks observed in the 
13
C NMR 
spectra of 1–7 at δ = 157.32–113.41 ppm region have been assigned to aromatic carbons, 
while the aliphatic protons appear at δ = 75.41–14.19 ppm region. The representative 13C 
NMR spectrum of 2 is shown in Figure 5.4. Due to the symmetry present in 2, half of the 
total number of protons and carbon atoms appear in the 
1
H and 
13
C NMR spectra, 
respectively. 
 
 
Figure 5.3. 
1
H NMR spectrum of [MoO2L
2
] (2). 
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Figure 5.4. 
13
C NMR spectrum of [MoO2L
2
] (2) in CDCl3. 
 
5.3.3. ESI-MS. ESI-MS of complexes (1−7) have been recorded in acetonitrile solution. 
Mass spectral analysis for 1‒4 and 7 show molecular ion peaks at m/z 612.94, 523.31, 
607.42, 636.72 and 727.12 respectively, whereas 5 and 6 shows the peaks for [5 ‒ EtOH]+ 
and [6 ‒ DMF ‒ H]+ at 468.46 and 592.48, respectively. In addition to the molecular ion 
peak, 1 shows peaks at m/z 621.58 and 533.81 corresponding to [1 ‒ CH3 + Na]
+
 and 
533.81 [1 ‒ Br]+. Figures 5.5, 5.6 and 5.7 depict representative ESI-MS spectra of 
complexes 1, 2 and 7, respectively. 
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Figure 5.5. ESI-MS of [MoO2L
1
] (1) in CH3CN. 
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Figure 5.6. ESI-MS of [MoO2L
2
] (2) in CH3CN. 
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.
 
Figure 5.7. ESI-MS of [MoO2L
7
] (7) in CH3CN. 
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5.3.4. Electrochemical Properties  
The electrochemical properties of complexes (1  7) have been examined in DMF solution 
by cyclic voltammetry using a Pt working electrode, Pt auxiliary electrode, and an 
Ag/AgCl reference electrode using 0.1 M TBAP as electrolyte. All the complexes show a 
quasi-reversible single electron wave (ΔEp = 151  179 mV) in the cathodic region at E1/2             
range   1.28 to   1.33 V, which is assigned to the Mo(VI)/ Mo(V) reduction.29c The ligand 
is redox inactive in the potential window of   1.0 to   1.6 V in the cathodic region. The 
one-electron nature of this reduction has been tentatively established by comparing its 
current height with that of the standard ferrocene-ferrocenium couple under the same 
experimental conditions. The potential data are listed in Table 5.3. A representative 
voltammogram of complex 7 is depicted in Figure 5.8.  
 
Table 5.3. Cyclic voltammetric results for [MoO2L
1-7
] (1–7) at 298 K.[a] 
 
Complex E1/2  (V) ΔEP (mV) 
[MoO2L
1
] (1)  –1.29 154 
[MoO2L
2
] (2)  –1.30 155 
[MoO2L
3
] (3)  –1.32 175 
[MoO2L
4
] (4)  –1.31 179 
[MoO2L
5
].EtOH (5)  –1.28 151 
[MoO2L
6
].DMF (6) –1.33 177 
[MoO2L
7
] (7)  –1.30 170 
 
[a]
1  7 in DMF at a scan rate of 100 mV s–1. E1/2 = (Ep
a
 + Ep
c
)/2, where Ep
a
 and Ep
c 
are 
anodic and cathodic peak potentials vs. Ag/AgCl, respectively. ΔEP = Ep
a
 – Ep
c
. 
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Figure 5.8. Cyclic voltammogram of [MoO2L
7
] (7) showing reduction                   
(Mo(VI)  Mo(V)) at the molybdenum(VI) center. 
 
5.3.5. Description of X-ray structures of [MoO2L
1  6] (1  6)  
The solid state structures of complexes 1‒6 are shown in Figure 5.9, selected bond 
parameters are listed in Table 5.4. The asymmetric unit of all these complexes consists of 
a complete formula unit with the exception of complex 2, which belongs to point group 
C2. Complexes 5 and 6 had EtOH and DMF, respectively, as solvent of crystallization. 
All complexes exhibit the same structural features with some conformational differences 
arising from steric and electronical requirements of the individual ligands. At the metal 
site, the MoO2-fragment with its double bonded oxygen atoms is only slightly affected by 
ligand effects. The Mo=O bonds are in a very narrow range [1.701(2)‒1.719(2) Å, mean 
value: 1.710(5) Å] as are the O=Mo=O bond angles [107.8(1)°‒109.7(2)°, mean value: 
108.7(6)°]. In each case, the ligand expands the coordination sphere of the Mo atom to a 
distorted octahedron via two oxygen and two nitrogen atoms (Figure 5.10). Small bond 
length variations are observed in case of the corresponding Mo-O bonds [1.932(3)–
1.959(3) Å, mean value: 1.944(8) Å] but larger ones in case of the much weaker Mo‒N 
bonds [2.303(3)–2.399(3) Å, mean value 2.347(41) Å]. In addition, bond angles are 
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sensitive to ligand variations. Especially, the bond angle between the two trans positioned 
oxygen atoms of the ligand shows a strong influence [(O1-Mo1-Mo2): 151.6(1)° ‒ 
160.1(1)°, mean value 156.2(33)°]. Within the ligand, the conformation of the                   
–CH2‒CH2‒, respectively –CHMe-CH2- bridge is very similar in all complexes as the 
corresponding torsion angles [(N1-C15-C16-N2), Table 5.4] demonstrate [53.3(2)° ‒ 
57.1(5)°, mean value: 55.8(14)°]. Most of the conformational differences between the 
different ligands, however, are picked up from the neighboring atoms C7 and C14 as the 
torsion angles C7-N1-C15-C16 [-155.7(3)° ‒ -170.0(3)°, mean value: 164.3(55)°] and 
C15-C16-N2-C14     [-161.6(3)° ‒ -171.2(2)°, mean value: 168.0(51)°] reveal. Therefore 
these two atoms constitute the rotatable linkage between the nitrogen atoms on the one 
side and the oxygen atoms of the phenyl rings on the other side, which allow the phenyl 
groups of the ligand to adopt different orientations relative to each other with respect to 
the different substituents they bear. Dihedral angles between the phenyl groups therefore 
vary from 41.3(1)° to 66.4(1)°. 
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1 2 
3 
 
4 
5 6 
 
Figure 5.9. Ball-and-stick models of complexes [MoO2L
1-6
] (1  6) with atomic numbering 
scheme used. For clarity solvent molecules as well as atoms of the CH3-groups of the i-
propyl and t-butyl groups of [MoO2L
3
] (3) and [MoO2L
4
] (4) have been omitted. In case 
of [MoO2L
2
] (2) the twofold rotation axis of point group C2 has been drawn in orange and 
only atoms of the asymmetric unit have been labelled. With exception of the hydrogen 
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atoms, which are drawn as spheres of arbitrary radius, all other atoms are represented as 
thermal displacement ellipsoids of 50% probability level. 
 
Table 5.4. Selected bond parameters of [MoO2L
1-6
] (1  6) 
 1 2
1
 3 4 5  6  
Bond distance [Å] 
Mo(1)-O(1)                     1.950(3) 1.943(2) 1.948(2) 1.946(1) 1.932(3) 1.945(2) 
Mo(1)-O(2)                  1.959(3) 1.943(2) 1.938(2) 1.941(1) 1.947(3) 1.948(2) 
Mo(1)-O(3)                     1.705(3) 1.713(2) 1.705(2) 1.705(2) 1.713(3) 1.708(2) 
Mo(1)-O(4)                     1.711(3) 1.713(2) 1.701(2) 1.715(2) 1.716(3) 1.719(2) 
Mo(1)-N(1)                     2.399(3) 2.390(2) 2.387(3) 2.329(2) 2.311(4) 2.303(3) 
Mo(1)-N(2)                     2.396(3) 2.390(2) 2.389(3) 2.345(2) 2.318(3) 2.311(3) 
Bond angles [°]  
O(1)-Mo(1)-O(2) 160.1(1) 158.97(9) 156.6(1) 151.55(6) 156.9(1) 153.1(1) 
O(1)-Mo(1)-O(3) 98.2(1) 98.07(6) 97.3(1) 99.19(7) 98.2(2) 100.0(1) 
O(1)-Mo(1)-O(4) 93.7(1) 94.15(6) 94.0(1) 99.22(7) 96.5(1) 96.8(1) 
O(1)-Mo(1)-N(1) 79.6(1) 79.22(5) 76.1(1) 76.85(6) 79.0(1) 78.4(1) 
O(1)-Mo(1)-N(2) 84.1(1) 83.95(6) 81.6(1) 80.08(6) 84.4(1) 81.8(1) 
O(2)-Mo(1)-O(3) 93.5(1) 94.15(6) 97.1(1) 96.99(6) 94.1(1) 96.6(1) 
O(2)-Mo(1)-O(4) 97.9(1) 98.08(6) 99.1(1) 97.45(7) 97.7(1) 97.8(1) 
O(2)-Mo(1)-N(1) 84.6(1) 83.95(6) 85.4(1) 79.68(6) 81.7(1) 80.8(1) 
O(2)-Mo(1)-N(2) 79.9(1) 79.22(5) 79.5(1) 77.76(6) 77.2(1) 76.2(1) 
O(3)-Mo(1)-O(4) 108.7(2) 108.7(1) 107.8(1) 108.88(8) 109.7(2) 108.2(1) 
O(3)-Mo(1)-N(1) 88.8(1) 89.09(7) 90.3(1) 90.81(7) 89.4(2) 89.6(1) 
O(3)-Mo(1)-N(2) 161.7(1) 161.86(7) 164.2(1) 163.33(7) 161.9(2) 162.7(1) 
O(4)-Mo(1)-N(1) 162.1(1) 161.86(7) 160.6(1) 160.31(7) 160.9(2) 162.1(1) 
O(4)-Mo(1)-N(2) 89.2(1) 89.09(7) 88.0(1) 87.59(7) 87.7(2) 88.5(1) 
N(1)-Mo(1)-N(2) 73.8(1) 73.52(8) 74.1(1) 72.75(6) 73.4(1) 73.9(1) 
Torsion angles [°] 
C(1)-C(7)-N(1)- 59.7(4) 55.8(2) 52.0(4) 68.3(2) 63.5(5) 62.5(4) 
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C(15) 
C(7)-N(1)-C(15)-
C(16) 
-
163.2(3) 
-161.7(2) -
155.7(3) 
-167.0(2) -
170.0(3) 
-168.2(3) 
N(1)-C(15)-
C(16)-N(2) 
56.0(4) 53.3(2) 56.9(4) 55.2(2) 57.1(5) 56.5(3) 
C(15)-C(16)-
N(2)-C(14) 
-
161.6(3) 
-161.7(2) -
168.5(3) 
-171.2(2) -
172.2(4) 
-172.8(3) 
C(16)-N(2)-
C(14)-C(8) 
57.1(4) 55.8(2) 62.2(4) 67.1(3) 68.3(5) 70.4(4) 
Angle between both phenyl rings [°] 
C(1)-C(6)/C(8)-
C(13) 
66.4(1) 63.45(5) 54.5(1) 43.0(1) 53.5(2) 41.3(1) 
 
1
As the asymmetric unit of [MoO2L
2
] (2) consists of half a molecule missing data have 
been included using the symmetry related values. 
 
 
Figure 5.10. The coordination sphere of the Mo atom and the conformational flexible 
parts of the ligand of [MoO2L
5
] (5). Phenyl groups are visualized as hexagons. 
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5.3.6. DNA binding studies 
Solution phase stability 
The solution phase stability was studied over a period of 72 h at 25 ºC for all the 
dioxidomolybdenum(VI) complexes (1–7) with the aid of electronic absorption 
spectroscopic studies. All the complexes were stable and did not show any change in the 
electronic absorption spectra after incubation at 25 ºC for 72 h (Figure 5.11). 
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Figure 5.11. Absorption spectral traces of [MoO2L
1
] (1) (A), [MoO2L
2
], (2) (B), 
[MoO2L
3
], (3) (C), [MoO2L
4
], (4) (D), [MoO2L
5
], (5) (E), [MoO2L
6
], (6) (F) and 
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[MoO2L
7
], (7) (G) (25 µM each) in 10 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. 
The spectra were recorded up to 72 h at room temperature.  
 
Absorption spectroscopic studies  
At first, the equilibrium binding constant (Kb) of the dioxidomolybdenum(VI) complex  
1–7 with CT-DNA was determined with the aid of UV-vis titration experiments (Figure 
5.12 and Table 5.5). Complexes 1–7 have in particular two distinct absorption bands in 
the region 388‒330 and 279–275 nm which is attributed to L–Mo(dπ) LMCT and intra-
ligand transitions, respectively. On addition of CT-DNA to the complex solution, the UV-
vis absorption bands in the region 390–275 nm showed a hypochromic shift for all the 
complexes (Figure 5.12) which indicated the interaction between the dioxidomolybdenum 
(VI) complexes with CT-DNA. The observed hypochromicity of 1–7, in the intra-ligand 
transition band may be due to the interaction between the electronic states of the 
chromophores of the ligands and the DNA bases.
52,53,54 
 
Table 5.5. DNA binding parameters for complexes [MoO2L
1-7
] (1–7) 
 
Complex Binding constant (Kb)
a
 (M
-1
) ∆Tm
b
 (
o
C) 
[MoO2L
1
], 1 1.06  104 +1.50 
[MoO2L
2
], 2 4.74  105 +3.00 
[MoO2L
3
], 3 8.85  104 +0.50 
[MoO2L
4
], 4 2.61  104 +1.00 
[MoO2L
5
], 5 5.37  104 +0.50 
[MoO2L
6
], 6 1.08  104 +0.50 
[MoO2L
7
], 7 2.43  104 +1.00 
 
a
 DNA binding constants were determined by the UV-vis spectral method. 
b
 Change in the melting temperature of CT-DNA. 
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Figure 5.12. Electronic absorption spectra of [MoO2L
1
] (1) (A), [MoO2L
2
], (2) (B), 
[MoO2L
3
], (3) (C), [MoO2L
4
], (4) (D), [MoO2L
5
], (5) (E), [MoO2L
6
], (6) (F) and 
[MoO2L
7
], (7) (G) (25 µM each) upon the titration of CT-DNA (0–70 µM). The 
experiments were performed with 10 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. 
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Arrow shows the changes in absorbance with respect to an increase in the CT-DNA 
concentration. The inset shows the linear fit of [DNA]/(εa - εf) vs [DNA] and the binding 
constant (Kb) was calculated using Eq. 5.1. 
 
The binding constant (Kb) of the interaction between CT-DNA and each of the 
dioxidomolybdenum (VI) complexes (1–7) was calculated using Eq. 5.1. The data is 
reported in Table 5.5 which reveal that the DNA binding strength of the 
dioxidomolybdenum(VI) complexes are in the order 2 > 3 > 5 > 4 > 7 > 6 ≈ 1, with the Kb 
values of complexes ranging from 1.06 × 10
4
 to 4.74 × 10
5
 M
−1
. The binding affinity of 
the ligands to CT-DNA showed the binding constant (Kb) values lower than their 
corresponding dioxidomolybdenum (VI) complexes (Figure 5.13 and Table 5.6.). 
 
Table 5.6. Binding constant (Kb) values for the "CT-DNA-ligand" interactions.
a
 
Ligand Binding constant (Kb) (M
-1
) 
H2L
1
 3.8  103 
H2L
2
 6.7  103 
H2L
3
 3.6  103 
H2L
4
 8.6  103 
H2L
5
 4.7  103 
H2L
6
 8.5  103 
H2L
7
 8.3  103 
 
a
 The DNA binding constant was determined by the UV-vis spectral method. 
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Figure 5.13. Electronic absorption spectra for H2L
1
 (A), H2L
2 
(B), H2L
3
 (C) H2L
4
 (D), 
H2L
5
 (E), H2L
6
 (F) and H2L
7
 (G) (25 µM each) upon the titration of CT-DNA                 
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(0 – 70 µM) in 10 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. The inset shows the 
linear fit of [DNA]/(εa - εf) vs [DNA] from which the binding constant (Kb) was calculated 
using Eq. 5.1. 
 
Thermal denaturation studies  
In order to investigate the stability of the CT-DNA in absence and presence of the 
dioxidomolybdenum(VI) complexes 1‒7, DNA melting experiments were performed.57 
The melting temperature (Tm) of CT-DNA in absence of any complex was ~66 °C which 
is in good agreement with our previous findings.
35
 Upon interaction with 
dioxidomolybdenum (VI) complexes 1 and 3–7, the Tm of CT-DNA increased very 
slightly (~0.50‒1.5 °C), whereas complex 2 exhibited a significant amount (~3.0 °C) of 
positive shift in the melting temperature of CT-DNA (Figure 5.14 and Table 5.5). The 
lower ΔTm values for the dioxidomolybdenum(VI) complexes 1 and 3–7 suggest that these 
complexes interact with CT-DNA by a groove binding mode. While the larger ΔTm value 
of dioxidomolybdenum(VI) complex 2 indicates that it may interact with CT-DNA 
through both groove binding as well as partial intercalative mode of binding.
55,56  
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Figure 5.14. Derivative plot of thermal denaturation of CT-DNA (100 µM) in the absence 
and presence of [MoO2L
1‒7
] (1–7) (25 µM) in 10 mM Tris-HCl buffer (pH 8.0) containing 
1  DMF. Inset shows the ∆Tm (
o
C) of the complexes as compared to CT-DNA. 
 
Circular dichroism studies  
Circular dichroism (CD) spectroscopy was used in order to study the conformational 
changes in CT-DNA upon the interaction with complexes.
57 
CT-DNA usually shows one 
positive band at 275 nm for base stacking interaction and a negative band at 245 nm for 
right-handed helicity.
57
 There is less or no perturbation on the base stacking and helicity 
bands when a small molecule interacts with CT-DNA by groove binding and electrostatic 
interaction but intercalation can induce intensity changes of both bands and can modulate 
the right-handed B-conformation of DNA.
57
 The CD spectra of 100 µM CT-DNA upon 
the interaction with the dioxidomolybdenum(VI) complexes (4–7) showed very slight 
changes, for the positive band at 275 nm as well as for the negative band at 245 nm 
(Figure 5.15). The dioxidomolybdenum(VI) complexes (1–3) exhibited minor alteration 
in the negative band at 245 nm while only complex 2 exhibited a moderate shift in the 
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positive ellipticity for the band at 275 nm. This suggests that the interaction of the 
dioxidomolybdenum(VI) complexes (1 and 3–7), were either electrostatic or groove 
binding in nature while complex 2 which showed intensity changes in both the negative 
and positive bands may possibly interact with CT-DNA by a partial intercalative mode of 
binding. 
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Figure 5.15. Circular dichroism spectra of CT-DNA (100 µM) in the presence and 
absence of [MoO2L
1‒7
] (1–7) (25 µM). The experiment was done in 10 mM Tris-HCl 
buffer (pH 8.0) containing 1% DMF. The path length of the cuvette was 10 mm. 
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Competitive binding studies 
The thermal denaturation and the circular dichroism experiments hinted that the 
dioxidomolybdenum (VI) complexes (1 and 3–7), bind to CT-DNA possibly through 
groove binding mode and complex 2 possibly by groove and partial intercalative binding 
mode. Therefore in order to find out the binding mode of the complexes with CT-DNA, 
we performed competitive binding experiments with three fluorescent dyes DAPI, MG 
and EB. DAPI and MG are mainly minor and major groove binders respectively, while 
EB binds to DNA through intercalation.
34b,d 
The titration of the DAPI bound CT-DNA 
with increasing amount of the complex concentration led to the quenching of the emission 
intensity of the DAPI bound CT-DNA at 455 nm (Figure 5.16). This indicated the 
displacement of the bound DAPI to CT-DNA by the dioxidomolybdenum (VI) complexes 
(1‒7) (Figure 5.16). Complex 2 exhibited the highest quenching (~38%), followed by 
complex 1 and 3 (~30% each) (Figure 5.16). Complexes 4‒7 showed the least quenching 
of the fluorescence intensity at 455 nm of ~25% each (Figure 5.16). Hence our data 
clearly showed that the dioxidomolybdenum (VI) complex 1–7 binds to the CT-DNA 
through minor groove binding mode.  
201 
 
400 450 500 550 600
0.0
3.0x10
5
6.0x10
5
9.0x10
5
1.2x10
6
400 450 500 550 600
0.0
3.0x10
5
6.0x10
5
9.0x10
5
1.2x10
6
400 450 500 550 600
0.0
3.0x10
5
6.0x10
5
9.0x10
5
1.2x10
6
400 450 500 550 600
0.0
3.0x10
5
6.0x10
5
9.0x10
5
1.2x10
6
400 450 500 550 600
0.0
3.0x10
5
6.0x10
5
9.0x10
5
1.2x10
6
400 450 500 550 600
0.0
3.0x10
5
6.0x10
5
9.0x10
5
1.2x10
6
400 450 500 550 600
0.0
3.0x10
5
6.0x10
5
9.0x10
5
1.2x10
6
A
 
 
B
C D
E F
Wavelength (nm)
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
G
 
Figure 5.16. Fluorescence emission spectra of DAPI (2 μM) bound to CT-DNA (50 μM) 
in the presence of [MoO2L
1
], 1 (A), [MoO2L
2
], 2 (B), [MoO2L
3
], 3 (C), [MoO2L
4
], 4 (D), 
[MoO2L
5
], 5 (E), [MoO2L
6
], 6 (F) and [MoO2L
7
], 7 (G) (0–90 μM) in 10 mM Tris–HCl 
buffer (pH 8.0) containing 1% DMF. The arrow indicates the effect of increasing the 
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concentration of the complex on the fluorescence emission of DAPI bound CT-DNA. The 
excitation and emission band width were 2.5 and 5.0 nm respectively. 
 
In order to assess whether the complexes interacted with CT-DNA by major groove 
binding, MG bound CT-DNA was titrated with increasing concentration of the 
complexes. The decrease in the emission intensity of the MG bound CT-DNA at 672 nm 
upon the addition of the complexes indicated that the complexes also interacted with CT-
DNA by major groove binding mode (Figure 5.17). Complex 2 showed the highest 
quenching of the emission intensity at 672 nm of ~21% followed by complex 3, 5, 6 and 
7, which exhibited quenching in the range of ~11-14 % (Figure 5.17). The least quenching 
of the emission intensity at 672 nm was showed by the complex 1 and 4 of ~5% each 
(Figure 5.17). Therefore our results revealed that the dioxidomolybdenum(VI) complexes 
(1–7) interacted with CT-DNA partially by major groove binding mode. 
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Figure 5.17. Fluorescence emission spectra of MG (2 μM) bound to CT-DNA (50 μM) in 
the presence of [MoO2L
1
], 1 (A), [MoO2L
2
], 2 (B), [MoO2L
3
], 3 (C), [MoO2L
4
], 4 (D), 
[MoO2L
5
], 5 (E), [MoO2L
6
], 6 (F) and [MoO2L
7
], 7 (G) (0–90 μM) in 10 mM Tris–HCl 
buffer (pH 8.0) containing 1% DMF. The arrow indicates the effect of increasing the 
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concentration of the complex on the fluorescence emission of MG bound CT-DNA. The 
excitation and emission band width were 5 and 10.0 nm respectively. 
 
Similar competitive experiments were also performed with EB bound CT-DNA. The 
addition of the dioxidomolybdenum (VI) complexes 1 and 3‒7 to EB bound CT-DNA 
negligibly quenched (< 2%) the emission intensity of EB bound CT-DNA at 597 nm 
(Figure 5.18), while complex 2 exhibited a quenching of ~23% at the similar wavelength 
(Figure 5.18). This clearly revealed that among all the complexes only complex 2 
interacted with the CT-DNA by partial intercalation which is in good agreement with our 
thermal denaturation and the circular dichroism studies. 
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Figure 5.18. Fluorescence emission spectra of EB (2 μM) bound to CT-DNA (50 μM) in 
the presence of [MoO2L
1
] (1) (A), [MoO2L
2
], (2) (B), [MoO2L
3
], (3) (C), [MoO2L
4
], (4) 
(D), [MoO2L
5
], (5) (E), [MoO2L
6
], (6) (F) and [MoO2L
7
], (7) (G) (0–90 μM) in 10 mM 
Tris–HCl buffer (pH 8.0) containing 1% DMF. The arrow indicates the effect of 
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increasing the concentration of the complex on the fluorescence emission of EB bound 
CT-DNA. The excitation and emission band width were 2.5 and 5.0 nm respectively. 
 
5.3.7. DNA cleavage studies 
Chemical-induced DNA cleavage. The chemical induced DNA cleavage capibility of the 
dioxidomolybdenum (VI) complexes 1–7 (1–100 μM) was studied using 300 ng 
supercoiled pUC19 DNA in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF in the 
dark in the presence of 0.5 mM hydrogen peroxide as the oxidising agent. The 
dioxidomolybdenum (VI) complexes do not exhibit any chemical-induced DNA cleavage 
activity (data not shown). 
Photo-induced DNA cleavage. Photo-induced DNA cleavage experiments were 
performed to find out whether the dioxidomolybdenum (VI) complexes 1‒7 possess any 
photo-nuclease activity. The photo-induced DNA nuclease activity of complexes 1–7 
upon irradiation of UVA light of 350 nm for 3 h in the absence and presence of the 
dioxidomolybdenum (VI) complexes was studied using 300 ng supercoiled (SC) pUC19 
DNA in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF (Figure 5.19). The 
decrease in the supercoiled pUC19 DNA (Form I) and subsequent formation of nicked 
circular DNA (Form II) and linear DNA (Form III) indicated the extent of the DNA 
cleavage. The percentage of net DNA cleavage by the complexes was estimated using Eq. 
5.3: 
                 
                    
                             
 
                    
                             
  Eq. 5.3 
The subscripts “s” and “c” refers to the sample and control, respectively.58 
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Figure 5.19. Gel diagram showing concentration dependent DNA cleavage by    
[MoO2L
1‒7
] (1–7); 300 ng of SC pUC19 DNA at different concentrations of the 
complexes [1–100 µM in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF] was 
photo-irradiated with UVA at 350 nm for 3 h. Lanes 1–8: 1, 2.5, 5.0, 7.5, 10, 50, 75, and 
100 µM of [MoO2L
1‒7
] (1–7). 
 
The DNA cleavage activity of the dioxidomolybdenum (VI) complexes 1–7 were carried 
out in a concentration dependent manner from 1‒100 µM. The net DNA cleavage percent 
by 1–7 was plotted with increasing concentration of the dioxidomolybdenum(VI) 
complexes (Figure 5.20). The photo-induced DNA cleavage activity of the complexes 4‒7 
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at a concentration of 100 µM complexes was between 6‒8 . The complex 1, 2 and 3 
exhibited a DNA cleavage of ~21%, ~23% and ~20% at a concentration of 50 µM which 
saturated at a concentration of 100 µM (Figure 5.20). At this concentration the photo-
nuclease activity of complex 1‒3 was approximately ~24%, ~28% and ~23% respectively. 
This indicated that complex 2 has the highest photo-nuclease activity among the complex 
series. Cleavage activity of the dioxidomolybdenum(VI) complexes (1−7) varies because 
of the different functional group present in their ligand moieties.
34b,d
 Control experiments 
revealed that neither DMF (1%) nor the ligand molecules H2L
1-7
 at a concentration of 100 
µM showed any photo-induced DNA cleavage activity, implying that DMF and the 
ligands are cleavage inactive under similar experimental conditions (Figure 5.21).  
 
Figure 5.20. Concentration dependent DNA cleavage of [MoO2L
1‒7
] (1–7); 300 ng of SC 
pUC19 DNA at different concentration of the complexes [1–100 µM in 50 mM Tris-HCl 
buffer (pH 8.0) containing 1% DMF] was photo-irradiated with UVA at 350 nm for 3 h. 
The net DNA cleavage percent was calculated using Eq. 5.3.  
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Figure 5.21. Gel diagram showing the effect of DMF (1%) and ligands on the photo-
induced cleavage of SC pUC19 DNA. 300 ng SC pUC19 DNA was photo-irradiated in 
absence and presence of 1% DMF and various ligands (100 µM) with UVA at 350 nm for 
3 h. Lane 1, DNA only; Lane 2, DNA in presence of 1% DMF; Lane 3, DNA + H2L
1
; 
Lane 4, DNA + H2L
2
;
 
Lane 5, DNA + H2L
3
; Lane 6, DNA + H2L
4
; Lane 7, DNA + H2L
5
; 
Lane 8, DNA + H2L
6
; Lane 9, DNA + H2L
7
. 
 
Since the photo-induced DNA cleavage activity of the complexes 4‒7 were less than ~ 
8%, the mechanistic aspect of the photo nuclease activity exhibited by these complexes 
was not explored. Only the photo-induced DNA cleavage activity of complexes 1–3 was 
investigated in the presence of various additives to understand the mechanistic pathways 
involved in the photo-cleavage reactions. The DNA cleavage reaction involving 
molecular oxygen can proceed in two mechanistic pathways: (a) a type-II process 
involving singlet oxygen species (
1
O2), or (b) by a photo-redox pathway involving 
reactive hydroxyl radicals (OH).
59
 To find out the pathway taken by the complexes to 
exhibit photo-induced DNA cleavage activity, the amount of nicked circular DNA formed 
in the presence of complex and the additives was analysed. The net nicked circular DNA 
(Form II) percentage (% NC DNA) by 1–3 was plotted against the various additives 
(Figure 5.22). The addition of singlet oxygen quenchers like NaN3 and L-histidine, 
inhibited the nicked circular DNA percentage of 2 substantially by ~11 and ~10%, 
respectively (Figure 5.22 and 5.23). In presence of hydroxyl radical quenchers such as KI 
and D-mannitol, the % NC DNA of 2 was restrained by ~6% and ~2%, respectively 
(Figure 5.22 and 5.23). For the dioxidomolybdenum (VI) complexes 1 and 3 the inhibition 
in the presence of the additives was negligible ranging between 1‒3  (Figure 5.22 and 
5.23). Therefore, from the above mechanistic studies it can be concluded that the photo-
induced DNA cleavage activity of complex 2 probably proceeds via singlet oxygen 
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pathway. The mechanistic pathways involved for the photo induced DNA cleavage 
activity of dioxidomolybdenum(VI) complexes 1 and 3 cannot be stated with certainty. 
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Figure 5.22. DNA cleavage of SC pUC19 DNA by [MoO2L
1‒3
] (1–3) in presence of 
various additives in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. SC pUC19 
DNA (300 ng) in the presence of various additives was photo-irradiated with UVA at 350 
nm for 3 h in presence of [MoO2L
1‒3
] (1–3) (100 µM). The additive concentrations were: 
sodium azide (0.5 mM), L-histidine (0.5 mM), KI (0.5 mM) and D-mannitol (0.5 mM). 
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Figure 5.23. Gel diagram depicting cleavage of SC pUC19 DNA by 1–3 in presence of 
various additives in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. SC pUC19 
DNA (300 ng) in the presence of various additives was photo-irradiated at 350 nm for 3 h 
with [MoO2L
1‒3
] (1–3) (100 µM). The additive concentrations were: sodium azide (0.5 
mM), L-histidine (0.5 mM), KI (0.5 mM) and D-mannitol (0.5 mM). Lane 1, DNA + 
complex; Lane 2, DNA + complex + sodium azide;  Lane 3, DNA + complex + L-
histidine;  Lane 4, DNA + complex + KI; Lane 5, DNA + complex + D -mannitol. 
 
 
 
 
 
 
 
 
 
 
212 
 
5.3.8. Cytotoxicity 
The study clearly showed that the cytotoxicity of the reported complexes (17) depends 
on the nature of the compounds (the phenolato and diamine substituents present in the 
ligand backbone), its concentration and cell type (Figure 5.24). Among all the 
compounds, 6 is the most potent cytotoxic agent and capable of killing 50% of the cancer 
cell population at a concentration of 10 μg/ml. Complexes 5 and 7 were found effective at 
higher concentration (100 and 50 μg/ml) but their cytotoxicity decreases with a decrease 
in concentration. The toxicity of these two compounds was found indifferent to the cancer 
cell type. Complex 2 showed a very unique cytotoxic property. It showed almost five fold 
higher cytotoxicity against HT-29 with respect to HeLa at all concentration. A similar 
kind of response was also observed for MoO2L
1
 (1) but the magnitude of the variation 
was less in comparison to MoO2L
2
 (2). Among all the compounds, complexes 3 and 4 
were found relatively less cytotoxic and capable of killing 3040% of cancer cell 
population even at a concentration of 100 μg/ml. Complexes 1‒4 showed a lower IC50 for 
HT-29 than the same for HeLa, 5 showed almost same IC50 for both the cell line whereas 
in case of complexes 6 and 7 a reverse trend was observed. Complex 6 has lowest IC50 
among all the compounds for both type of cancer cell lines. The complexes also showed 
higher antiproliferative activity as compared to the ligands or metal precursor, 
MoO2(acac)2  (IC50 > 250 µM). A plausible elucidation is that by coordination, the 
polarity of the ligand and the central metal ion are reduced through the charge 
equilibration, which favors permeation of the complexes through the lipid layer of the cell 
membrane.
34
 
Loss of nuclear integrity (fragmentation) is common for many metal complexes which 
actually exhibit their action by intercalating with nucleic acids and destabilizing the 
DNA.
60
 Keeping this perspective in mind here we looked for the nuclear damage. For this 
purpose cells were stained with DAPI after 36 h of treatment. Surprisingly, here we did 
not notice any sign of nuclear damage (Figure 5.25). In all the samples, nucleus was found 
intact and of conventional shape and size. However, during this microscopy based 
investigation we noticed abrupt variation in cytoskeletal organization of the cells. 
Cytoskeleton of cell is majorly comprised of actino-myosin filamentous network. Among 
the components, F-actin plays a major role in determining the cell shape and adherence 
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which in turn govern the physiology of the cells.
61
 Now a days a number of cytotoxic 
drugs are available that actually works on cytoskeleton.
51,62
 Our investigation revealed 
that, the compounds which exhibited cytotoxicity in MTT assay actually disrupt the 
colony of both HeLa and HT-29. This was most evident in case of complexes 1 and 5‒7. 
Especially in case of complex 6, both type of cancer cells started producing elongated 
actin stress fibre unlike their characteristic morphology. Our MTT data showed that at 100 
μg/ml concentration 2 showed higher activity against HT-29 than HeLa. The microscopy 
study demonstrated that, under the exposure of complex 2, both the cells started losing 
their individualistic appearance in the colony and seems as a fused system. The cells 
under the exposure of complexes 3 and 4 appeared less perturbed. The studies altogether 
suggest that these set of compounds exhibit cytotoxic effect by disrupting the cytoskeletal 
organization of the cells.  
In the recent past, some oxidomolybdenum(VI) complexes have been reported to have 
significant cytotoxic activities against various human cancer cell lines including HL-60 
and K562 (leukemia), A-549 (lung cancer), HeLa (cervical carcinoma) and MCF-7 (breast 
carcinoma).
24a-l,25‒27
 Among our synthesized Mo(VI)-salan complexes, 5, 6 and 7 have 
been found to exhibit comparable
25c,27a
 or higher
26a,25c
 cytotoxicity than some of the other 
reported Mo complexes against HeLa. A table containing the IC50 values of the 1‒7 and 
some of the known anticancer drug is provided in Table 5.7.
30,63,64
 The lower 
antiproliferative behavior of 3 and 4 in both cell lines could be attributed to their reduced 
solubility, and the steric bulk
33a,e
 of the ortho 
iso
Pr and 
tert
Bu group, respectively, inhibiting 
interaction with cellular target. However, no clear cytotoxicity order is observed based on 
electronic effects. The solubility factor plays a major role in the antiproliferative activity 
of the complexes as has previously been cited for other salan complexes of vanadium and 
titanium.
30,33g,i
 Though 6 also has an ortho 
iso
Pr group but the asymmetry present in its 
ligand backbone could possibly result in making this complex substantially more active 
than its symmetrical analogue, 3. The IC50 values of 6 and 7 are comparable to salan 
complexes of Ti and V against HT-29 cancer cells.
33a,e,j
 These biological observations 
emphasize on the significance of fine tuning the ligand environment to execute higher 
cytotoxicity, and thus encourage further development and analysis of the mechanistic 
action of this family of complexes. 
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Figure 5.24. Cytotoxicity of [MoO2L
1‒7
] (1‒7) against HT-29 (A) and HeLa cells (B) 
after  48 h exposure. The experiments were performed in quadruplets and the data were 
expressed as mean ± S.D. 
 
Table 5.7. Antiproliferative effect of complexes (1‒7) against HT-29 and HeLa cell lines 
after 48 h exposure. 
Complexes IC50 (in μM)  
 HT-29 HeLa 
[MoO2L
1
], 1 32.52 102.94 
[MoO2L
2
], 2 51.94 275.20 
[MoO2L
3
], 3 201.94 209.89 
[MoO2L
4
], 4 221.81 217.16 
[MoO2L
5
], 5 57.88 42.18 
[MoO2L
6
], 6 2.62 10.74 
[MoO2L
7
], 7 11.79 30.48 
Cisplatin 70  12.2  
Cyclophosphamide 21.5
 
 1689  
Tamoxifen  9.3  8.82  
5-Fluorouridine 0.3  2.85  
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Figure 5.25. Morphology of HeLa and HT-29 cells treated with complexes (1‒7) for 36 h. 
Cells were stained with DAPI (Blue color – nucleus) and TRITC Phalloidin (Red color- 
F-actin) and visualized under fluorescent microscope. 
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5.4. CONCLUSION 
Seven tetradentate salan ligands (H2L
17
) and their correspondin cis-
dioxidomolybdenum(VI) complexes, [MoO2L
17
] (17), were synthesized and 
characterized by various analytical techniques (IR, UV-vis, 
1
H and 
13
C NMR 
spectroscopy, ESI-MS and cyclic voltammetry). The molecular structures of [MoO2L
16
] 
(1‒6) were solved by single crystal X-ray diffraction analysis.The asymmetric unit of all 
these complexes consists of a complete formula unit with the exception of complex 2, 
which belongs to point group C2. All complexes have a distorted octahedral geometry 
with the ONNO ligand coordinated in a folded fashion to the molybdenum centre. The 
conformational differences which arise are due to the steric and electronical requirements 
of the individual ligands and most of the differences are picked up from the neighboring 
atoms C7 and C14, as revealed from their torsion angles.  
These complexes showed moderate DNA binding propensity with binding constants 
ranging from 10
4−105 M-1. The experimental results showed that the complexes 1‒7 
effectively interact with CT-DNA by both minor and major groove binding mode, while 
complex 2 additionally interacts by partial intercalative mode of binding. The 
dioxidomolybdenum (VI) complexes (1‒3) showed moderate photo-induced cleavage of 
pUC19 supercoiled plasmid DNA. The results from the mechanistic study suggest that the 
photolytic DNA cleavage of complex 2 proceeded via singlet oxygen pathway. The 
results obtained are significant in the context that dioxidomolybdenum (VI) complexes 
showing only DNA photo-cleavage activity but no chemical nuclease activity are sparse.  
Among the series of complexes synthesized, remarkable cytotoxic results were obtained 
for complexes 6 and 7 against both HT-29 colon and HeLa cervical carcinoma cells. The 
higher cytotoxicity of these complexes can be correlated to their better solubility in 
DMSO, which is of particular interest to therapeutic applications
33g
 in addition to the 
effect of substituents in the ligand backbone, which might affect its interaction in the cell 
medium. The results encourage further insights into the mechanism of anticancer activity, 
and test on other cancer cell lines is the scope of future research. 
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Chapter 6 
 
Synthesis, characterization and superoxide dismutase activity of Cu(II) salan 
complexes: Unprecedented Cu(II) catalyzed acetal formation 
ABSTRACT 
________________________________________________________________________ 
The synthesis and characterization (elemental analysis, UV–vis spectroscopy and ESI-
MS) of Cu(II) complexes ([CuL
1,2
] (1 and 2) and [CuL
3′,4′
]2 (3 and 4)) using tetradentate 
diamino bis(phenolato) “salan” ligands, N,Nʹ-dimethyl-N,Nʹ-bis-(2-hydroxy-3-X-5-Y-6-Z-
benzyl)-1,2-diaminoethane (X = 
i
Pr, Y = Cl, Z = Me (H2L
1
); X = OCH3, Y = allyl, Z = H 
(H2L
2
)) and N,Nʹ-bis-(2-hydroxy-3-X–5-Y-6-Z-benzyl)-1,2-diaminopropane ( X = iPr, Y= 
Cl, Z = Me (H2L
3
); X = Y = CH3, Z = H (H2L
4
)) have been discussed. The redox property 
of the complexes has been ascertained by cyclic voltammetry. The molecular structures of 
the complexes (1 and 3) have been determined by X–ray crystallography. While 1 and 2 
have the expected square planar geometry, with the ligand coordinating to the metal 
center in the usual tetradentate fashion, an unprecedented ligand transformation occurs in 
the case of 3 and 4, leading to the formation of phenolato bridged Cu(II) dimeric 
complexes, [CuL
3′,4′
]2,  having an elongated octahedron structure. The organic 
transformation in the ligands (H2L
3 
and H2L
4
) has been mechanistically elucidated to be 
Cu(II) catalysed. In order to fortify the ligand modification to be Cu(II) assisted, the 
corresponding Ni
II
, Fe
III
 and
 
Mo
VI
 complexes (5‒7) with the same ligand environment, 
were synthesized and characterized. The anomaly in the ligand backbone was however 
not observed in the case of other transition metal complexes (5‒7). In addition, the 
superoxide dismutase (SOD) activity of the Cu(II) complexes (1‒3) has also been 
investigated; the activity follows the order 3> 1> 2. Due to the deliquescent nature of 
[CuL
4′
]2
 
(4), its SOD activity could not be evaluated.  
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6.1. INTRODUCTION 
Copper plays diverse roles in nature which involve electron transfer, O2 binding, 
activation and reduction, NO
2- 
and N2O reduction, and substrate activation.
1
 These 
properties are largely attributed to its accessible redox states (I/II) and bioavailability.
1
 
Relatively high redox potential working between +0.25 and +0.75 V for the Cu(II)–Cu(I) 
system in copper enzymes
2
 is utilized for direct oxidation of substrates, such as 
superoxide (in superoxide dismutase),
3
 ascorbate (in ascorbate oxidase)
4
 or catechols (in 
catecholase, tyrosinase or in laccases).
5,6
  
The Cu/Zn- SOD that predominates in the extracellular spaces provides a natural defense 
mechanism in living systems against superoxide-mediated oxidative damages such as 
those associated with inflammatory diseases and reperfusion as well as neurological 
disorders like, Parkinson‟s and Alzheimer‟s disease.7 However, short plasma half-life, 
inability to cross cell membranes, and immunogenic responses of application of natural 
SODs have limited their therapeutic applications.
8
 Therefore, low-molecular-weight SOD 
mimics are being extensively investigated as potential pharmaceutical agents for treating 
such diseases.
9
 In the last few years, research on biocompatible Cu(I,II) coordination 
compounds for their anticancer properties has boosted dramatically.
10
 Due to an increase 
in uptake of copper by malignant cells and its contribution to cancer progression, 
angiogenesis and metastasis, cellular copper is evolving as a promising target for 
developing new anti-cancer therapeutics.
11‒14 
Again, the Cu(II) salan complexes have been extensively utilised in the asymmetric Henry 
reaction, wherein the variation of electron properties and location of the substituents on 
aromatic rings have had an influence on the enantioselectivity in the reactions.
15
 Though 
copper compounds derived from dianionic salan ligand precursors have been 
investigated,
15‒21
 yet it has not been fully explored, in context of their biological 
applicability. The environment around the Cu center and its conformational flexibility 
plays a significant role in order to mimic closely a metalloprotein in properties, for 
carrying out specific physiological function, such as dioxygen binding and oxygen 
utilization. In this respect, the tetrahydro derivative of salen ligand holds an advantage 
due to its greater flexibility and higher resistance to hydrolytic decomposition.
22
 As 
compared to salen, its reduced analogue coordinates more easily in a folded fashion as a 
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consequence of C=N bond hydrogenation.
23
 The Cu-salan complexes scrutinized so far 
either contain tertiary amine or sterically hindered secondary amine in their ligand 
backbone,
15‒21
 but no attempts to synthesize complexes with salan ligands containing 
unhindered secondary amines have been made.  
Over the past few years, we have been studying the chemistry and biological applicability 
of transition metal complexes with O and N donoting ligands.
24
 As an extension of our 
work on the coordination and biochemistry of copper(I/II) complexes,
25
 we have herein 
synthesized four novel mono- and dinuclear bis(phenoxido)-bridged Cu(II) complexes 
with tetrapodal salan ligands (H2L
1-4
). These ligands have been designed using either N, 
Nʹ˗ethylenediamine (H2L
1,2
) or 1,2-diaminopropane (H2L
3,4
) by one step Mannich 
condensation with aqueous HCHO and o, p-disubstituted phenols. The presence of tertiary 
amine group in the ligand (H2L
1,2
) leads to normal square planar coordination of the Cu 
atom to the metal center, [CuL
1,2
] (1, 2), however, metallation of salan ligand containing 
secondary amine (H2L
3,4
) leads to an intriguing chemical transformation in the ligands by 
an in situ bonding of a pendent -CH2OCH3 group to one of the N atoms and formation of 
an elongated octahedron [CuL
3',4'
] (3, 4). The anomalous chemistry of 3 and 4 was 
compared with the corresponding Ni(II), Fe(III) and Mo(VI) complexes. It is noteworthy 
that no such chemical transformation is perceived in the corresponding molybdenum 
[MoO2L
3
] (5), nickel [NiL
3
] (6) or iron [FeL
3
(Cl)] (7) complexes with H2L
3
. Mechanistic 
insights into the unprecedented Cu-assisted acetal formation, with the subsequent 
coordination of the latter to the metal ion have been discussed. All the ligands and 
complexes have been characterized by various physicochemical techniques, viz., 
elemental analyses, IR, UV-vis and NMR spectroscopy, ESI-MS, and cyclic voltammetry. 
The molecular structures of the 1 and 3 have been further confirmed by single-crystal X-
ray diffraction study. The Cu(II)-salan complexes have also been studied for the 
dismutation of superoxide anion radicals (O2
-
). 
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6.2. EXPERIMENTAL SECTION 
6.2.1. General Methods and Materials. Chemicals were purchased from commercial 
sources and used without further purification. CuClO4.6H2O, N, Nʹ-
dimethylethylenediamine and 1, 2-diaminopropane were purchased from Loba Chemie. 
The substituted phenols were purchased from Sigma Aldrich. Reagent grade solvents 
were dried and distilled prior to use. Elemental analyses were performed on a Vario 
ELcube CHNS Elemental analyzer. 
1
H and
 13
C NMR spectra were recorded on a Bruker 
Ultrashield 400 MHz spectrometer using SiMe4 as an internal standard. Electronic spectra 
were recorded on a Lamda25, PerkinElmer spectrophotometer. ESI-MS were obtained on 
a SQ–300 MS instrument. A CH-Instruments (Model No. CHI6003E) electrochemical 
analyzer was used for cyclic voltammetric experiments with CH3CN solutions of the 
complexes containing TBAP (tetra butyl ammonium perchlorate) as the supporting 
electrolyte. The three electrode measurements were carried out at 298 K with a platinum 
working electrode, platinum auxiliary electrode and SCE as a reference electrode. 
Caution: Although no problems were encountered during the course of this work, 
attention is drawn to the potentially explosive nature of perchlorates.  
 
6.2.2. Synthesis of ligands (H2L
1-4
). The diamine bis-phenolato “salan” ligands (H2L
1-4
) 
were prepared by essentially the same procedure as reported in Section 5.2.2.
26
 The 
resulting white compounds were filtered, washed with methanol and dried over fused 
CaCl2. Elemental analysis, NMR (
1
H and 
13
C) and IR data of the ligands confirmed their 
structures. 
H2L
1
: Same as reported for ligand H2L
3
 in Section 5.2.2 
H2L
2
: Yield: 86%. Anal. calc. for C26H36N2O4: C, 70.88; H, 8.24; N, 6.36. Found: C, 
70.84; H, 8.27; N, 6.33. Main IR peaks (KBr pellet, cm
–1
): 2966 ν(O–H/ N–H)H-bonded
. 1
H 
NMR (CDCl3, 400 MHz)  (ppm): 7.54‒7.01 (2H, aromatic), 5.09–5.04 (d, 2H, =CH2), 
5.97 (1H, quin., –CH2CH=CH2) 3.86 (s, 3H, –OCH3), 3.67 (s, 2H, –NCH2Ar), 3.28 (d, 
2H, ‒CH2–CH=CH2), 2.69 (s, 2H, ‒NCH2), 2.30 (s, 3H, –NCH3). 
13
C NMR (CDCl3, 100 
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MHz)  (ppm): 147.76, 145.09, 137.84, 130.45, 121.51, 120.36, 115.52, 111.46, 61.41, 
55.88, 54.49, 41.97, 39.82. 
H2L
3
: Same as described for ligand H2L
6
 in Section 5.2.2 
H2L
4
: Yield: 86%. Anal. calc. for C27H42N2O2: C, 76.01; H, 9.92; N, 6.57. Found: C, 
76.05; H, 9.97; N, 6.52. Main IR peaks (KBr, cm
–1
): 2981 ν(O–H/N‒H)H-bonded. 
1
H NMR 
(CDCl3, 400 MHz)  (ppm): 7.28‒7.09 (m, 4H, aromatic), 4.42‒4.21 (s, 4H, ArCH2), 
3.77–3.70 (m, 2H, NCH2), 3.18 (sextet, 1H, CHCH3), 2.97‒2.89 (s, 6H, p-ArCH3), 2.57‒
2.32 (m, 18H, 2C(CH3)3), 1.26‒1.22 (d, 3H, CHCH3). 
13
C NMR (CDCl3, 100 MHz)  
(ppm): 162.61, 162.01, 148.24, 148.08, 147.77, 147.48, 133.07, 132.88, 129.71, 129.27, 
126.73, 126.37, 125.54, 125.27, 121.72, 121.26, 121.08, 120.77, 58.44, 53.49, 44.81, 
44.25, 41.87, 36.53, 31.47, 31.11, 18.42. 
6.2.3. Synthesis of Cu(II) complexes (1‒4). Triethylamine (1 mmol) was added to a hot 
methanolic solution of H2L
1-4
 (1 mmol), followed by the addition of CuClO4·6H2O         
(1 mmol). The mixture was refluxed for 12 h. The resulting dark green solution was 
filtered and slow evaporation of the filtrate over a week, produced deep green compounds. 
[CuL
1
] (1): Yield: 74%. Anal. calc. for C26H36CuN2O2: C, 57.51; H, 6.68; N, 5.16. Found: 
C 57.55; H, 6.67; N, 5.19. 
[CuL
2
] (2): Yield: 77%. Anal. calc. for C26H34CuN2O4: C, 62.83, H, 7.03, N, 5.43. Found: 
C, 62.84, H, 7.08, N, 5.41. 
[CuL
3ʹ
]2 (3): Yield: 63%. Anal. calc. for C34H30Cl2Cu2N6O10: C, 37.84; H, 2.80; N, 7.79. 
Found: C, 37.81; H, 2.84; N, 7.76. 
[CuL
4ʹ
]2 (4): Yield: 62%. Anal. calc. for C58H88N4O6Cu2: C, 65.45; H, 8.33; N, 5.26. 
Found: C, 65.42; H, 8.35; N, 5.22. 
 
6.2.4. Synthesis of [Ni
II
L
3
] (5), [Fe
III
L
3
(Cl)] (6) and [Mo
VI
O2L
3
]
 
(7) complexes. 
Triethylamine (1 mmol) was added to a hot methanolic solution of H2L
3
 (1 mmol), 
followed by the addition of 1 mmol of Ni(OAc)2.4H2O, anhydrous FeCl2 and 
MoO2(acac)2 for synthesis of complexes 5‒7, respectively. Each solution mixture was 
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refluxed for 12 h. Red, brown and yellow crystalline residue was obtained from the 
reaction mixture for the Ni
II
 (5), Fe
III 
(6) and Mo
VI 
(7) complexes respectively. 
[NiL
3
] (5): Yield: 70%. Anal. calc. for C25H34Cl2N2NiO2: C, 57.29; H, 6.54; N, 5.34. 
Found: C, 57.25; H, 6.50; N, 5.37. 
[FeL
3
(Cl)] (6): Yield: 63%. Anal. calc. for C25H34Cl3FeN2O2: C, 53.93; H, 6.16; N, 5.03. 
Found: C, 53.88; H, 6.21; N, 5.07. 
[Mo
VI
O2L
3
] (7): Same as complex 6 described in Section 5.2.2. 
 
6.2.5. X-ray Crystallography 
[CuL
1
] (1): A blue platelet crystal of C26H36Cl2CuN2O2 having approximate dimensions 
of 0.240 x 0.140 x 0.080 mm was mounted on a glass fiber. All measurements were made 
on a Rigaku XtaLAB mini diffractometer using graphite monochromated Mo-Kα 
radiation.
27
  
The crystal-to-detector distance was 50.00 mm. Cell constants and an orientation matrix 
for data collection corresponded to a primitive monoclinic cell with dimensions: 
The data were collected at a temperature of 20 + 1oC to a maximum 2Ө value of 55.0o. A 
total of 540 oscillation images were collected. A sweep of data was done using ω 
oscillations from -60.0 to 120.0o in 1.0o steps. The exposure rate was 10.0 [sec./o]. The 
detector swing angle was 29.50o. A second sweep was performed using ω oscillations 
from -60.0 to 120.0o in 1.0o steps. The exposure rate was 10.0 [sec./o]. The detector 
swing angle was 29.50o. Another sweep was performed using ω oscillations from -60.0 to 
120.0o in 1.0o steps. The exposure rate was 10.0 [sec/o]. The detector swing angle was 
29.50o. Another sweep was performed using ω oscillations from -60.0 to 120.0o in 1.0o 
steps. The exposure rate was 10.0 [sec/o]. The detector swing angle was 29.50o. Another 
sweep was performed using ω oscillations from -60.0 to 120.0o in 1.0o steps. The 
exposure rate was 10.0 [sec/o]. The detector swing angle was 29.50o. Another sweep was 
performed using ω oscillations from -60.0 to 120.0o in 1.0o steps. The exposure rate was 
10.0 [sec./o]. The detector swing angle was 29.50o. The crystal-to-detector distance was 
50.00 mm. Readout was performed in the 0.146 mm pixel mode. 
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Data Reduction 
Of the 51379 reflections that were collected, 12362 were unique (Rint = 0.3084). Data 
were collected and processed using CrystalClear (Rigaku).
27
 
The linear absorption coefficient, µ, for Mo-Kα radiation is 10.304 cm-1. The data were 
corrected for Lorentz and polarization effects.  
Structure Solution and Refinement 
The structure was solved by direct methods
28
 and expanded using Fourier techniques. The 
non-hydrogen atoms were refined anisotropically. Hydrogen atoms were refined using the 
riding model. The final cycle of full-matrix least-squares refinement on F2 was based on 
12362 observed reflections and 611 variable parameters and converged (largest parameter 
shift was 0.00 times its esd) with unweighted and weighted agreement factors of:  
R1 = Σ ||Fo| - |Fc|| / Σ |Fo| = 0.1010  
 wR2 = [ Σ ( w (Fo2 - Fc2)2 )/ Σ w(Fo2)2]1/2 = 0.2262  
The standard deviation of an observation of unit weight was 0.99. Unit weights were used.  
The maximum and minimum peaks on the final difference Fourier map corresponded to 
0.51 and -0.38 e‒/Å3, respectively.  
Neutral atom scattering factors were taken from Cromer and Waber.
29
 Anomalous 
dispersion effects were included in Fcalc;
30
 the values for Δf' and Δf" were those of 
Creagh and McAuley.
31
 The values for the mass attenuation coefficients are those of 
Creagh and Hubbell.
32
 All calculations were performed using the CrystalStructure
33
 
crystallographic software package except for refinement, which was performed using 
SHELXL-97.
34
 
[CuL
3′
]2 (3): A blue prism, measuring 0.48 x 0.04 x 0.03 mm
3
 was mounted on a loop 
with oil. Data was collected at 22
o
C on a Nonius Kappa CCD FR590 single crystal X-ray 
diffractometer, Mo-radiation. 
Crystal-to-detector distance was 30 mm and exposure time was 60 seconds per degree for 
all sets. The scan width was 2
o
. Data collection was 99.7% complete to 25
o
 in . A total 
of 11220 merged reflections were collected covering the indices -12<=h<=13,                    
-16<=k<=16, -16<=l<=16. 6739 reflections were symmetry independent and the Rint = 
0.0721 indicated that the data was of average quality. Indexing and unit cell refinement 
indicated a triclinic P lattice.  The space group was found to be P1 (No.2).  
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The data was integrated and scaled using hkl-SCALEPACK.
35
 This program applies a 
multiplicative correction factor (S) to the observed intensities (I) and has the following 
form: 
2 22 (sin ) /S = ( ) / scaleBe    
S is calculated from the scale and the B factor determined for each frame and is then 
applied to I to give the corrected intensity (Icorr). 
Solution by direct methods (SHELXS, SIR97
36
) produced a complete heavy atom phasing 
model consistent with the proposed structure. The structure was completed by difference 
Fourier synthesis with SHELXL97.
37,38
 Scattering factors are from Waasmair and Kirfel.
39
 
Hydrogen atoms were placed in geometrically idealised positions and constrained to ride 
on their parent atoms with C---H distances in the range 0.95‒1.00 Angstrom. Isotropic 
thermal parameters Ueq were fixed such that they were 1.2Ueq of their parent atom Ueq for 
CH's and 1.5Ueq of their parent atom Ueq in case of methyl groups. All non-hydrogen 
atoms were refined anisotropically by full-matrix least-squares. 
Details on the data collection parameters applied on the individual crystals of 1 and 3 are 
summarized in Table 6.1 
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Table 6.1. Crystal and refinement data of complexes [CuL
1
] (1) and [CuL
3ʹ
]2 (3)  
Compound 1 3 
Emperical Formula C
26
H
36
Cl
2
CuN
2
O
2
 C54H76Cl4Cu2N4O6 
M 543.03 1146.06 
Crystal system triclinic monoclinic 
Space group P-1 P 21/a 
a(Å) 14.524 (3) 15.048(2) 
b(Å) 21.071(4) 21.675(3) 
c(Å) 18.875(3) 16.615(2) 
 (°) 90 90 
β (°) 110.690(8) 93.091(8) 
γ (°) 90 90 
V (Å
3
) 5404 (2) 5411.2 (12) 
Z 8 4 
Dcalc (g.cm
–3
) 1.335  1.417 
Absorption Coefficient 1.030 mm
-1 
1.0361 mm
-1
 
F(000) 2280 2408 
Crystal size (mm
3
) 0.240 X 0.140 X 0.080
 
0.170 x 0.150 x 0.050  
Theta range for data 
collection(º) 
3 to 27.30 1.546 to 27.968 
R1[I>2(I)] R1 = 0.0461 
wR2 = 0.137 
R1 = 0.0361, 
wR2 = 0.078 
wR2[all data] R1 = 0.049 
wR2 =0.142 
R1 = 0.059, 
wR2 = 0.088 
S[goodness of fit] 1.100 1.002 
max. / min. res. 
(e.Å
–3
) 
1.404 and –0.842 0.387 and –0.341 
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6.2.6. Superoxide Dismutase activity 
The SOD activity was evaluated with the nitroblue tetrazolium (NBT) method using 
xanthine/xanthine oxidase as the source of the superoxide anion as has been previously 
described.
40
 However, since the compounds were not soluble in phosphate buffer (pH 
7.4), stock solutions (5 x 10
-6
 mol dm
-3
) of them were prepared in DMSO and suitable 
volumes (0.050‒0.400 cm3) of them were added to the cuvettes containing NBT            
(4.8 x 10
-5
 mol dm
-3
) and xanthine (1.9 x 10
-4 
mol dm
-3
). The IC50 was determined by 
plotting V/v versus the concentration of the complex, where V is the velocity of NBT 
reduction in the absence of the copper compound and v is the velocity of NBT reduction 
in the presence of the complex. The reaction was followed for 10 min and the velocity of 
NBT reduction was taken as the slope of the curve at 560 nm between 1 and 3 min.  
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6.3. RESULTS AND DISCUSSION 
6.3.1. Synthesis. The synthetic methodology for the ligand and complexes are illustrated 
in Scheme 6.1. Reaction of Cu(ClO4)2.6H2O with tetradentate diamino bis(phenolato) 
(ONNO) “salan” ligands (H2L
1-4
) in the molar ratio of 1:1 in MeOH, resulted in the 
formation of the green filtrate. Cu(II) complexes (1‒4) were obtained from the filtrate 
upon slow evaporation. The purity of these compounds was further confirmed by 
elemental analyses, UV-vis spectroscopy and ESI-MS, which were also consistent with 
the X-ray structures. The complexes were soluble in aprotic solvents, DMF and DMSO, 
and sparingly soluble in protic solvents. All the complexes were stable in both solid and 
solution phases.  
 
OHY
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HO
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Y
Z
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O
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Scheme 6.1. Schematic diagram for synthesis of Cu(II) complexes (1‒4). 
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An unprecedented ligand transformation occurred upon complex formation in the case of 
3 and 4 as reflected in Scheme 6.1 and as evidenced from other physico-chemical 
characterizations. In these complexes an extra acetal fragment (CH2OCH3) is bonded to 
the unhindered N atom of the secondary amine, which in turn is weakly coordinated to the 
Cu center. In addition, there is also a weak interaction of the Cu center with the phenolic 
O atom of the neighboring Cu molecule, resulting in the formation of a distorted 
elongated octahedron. Further investigation to explain the unusual transformation in the 
case of 3 and 4 has been done by taking [CuL
3′
]2 as a representative compound. To 
confirm that the organic rearrangement is copper assisted, the corresponding nickel, iron 
and molybdenum complexes of H2L
3
 were prepared following a similar approach, by 
using [Ni(OAc)2].4H2O, FeCl2 and [MoO2(acac)2] as metal precursors. It was observed 
that the analogues Ni(II), Fe(III) and Mo(VI) complexes, [NiL
3
] (5), [FeL
3
(Cl)] (6) and 
[MoO2L
3
] (7), respectively, did not initiate the type of ligand rearrangement seen in the 
Cu scenario (3) (Scheme 6.2), and the ligand coordinated in the usual manner, as verified 
from other spectral and structural characterizations, thereby fortifying the mechanism to 
be Cu(II) catalysed.  
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Scheme 6.2. Synthesis of [CuL
3ʹ
]2
 
(3), [NiL
3
] (5), [Fe
III
L
3
(Cl)] (6) and [MoO2L
3
] (7). 
As elucidated in Scheme 6.3, the carbonyl group of HCHO (used in excess during ligand 
synthesis) is activated („A‟) by the Lewis acid (Cu+2, from CuClO4), followed by the 
nucleophilic attack of methanol (used as solvent), thereby resulting in the formation of the 
intermediate compound „B‟. In the subsequent step, the parent ligand H2L
3
 then attacks 
the electrophilic center generated upon departure of [CuOClO4]
‒
 from „B‟, leading to the 
formation of „C‟. „C‟ is then stabilized as H2L
3′ 
(modified ligand)
 
upon release of a proton 
to the transient [CuOClO4]
‒
 species (forming CuClO4(OH) in solution).This in situ 
generated ligand, H2L
3′
,
 
then forms the final complex [CuL
3′
]2
 
(3) upon reaction with the 
metal precursor, CuClO4. Presumably, the formation of the acetal fragments allows the 
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coordination of the oxygen atoms to the Cu(II) ion, which in turn stabilises the complex 
formed. Cu(II) ion is a typical example of a 3d metal ion, capable of showing the presence 
of a Jahn–Teller effect.41 Jahn Teller distortion effect does not occur in the case of Ni(II), 
Fe(III) and Mo(VI) complexes (5‒7), wherein a regular chemistry is observed. The 
stability of the Cu(II) complexes, [CuL
3′
]2 is also influenced by the presence of an 
additional Cu–O interaction. 
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Scheme 6.3. Plausible reaction mechanism leading to formation of [CuL
3′
]2 (3). 
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6.3.2. Spectral Characteristics 
UV-vis Spectroscopy. The electronic spectra of all the complexes were recorded in 
DMSO solutions. The UV-vis data of complexes 1‒6 is tabulated in Table 6.2. In the 
spectra of 1‒4 the lower energy absorptions (432–346 nm) are ascribable to ligand to 
metal charge transfer transitions whereas the higher energy absorptions (299–211 nm) are 
likely to be due to ligand centered transitions.
25
 Weak absorptions observed in the range 
625−613 nm are assigned to d−d transition in the Cu(II) complexes.25 A representative 
spectrum of the Cu(II) complexes, [CuL
1
] (1) is shown in Figure 6.1. UV-vis spectra of 
Ni(II), [NiL
3
] (5) and Fe(III), [FeL
3
(Cl)] (6) complexes is shown in Figure 6.2 and Figure 
6.3 respectively. The peak at 317 nm and a shoulder band at 348 nm in [NiL
3
] (5) are 
attributed to the ligand to metal charge transfer bands, while the weaker d−d peak is 
observed at 419 nm.
19b
 The peak at higher energy, 278 nm, in [NiL
3
] (5) is due to intra 
ligand π→π* transition. In [FeL3(Cl)] (6), the absorption maxima observed in the near-UV 
regions, below 300 nm are due to intra-ligand π→π* transitions, while the peak at 487 nm 
is proposed to arise from charge-transfer transitions from the in-plane pπ orbital of the 
phenolate to the half-filled dπ* orbital of Fe(III).
42 
Related results of the UV-vis spectra of 
MoO2L
3 
(7) is discussed in Section 5.3.2.  
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Figure 6.1. UV-vis spectrum of [CuL
1
] (1) in DMSO.
 
Figure 6.2. UV-vis spectrum of [NiL
3
] (5) in DMSO. 
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Figure 6.3. UV-vis spectrum of [FeL
3
(Cl)] (6) in DMSO. 
 
Table 6.2. Electronic spectra for complexes [CuL
1,2
] (1, 2), [CuL3ʹ,4ʹ]2 (3, 4), [NiL
3] (5), 
[FeL
3
(Cl)] (6) in DMSO 
 
Complex λmax/nm (εmax/M
–1
cm
–1
) 
[CuL
1
] (1) 212(31600), 256(27630), 299(12990), 352(6610), 432(9921), 613(1200)  
[CuL
2
] (2) 215(29660), 255(23200), 285(11660), 346(5100), 429(9342), 625(1160) 
[CuL3ʹ]2 (3) 211(30000), 254(24685), 295(12685), 353(6120), 429(9511), 617(1232) 
[CuL
4ʹ
]2 (4) 211(29790), 252(23258), 294(11768), 352(5132), 419(8526), 621(1210) 
[NiL
3
] (5) 278(24000), 317(21750), 348(558), 491(160) 
[FeL
3
(Cl)] (6) 209(29500), 241(9100), 290(6700), 487(940) 
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6.3.3. ESI-MS. ESI-MS data of 1‒5 have been recorded in the positive ion mode and that 
of 6 and 7 in the negative ion mode, in acetonitrile solution. ESI-MS analysis for CuL
1
(1) 
and CuL
2 
(2) shows peaks at m/z 544.26 [M + H]
+
 and 441.58 [M + H]
+
 respectively, 
whereas [CuL
3′
]2 (3) and [CuL
4′
]2 (4) exhibits the major ionic peak at m/z 572.06 [1/2M + 
H]
+
 and 532.21 [1/2M + H]
+
, indicating coordination of the modified ligand to the Cu 
center in 3 and 4. Representative spectra of Cu(II) complexes (1 and 3) is shown in Figure 
6.4 and 6.5 respectively. The presence of a peak at m/z 523.15 [M + H]
+ 
in the ESI-MS of 
NiL
3
(5) (Figure 6.6) and three major peaks at m/z 554.32 [M ‒ H]‒, 591.99 [M + K ‒ 2H]‒ 
and 599.64 [M + FA ‒ H]‒ (where FA= formic acid) in the ESI-MS of [FeL3(Cl)]  (6) 
(Figure 6.7) and the major peak at m/z 593.22 [M ‒ H]‒ in the ESI-MS of MoO2L
3 
(7) 
(Figure 6.8), confirmed the regular coordination of the tetradentate salan ligand, H2L
3
, to 
the Ni(II), Fe(III) and Mo(VI) centers, without any ligand modification.  
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Figure 6.4. ESI-MS of [CuL
1
] (1) in CH3CN. 
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Figure 6.5. ESI-MS of [CuL
3′
]2
 
(3) in CH3CN . 
 
 
Figure 6.6. ESI-MS of [NiL
3
]
 
(5) in CH3CN. 
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Figure 6.7. ESI-MS of [FeL
3
(Cl)]
 
(6) in CH3CN. 
 
 
Figure 6.8. ESI-MS of [MoO2L
3
]
 
(7) in CH3CN. 
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6.3.4. Electrochemical Properties. Electrochemical properties of the complexes have 
been studied by cyclic voltammetry in DMF solution (0.1 M TBAP), and the 
voltammetric data are listed in Table 6.3. The cyclic voltammogram of all the four 
complexes exhibit an irreversible reductive response within the potential window of ˗1.32 
to ˗1.29 V, which is assigned to the Cu(II)/Cu(I) process.25 The ligand is redox inactive in 
the potential window of 0 to ˗2 V in the cathodic region. A representative voltammogram 
of complex 3 is given in Figure 6.9. Single electron processes were verified by comparing 
the current height of the quasi-reversible reductive response with that of the standard 
ferrocene–ferrocenium couple under identical experimental conditions. 
 
Table 6.3. Cyclic voltammetric
[a]
 results for complexes 1–4 at 298 K 
Complex Ep
c
  (V)
[a]
 Complex Ep
c
 (V)
[a]
 
 
[CuL
1
] (1) 
 
˗1.29 
 
[CuL
3ʹ
]2 (3) 
 
˗1.32 
[CuL
2
] (2) ˗1.30 [CuL4ʹ]2 (4) ˗1.31 
 
[a]
1‒4 in DMF at a scan rate of 100 mV s–1. where Ep
c 
is the cathodic peak potentials vs. 
Ag/AgCl. 
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Figure 6.9. Cyclic voltammogram of 3 showing reduction (Cu(II)  Cu(I)) at the 
copper(II) center. 
 
6.3.5. Description of X–ray structure of [CuL1] (1) and [CuL3ʹ]2 (3) 
The observed elemental analysis (C, H, N) data of all the complexes (1‒4) are consistent 
with their composition. In order to authenticate the molecular structures of the complexes, 
single crystals of 1 and 3 were analysed by X-ray crystallography. 
[CuL
1
] (1): ORTEP diagram of 1 is depicted in Figure 6.10. 1 crystallized in the 
monoclinic system, space group P 21/c, with the unit cell containing two molecules in the 
asymmetric unit. Both molecules present square-planar coordination around the Cu center 
with the equatorial planes defined by atoms O1, O2, N1 and N2. The planar arrangement 
of the chromophore is tetrahedrally distorted with the four bond angles, O(1)‒Cu(1)‒O(2), 
O(1)‒Cu(1)‒N(1), O(2)‒Cu(1)‒N(2), N(1)‒Cu(1)‒N(2) differing slightly from 90º. The 
two methyl groups on the tertiary amine are situated out of the N2O2 plane and positioned 
trans to each other. The bond parameters of 1 are tabulated in Table 6.4.  
 
 
 
0.0 -0.5 -1.0 -1.5 -2.0
1A
E(V) vs Ag/AgCl
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Table 6.4. Selected geometric parameters for [CuL
1
] (1) 
 
Bond lengths (Å) 
Cu(1)‒O(1) 1.879 (6) Cu(1)‒N(1) 2.039 (7) 
Cu(1)‒O(2) 1.880 (5) Cu(1)‒O(2) 2.030 (9) 
Bond angles (º) 
O(1)‒Cu(1)‒O(2) 93.7 (3) O(2)‒Cu(1)‒N(1) 157.6 (3) 
O(1)‒Cu(1)‒N(1) 94.4 (3) O(2)‒Cu(1)‒N(2) 93.1 (3) 
O(1)‒Cu(1)‒N(2) 155.4 (3) N(1)‒Cu(1)‒N(2) 88.1 (3) 
 
 
 
Figure 6.10. ORTEP diagram of [CuL
1
] (1) with atom labeling scheme. 
 
[CuL
3ʹ
]2 (3): ORTEP diagram of 3 is presented in Figure 6.11. The crystal structure of 3 
revealed that each Cu(II) ion resides in a distorted octahedral environment (Figure 6.12). 
The asymmetric unit contains two independent molecules. The copper center is 
coordinated to two amine nitrogen atoms (N1, N2) and two phenolic oxygen atoms (O1, 
O2) in the equatorial plane. In addition, the Cu atom is also coordinated in the axial 
position to the phenolate O(1
i
) of the neighboring symmetry related molecule to form 
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Cu(1)‒O(1)‒Cu(1i)‒O(1i) dimer (Figure 6.12). The oxygen atom (O3) of the CH2‒O‒CH3 
moiety occupies the other axial site in the complex to complete the octahedral geometry. 
The intermolecular Cu(1)‒O(1i) bond lengths are significantly longer compared to 
intramolecular Cu(1)‒O(1) distance (Table 6.5). The extended intermolecular Cu(1)‒O(1i) 
bond may be a result of hindrance due to the geometrical complexity of the involved 
molecules. 
Table 6.5. Selected geometric parameters for [CuL3ʹ]2 (3)  
 
Bond lengths (Å) 
O(1)‒Cu(1) 1.971(8) N(1)‒Cu(1) 1.968(10) 
O(2)‒Cu(1) 1.909(8) N(2)‒Cu(1)  2.042(9) 
O(1
i
)‒Cu(1) 2.786(10) O(3)‒Cu(1) 2.544(9) 
Bond angles (º) 
O(2)‒Cu(1)‒N(1) 151.5(4) O(2)‒Cu(1)‒O(1) 100.2(3) 
N(1)‒Cu(1)‒O(1) 91.3(4) O(2)‒Cu(1)‒N(2) 91.9(4) 
N(1)‒Cu(1)‒N(2) 86.2(4) O(1)‒Cu(1)‒N(2) 158.7(4) 
 
 
Figure 6.11. ORTEP diagram of the asymmetric unit of [CuL
3ʹ
]2 (3) with atom labeling 
scheme. 
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Figure 6.12. ORTEP diagram of [CuL
3ʹ
]2 (3) showing the weak interactions. 
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6.3.6. Superoxide Dismutase Activity 
The SOD activity of complexes 1‒3 was investigated by employing the xanthine/ xanthine 
oxidase/ NBT system. Complex 4 could not be evaluated due to its deliquescent nature. In 
the presence of xanthine, xanthine oxidase generates superoxide anion at a constant rate, 
which promotes the reduction of NBT to formazan. This latter shows an intense 
absorption at 560 nm. Thus, by monitoring the increase of the absorption at 560 nm in the 
presence and in the absence of the copper compounds, it is possible to evaluate if they 
show SOD-like activity. In this regard, the concentration of the compound that decreases 
the velocity of NBT reduction by 50% is considered the IC50. This value can be accessed 
by carrying out experiments with different concentrations of the compound under 
evaluation (Figures 6.13 and 6.14).  
The IC50 values presented by complexes 1‒3
 
are in the middle range observed for other 
copper complexes previously described in the literature (Table 6.6). It is assumed that 
complex 3 exists as a monomer, CuL
3´
,
 
in solution in the biological assay. The observed 
order of activity was CuL
3´
 (3) > CuL
1
 (1) > CuL
2 
(2). The IC50 could not be determined 
for CuL
2 
(2) due to its low solubility in the phosphate buffer. The highest concentration 
that was possible to reach (3.0 µmol dm
-3
) is lower than the IC50, which means that its 
IC50 value is higher than 3.0 µmol dm
-3
.  
The IC50 presented by CuL
3′ 
is twice lower than the value observed for CuL
1
. Different 
factors have been considered of relevance for a synthetic compound to show satisfactory 
SOD activity, including redox potential, ligand design and coordination environment.
43
 
The redox potential (Table 6.3) presented by the compounds described here are very 
similar, which suggested that it is not the driving force of the SOD activity. On the other 
hand, compound CuL
1
 shows a square planar geometry; while the copper center in CuL
3′
 
is square pyramidal in solution, suggesting that a five-coordinated environment may be of 
relevance to increase the SOD. However, a feature that may have the highest influence on 
the IC50 values of the complexes are the substituents present in the ligand backbone.  
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Table 6.6. Superoxide dismutase activity (IC50) presented by complexes (1–3), CuZn-
SOD, CuCl2 and other compounds described in the literature. 
Compound IC50/ mol dm
-3
 
 
CuL
1 a 
(1) 
 
1.55±0.050.07 
CuL
2 a 
(2) >3.0 
CuL
3′ a
 (3) 0.75±0.05 
[Cu(BCEN)]Cl2.2H2O
 a, 43
 0.179 ± 0.017 
[Cu(BPAP)H2O]Cl2
 a, 43
 0.168 ± 0.030 
[Cu(BPAH)H2O]Cl2
 a, 43
 0.129 ± 0.033 
CuCl2.2H2O
 a, 43
 0.910±0.191 
[Cu(en)2Cl]
 a, 44
 1000 
[(en)Cu-PMDT](ClO4)3 
b, 45 
41 
[(en)2Cu-Im-Cu(en)2](ClO4)3
 b, 45
 52 
[(en)2Cu-M-Im-Cu(en)2](ClO4)3
 b, 45 
(en)2Cu-E-Im-Cu(en)2](ClO4)3 
b, 45
 
20 
42 
[Cu(dipsH)2(BZDH)2]
 a, 46
 0.94 
[Cu2(indo)4(H2O)2]
 a, 46
 1.31 
CuZn-SOD
 a, 44
  0.15 
CuZn-SOD
 a, 47 
0.03 
CuZn-SOD 
c, 48 
0.0026 
 
a
IC50 was determined by employing xanthine/xanthine oxidase-mediated reduction of 
NBT; 
b
NBT assay in the presence of alkaline DMSO; 
c
IC50 was determined by measuring 
the inhibition of the photoreduction of NBT.  
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Figure 6.13. Plot of V/v vs concentration of complex 1 employed for IC50 calculation. 
V/v is the ratio between the NBT reduction rate in the absence (V) and in the presence (v) 
of different concentration of the complexes. The IC50 is the value at V/v = 2. 
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Figure 6.14. Plot of V/v vs concentration of complex 3 employed for IC50 calculation. 
V/v is the ratio between the NBT reduction rate in the absence (V) and in the presence (v) 
of different concentration of the complexes. The IC50 is the value at V/v = 2.  
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6.4. CONCLUSION 
Four tetradentate diamino bis(phenolato) “salan” ligands and their corresponding Cu(II) 
complexes (1‒4) have been synthesized and characterized by various physico-chemical 
techniques, including solving of the single crystal X-ray structure of [CuL
1
] (1)and 
[CuL
3′
]2 (3). While the coordination geometry of the asymmetric unit of complex 1 
displays a near square planar geometry that of complex 3 shows a distorted elongated 
octahedron. The copper(II) catalyzed organic transformation in the ligands (H2L
3,4
) has 
been mechanistically established. Similar chemical transformation was however not 
observed for other transition metal complexes ([Ni
II
L
3
] (5), [Fe
III
L
3
(Cl)] (6) and 
[Mo
VI
O2L
3
] (7)), as concluded from other analytical data. In order to ascertain the 
mechanism further, alternative synthetic methodology by employing different solvent 
medium (ethanol or acetonitrile) and using acetaldehyde as an external reagent into the 
reaction medium is under process. The superoxide dismutase activity of Cu(II) complexes 
(1‒3) has also been probed and it is found to follow the order 3 > 2 > 1; the SOD mimetic 
activity being dependent on the ligand design. Compound [CuL
4´
]2 (4) could not be 
evaluated due to its deliquescent nature.  
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7.1. A Brief Resume of the Work Embodied in this Dissertation and Concluding 
Remarks  
The aim of this dissertation was to explore in depth certain aspects of the chemistry of a 
series of variable valence transition metal (V, Ru and Ir) complexes of some selected bi- 
and tridentate ON, ONO, ONN donating azo ligands and Mo and Cu complexes of 
tetradentate ONNO salan ligands. Major emphasis was given to the structural and 
spectroscopic characterization of the synthesized complexes as well as the study of their 
chemical, electrochemical, magnetic and pharmacological properties. The following 
chapter-wise summary of the work presented in this dissertation reveals the extent to 
which the above-mentioned objectives are fulfilled. 
Chapter 2 deals with the synthesis of ethoxido bridged divanadium(IV/IV) complexes 
[(VOL
1-3
)2(µ-OEt)][Et3NH] (1‒3) of three azo dyes, 2-(2′-carboxy-5′-X-phenylazo)-4-
methylphenol (H2L
1
, X = H; H2L
2
, X = NO2) and 2-(2′-carboxy-5′-Br-phenylazo)-2-
naphthol (H2L
3
), differing in the substituents of the phenyl ring, in order to discern their 
influence, if any, on their redox potentials, biological activity and magnetochemistry. All 
the synthesized ligands and the vanadium(IV) complexes are successfully characterized 
by various physicochemical techniques, viz. elemental analysis, IR, UV‒vis and NMR 
spectroscopy, ESI-MS and cyclic voltammetry. Molecular structures of complexes 1 and 
3 have been determined by X‒ray crystallography. Antiferromagnetic exchange 
interaction was observed between the vanadium d
1‒d1 centers of the complexes and this 
phenomenon was also established theoretically. The complexes were also screened for 
their in vitro cytotoxicity against HT-29 and HeLa cancer cell lines. The results confirmed 
the antiproliferative effect of all the complexes (1‒3) and their specificity over particular 
cell type, with 1 being the most potent against HeLa cancer cell line (IC50 1.92 µM). 
 
In Chapter 3 the synthesis of three new monooxidovanadium(IV), [V
IV
OL
1–3
2] (1–3) and 
two new alkoxido bridged trioxidovanadium(IV), [V
IV
3O3(µ-OMe)3(µ3-OMe)L
4,5
2] (4 and 
5) complexes have been reported, which were obtained upon reaction of 2–{(2–X)–
diazo)}–4–methylphenol (where X = benzo[1,3]dioxol–5–yl (HL1), phenyl (HL2) and 4-
methoxyphenyl (HL
3
)), 1–(2–(thiazol–2–yl)diazenyl)naphthalene–2–ol (HL4) and 2–(2–
(thiazol–2–yl)diazenyl)–4–methylphenol (HL5) with VOSO4.5H2O. The synthesized 
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complexes were successfully characterized by elemental analysis, IR and UV–vis 
spectroscopy, ESI–MS and their redox properties studied by cyclic voltammetry. 
Molecular structure of 4 has been determined by single crystal X‒ray diffraction study. 
X‒ray structure showed the molecule to be composed of three slightly distorted octahedral 
vanadium atoms forming an almost butterfly-shaped V3O4 unit similar to the well-known 
3Fe-4S iron sulfur cluster. The complexes were probed for their in vitro insulin-mimetic 
activity against insulin responsive L6 myoblast cells. The complexes (1−5) have been 
screened for their cytotoxicity in human breast adenocarcinoma cell line, MCF-7. The 
cyotoxicity of the complexes is affected by the functional groups on the arylazo ligand 
backbone. IC50 values of the complexes were found to be comparable with clinically 
referred chemotherapeutic drug, cisplatin. The insulin-mimetic activity of 1−5 was probed 
on rat L6 myoblast cells. The percent glucose uptake of the complexes was found to be 
significant as compared to insulin, where complex 2 (25 μM) proved to be most potent. In 
order to further confirm whether these compounds act via insulin signaling pathway, 
immunoblot analysis for IRS-1 protein was carried out. 
 
Chapter 4 describes the reaction of 2-(arylazo)phenols (HL) with [Ru(PPh3)3Cl2] in an 
ethanolic medium under basic conditions to afford two organometallic Ru(II) complexes, 
[RuL(PPh3)2(CO)], 1 and [RuL(PPh3)2(CH3CN)], 2. A similar reaction of HL with 
Ir(PPh3)3Cl results in formation of the organometallic Ir(III) complex, [IrL(PPh3)2(H)] (3). 
The 2-(arylazo)phenolate ligand is coordinated to the metal center in each complex (1‒3) 
as a tridentate C, N, O-donor via C‒H activation of the ligand. The sixth coordination site 
in the equatorial plane of 1‒3 is occupied by CO, CH3CN and H
‒
, respectively. The 
plausible solvent assisted mechanistic pathway for the unprecedented CO coordination to 
the Ru(II) center in the case of 1 has been explained. The synthesized complexes have 
been characterized by various spectroscopic techniques (viz., IR, UV-vis and NMR 
spectroscopy), ESI-MS and their electrochemical behavior studied by cyclic voltammetry. 
Molecular structures of 1‒3 have been determined by X-ray crystallography. 
 
In Chapter 5 the synthesis and structural characterization of seven hexacoordinated cis 
dioxidomolybdenum(VI) complexes, [MoO2L
17
] (17) derived from various substituted 
tetradentate diaminobis(phenolato) “salan” ligands, N,Nʹ-dimethyl-N,Nʹ-bis-(2-hydroxy-3-
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X-5-Y-6-Z-benzyl)-1,2-diaminoethane {(X = Br, Y = Me, Z = H (H2L
1
); X = Me, Y = Cl, 
Z = H (H2L
2
); X = 
i
Pr, Y = Cl, Z = Me (H2L
3
)} and N,Nʹ-bis-(2-hydroxy-3-X–5-Y-6-Z-
benzyl)-1,2-diaminopropane {(X = Y = 
t
Bu, Z = H (H2L
4
); X = Y = Me, Z = H (H2L
5
); X 
= 
i
Pr, Y = Cl, Z = Me (H2L
6
); X = Y = Br, Z = H (H2L
7
)} containing ON donor atoms, 
have been discussed. The formation of dioxidomolybdenum(VI) complexes was 
confirmed by elemental analysis, IR, UV-vis and NMR spectroscopy, ESI-MS and cyclic 
voltammetry measurements. Molecular structures of 16 were solved by X-ray 
crystallography. X-ray crystallography showed the O2N2 donor set to define an octahedral 
geometry in each case. The asymmetric unit of all the complexes consists of a complete 
formula unit with the exception of 2, which belongs to point group C2. The complexes 
(1‒7) showed moderate DNA binding propensity with binding constants ranging from 
10
4−105 M-1. The experimental results showed that the complexes 1‒7 effectively interact 
with CT-DNA by both minor and major groove binding mode, while complex 2 
additionally interacts by partial intercalative mode of binding. The dioxidomolybdenum 
(VI) complexes (1‒3) showed moderate photo-induced cleavage of pUC19 supercoiled 
plasmid DNA. All the complexes (1–7) were tested for their in vitro antiproliferative 
activity against HT-29 and HeLa cancer cell lines. IC50 values of the complexes in HT-29 
cell line follow the order 6 < 7 << 1 < 2 < 5 << 3 < 4 while the order was 6 << 7 < 5 < 1 
<< 3 < 4 < 2 in HeLa cells. Some of the complexes proved to be as active as the clinical 
referred drugs, and the greater potency of 6 and 7 (IC50 values of 6 are 2.62 and 10.74 µM 
and that of 7 is 11.79 and 30.48 µM in HT-29 and HeLa cells, respectively) may be 
dependent on the substituents in the salan ligand environment coordinated to the metal. 
 
In Chapter 6 the synthesis and characterization (elemental analysis, UV–vis spectroscopy 
and ESI-MS) of Cu(II) complexes ([CuL
1,2
] (1 and 2) and [CuL
3′,4′
]2 (3 and 4)) using 
tetradentate diamino bis(phenolato) “salan” ligands, N,Nʹ-dimethyl-N,Nʹ-bis-(2-hydroxy-
3-X-5-Y-6-Z-benzyl)-1,2-diaminoethane (X = 
i
Pr, Y = Cl, Z = Me (H2L
1
); X = OCH3, Y 
= allyl, Z = H (H2L
2
)) and N,Nʹ-bis-(2-hydroxy-3-X–5-Y-6-Z-benzyl)-1,2-
diaminopropane ( X = 
i
Pr, Y= Cl, Z = Me (H2L
3
); X = Y = CH3, Z = H (H2L
4
)) have been 
studied. The redox property of the complexes has been ascertained by cyclic voltammetry. 
Molecular structures of the complexes (1 and 3) have been determined by X–ray 
crystallography. While 1 and 2 have the expected square planar geometry, with the ligand 
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coordinating to the metal center in the usual tetradentate fashion, an unprecedented ligand 
transformation occurs in the case of 3 and 4, leading to the formation of phenolato bridged 
Cu(II) dimeric complexes, [CuL
3′,4′
]2,  having an elongated octahedron structure. The 
organic transformation in the ligands (H2L
3 
and H2L
4
) has been mechanistically elucidated 
to be Cu(II) catalysed. In order to fortify the ligand modification to be Cu(II) assisted, the 
corresponding Ni
II
, Fe
III
 and
 
Mo
VI
 complexes (5‒7) with the same ligand environment, 
were synthesized and characterized. The anomaly in the ligand backbone was however 
not observed in the case of other transition metal complexes (5‒7). In addition, the 
superoxide dismutase (SOD) activity of the Cu(II) complexes (1‒3) has also been 
investigated; the activity follows the order 3 > 1 > 2. Due to the deliquescent nature of 
[CuL
4′
]2
 
(4), its SOD activity could not be evaluated.  
 
7.2. Scope for Further Research 
There is further scope for research in relation to the catalytic activities of the synthesized 
molybdenum and vanadium complexes (in the bromoperoxidation, deperoxidation and the 
oxidation of benzoin) and platinum group organometallic complexes (in hydrogenation 
reaction). Other pharmacological activities (insulin-mimetic activity of the vanadium (IV) 
dimers, hydrolase and catecholase activity of the Cu(II) complexes, the DNA and protein 
binding and cleavage and the antimicrobial activity) of the complexes can be studied. 
Interaction of the synthesized complexes with bioligands and proteins of the blood and 
cytosol can be studied to understand biospeciation processes in the biofluids and potential 
pharmacologically active species in the organism. Moreover, using the synthesized ligand 
systems, mixed transition metal complexes can be prepared. In addition, mixed-valence 
divanadium(IV,V) species can be synthesized from the divanadium(IV) complexes 
analogues by controlled potential electrolysis (CPE). Considering the attractive chemical 
and physical properties pertaining to catalysis, sensor technology, magnetochemistry and 
bioinorganic chemistry of polyoxidovanadates, the variable temperature magnetic 
susceptibility measurements of the trinuclear vanadium(IV) arylazo complexes can be 
carried out. 
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